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ABSTRACT OF THE DISSERTATION 
 
Technological Advances and New Physiological Insights for Reliably Probing Myocardial 
Oxygenation with Magnetic Resonance Imaging 
by 
Hsin-Jung Yang 
Doctor of Philosophy in Biomedical Engineering 
University of California, Los Angeles, 2016 
Professor Daniel B. Ennis, Chair 
 
Coronary artery disease (CAD) is the leading cause of death in the developed world. Evaluation 
of coronary function is critically important in the course of CAD management.  Myocardial 
perfusion imaging (MPI) is the most popular noninvasive means of probing coronary function. 
While various imaging modalities have been used to image myocardial perfusion, the current 
clinical standards usually require the use of ionizing radiation or the exogenous contrast agent. 
The requirements increase the potential risks and render MPI infeeasible in a large segment of 
patients with CAD.  
  Blood oxygenation level dependent (BOLD) cardiac MRI (CMR) is a newer approach for 
imaging myocardial perfusion. BOLD CMR utilizes the intrinsic contrast of the deoxygenated 
blood to probe myocardial oxygenation without ionizing radiation and contrast agent. 
 iii 
Developments in the past twenty years have made significant advance in BOLD CMR and recent 
studies have shown promising results for the clinical application of the approach. However, 
BOLD CMR still suffer from multiple challenges, such as inadequate accuracy, imaging 
confounders, limited imaging speed, and sub optimal stress imaging protocols, all which 
significantly limit its reliability and clinical applicability. In this dissertation, we propose to 
overcome these limitations from the technical and physiological vantage points to enable a 
reliable BOLD CMR exam, which can rapidly accelerate the clinical translation and adoption of 
the approach.      
  The first objective of this dissertation is to develop, test and validate a cardiac MRI technique 
that is robust, reliable and fast. To overcome the challenging cardiac imaging condition at 3T and 
provide reliable and sensitive BOLD signal, this dissertation utilized multiple techniques, such as 
motion correction, SR preparation, adiabatic pulses and novel reconstruction methods, to realize 
a confounder-corrected, free-breathing 3D T2 mapping technique at 3T that can be completed 
within the period of adenosine stress. The technique was tested and validated with 
simultaneously acquired 13N-ammonia PET perfusion in a whole-body PET/MR system. Ex-vivo 
studies demonstrated the proposed approach could be used to overcome the heart-rate dependent 
changes in T2 between rest and stress. In canines without coronary stenosis, T2 under adenosine 
stress was significantly greater than at rest, which was consistent with the observed increase in 
PET perfusion measurements. The changes in BOLD signal between rest and stress was highly 
correlated to myocardial perfusion reserve. In animals with coronary stenosis, perfusion 
anomalies were consistently detected between the developed technique and PET. These results 
demonstrate the proposed approach has the capability to enable rapid and reliable measurements 
of whole heart perfusion.  
 iv 
  The second objective of the dissertation is to explore innovative vasodilation strategies to 
improve the reliability and applicability of BOLD CMR exams. Two novel ways of inducing 
vasodilation (Regadenoson and hypercapnia) for BOLD CMR were studied. Regadenoson is a 
new pharmacological vasodilator that has a prolonged vasodilation effect compared to the 
standard stress agent (adenosine). Utilizing the longer vasodilation period, we found that a 
significantly improved stress image quality and reliability can be achieved by imaging at a 
delayed time point (10 mins after the regadenoson administration). For validation purpose, 
BOLD and PET images were acquired simultaneously in healthy animals. The delayed 
acquisitions showed markedly increased myocardial T2 from the BOLD images and increased 
myocardial blood flow from 13N-ammonia PET perfusion. To further improve the sensitivity and 
reliability of regadenoson BOLD exam, a repeated BOLD image acquisition strategy was 
proposed to continuously monitor the dynamics of BOLD signal after regadenoson injection. The 
BOLD signal changes were used to investigate the coronary dynamics after the peak vasodilation 
in healthy and diseased subjects. The coronary dynamic parameters (CDPs) were derived and 
were used to compare to the conventional single time point approach. CDPs showed the 
capability of extracting greater BOLD response in the healthy subjects and improved 
performance in disease identification in the animals with impaired coronary arteries. This 
preliminary study showed the potential of improving BOLD CMR performance with existing 
stress agents and better-designed strategies to assess coronary vasodilatation. 
  Hypercapnia (elevated arterial CO2 (PaCO2)) is a known mediator of carotid vasodilation, but 
its effects on the coronary arteries had been unclear given the lack of tools to accurately and 
rapidly alter arterial CO2. By prospectively and independently controlling PaCO2, this 
dissertation first investigated whether a physiologically tolerable hypercapnic stimulus can 
 v 
increase MBF in healthy and diseased animals. The extent of effect on MBF due to hypercapnia 
was compared to adenosine using quantitative 13N-ammonia PET measurements. In the healthy 
animals, MBF under hypercapnia and adenosine were positively correlated; and were not 
different. Under LAD stenosis, MBF increased under hypercapnia and adenosine but the effect 
was significantly lower in the affected territories. Mean perfusion defect volumes measured with 
adenosine and hypercapnia were significantly correlated and were not different.  The BOLD MR 
signal response to the controlled hypercapnia was also investigated under similar setup. In intact 
canines, changes in myocardial BOLD MR signal were equivalent to changes with adenosine. In 
addition, BOLD response under repeat hypercapnic stimulations were also tested. Reproducible 
BOLD responses were observed following repeat stimulation between baseline and equivalent 
hypercapnic states. In the dogs with coronary artery stenosis, BOLD MR signal changes during 
hypercapnia and adenosine infusion were also not different. The results demonstrate arterial 
blood CO2 tension is an independent variable of MBF, which can induce MBF and BOLD signal 
to the same level as standard dose of adenosine. 
In summary, this dissertation culminates in key advancements which have the capacity to 
reliably advance cardiac BOLD in the clinical arena in the assessment of myocardial perfusion in 
the setting of ischemic heart disease. The technical and physiological advances direly address the 
key obstacles present with in the current BOLD techniques and build the foundation for a 
reliable, robust and practical myocardial BOLD exam. 
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1  Chapter 1: Introduction 
1.1  Significance 
    Coronary Artery Disease (CAD) is the most common type of heart disease and the number one 
cause of death in the United States (1). Reliable detection and quantification of the ischemic 
volume associated with prognostically significant CAD are critically important in the clinical 
management of the disease (2,3). Ischemia testing is commonly used to assess the extent and 
severity of myocardial ischemia, which have been shown to provide incremental prognostic 
value over standard clinical variables across the spectrum of presentations of CAD (2,4,5). 
1.2   Current State of Ischemia Testing 
  For many years, x-ray contrast angiography (XCA) has been used as gold standard for CAD 
evaluation. However, the determination of coronary artery stenosis on the basis of XCA or 
coronary CTA has proven to be a poor predictor of ischemic burden (6,7). While Fractional flow 
reserve (FFR), determined as the relative pressure differences across the stenotic coronary artery, 
has emerged as the new standard for determining clinically significant ischemia (FFR ≤0.75) (8-
10), it is invasive, expensive, and exposes the patient to ionizing radiation. Direct measures of 
ischemic burden may be determined on the basis of SPECT, PET, CT perfusion, MCE, and first-
pass perfusion MRI (FPP-MRI) (11-14). While SPECT and PET studies account for 
approximately 90% of the nearly 10-million myocardial ischemia-testing studies in the US (15), 
the sensitivity and specificity for both methods combined for the determination of severe 
ischemia is below 70% (16). CT perfusion, MCE and FPP-MRI are relatively newer approaches 
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that require the use of exogenous contrast media and intravenous pharmacological stress agent 
(adenosine), all carrying significant risks and side effects in certain patient populations (17). 
An ideal test to assess for myocardial ischemia would be truly non-invasive and would have 
minimal potential risks and side effects; that is, in addition to avoiding the risks of cardiac 
catheterization, it would be free of ionizing radiation, exogenous contrast media, and intravenous 
stress-agents. Additionally, the strategy would provide physiological insight into the disease 
based on reliable measurements of impaired oxygen supply, and not from surrogate tests (wall 
motion, ECG changes, or contrast kinetics).  
    Although current clinical standards do not provide many of these benefits, a number of these 
requirements can be met by cardiac Blood-Oxygen-Level-Dependent (BOLD) Magnetic 
Resonance Imaging (MRI) (18-20). However, the widespread use of this approach is currently 
limited by inadequate accuracy, undesirable imaging confounders, and the need for intravenous 
stress, all of which pose considerable limitations in clinical practice. A highly efficient, robust, 
and accurate BOLD exam with minimum stress inducing side effects is hugely beneficial for the 
patients that are limited from the current medical standard methodologies. 
1.3  Noninvasive, Ionizing Radiation Free, Non-Contrast-Enhanced Ischemia 
Testing with Myocardial BOLD MRI 
 BOLD (Blood-Oxygen-Level-Dependent) MRI, relies on endogenous contrast mechanism 
(changes in blood oxygen saturation, %O2) to identify ischemic territories.  The intrinsic contrast 
derived on the basis of %O2 using MRI makes BOLD imaging free of exogenous contrast agent 
and ionizing radiation. Although FPP-MRI is another approach which enables the acquisition of 
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high resolution perfusion images without ionizing radiation, it requires infusion of gadolinium-
based contrast agents, which are toxic to patients with late stage chronic kidney disease (CKD) 
(21-23). Given the comorbidity of CKD in patients with heart disease, FPP-MRI is estimated to 
be contraindicated in at least 1 million patients in the US(24-26). Importantly, late stage CKD 
patients who cannot undergo FPP-MRI are in great need of ischemia assessment since the risk of 
cardiac mortality is substantially elevated in this population(27,28). Thus, there is an unmet and 
growing need for accurate assessment of chronic MI without contrast agents in this patient 
population.  
 The potential benefits of BOLD MRI for detecting global or regional myocardial ischemia due 
to CAD were demonstrated by our group and others at least a decade ago (29-32). Although a 
number of pilot clinical studies have demonstrated the feasibility of using BOLD MRI for 
identifying clinically significant myocardial ischemia due to CAD, the method is currently 
limited by several technical and physiological challenges.  
1.4   Major Challenges of Cardiac BOLD MRI 
1.4.1 Technical Challenges 
Although BOLD CMR has progressed significantly in the past 20 years, a number of technical 
challenges still limit its reliability, robustness and applicability in the clinical routines. Major 
technical challenges include:  
 Limited imaging speed and coverage to accommodate the limited vasodilation time. 
 Imaging confounders (T1 weighing, coil bias and heart rate dependency) degrade the 
BOLD sensitivity.  
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 2D methods with multiple breath holds can lead to patient discomfort and slice mismatch. 
 Limited sensitivity due to modest contrast to noise ratio (CNR), particularly at lower field 
strength (1.5T). 
 Image artifacts (cardiac and respiratory motion; B0 and B1 field inhomogeneity) 
particularly at 3T leads to diminished imaging quality.  
 Weighted images sacrifice the potential of quantitative evaluation of the BOLD effect 
(33). 
In addition to the aforementioned technical limitations, another important component of of 
BOLD CMR exams are the need for vasodilation. 
1.4.2  Physiological Challenges 
When exercise stress testing is contraindicated (in nearly 50% of patients) (34), existing imaging 
modalities use pharmacologic stress agents such as adenosine to induce hyperemia. Although the 
stress agents can induce vasodilation for imaging purpose, the current stress methods rely on 
imaging within a short period of time (2-4 mins) with unpredictable and rapidly changing cardiac 
activities to capture the peak coronary vasodilatory state.  The suboptimal imaging conditions are 
compensated by other modalities with lower spatial resolution, higher contrast to noise ratio and 
the use of contrast agents. Although several BOLD studies have shown promising results 
adopting similar approaches, such procedures are not optimal for BOLD CMR acquisitions. For 
BOLD acquisitions to be reliable, images need to be of high quality and should have sufficient 
image contrast. The current stress methods hold key challenges against BOLD MRI, which are:  
 Unpredictable cardiac activity leading to motion artifacts, undesired confounders and 
cardiac phase mismatch during stress imaging.  
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 Marked changes in cardiac activity, which can lead to, increased oxygen consumption 
during image acquisition and decrease the BOLD response during hyperemia. 
 Restricted peak vasodilatory duration during adenosine stress limits the spatial resolution 
resolution and coverage, and the reliability of BOLD images due to motion artifacts. 
Thus, both technical and physiological challenges restrict the robustness and reliability of BOLD 
CMR in the clinical settings. A practical BOLD CMR technique would needs to overcome the 
limitations to accurately and rapidly identify the ischemic myocardium. 
1.5  Specific Aims of This Dissertation 
The overall aim of this dissertation is to improve the technical and physiological changes facing 
cardiac BOLD MRI in order to pave the path for effective clinical translation.  To achieve this, 
we wish to first develop a suitable BOLD CMR sequence and validate it against gold standard 
PET perfusion; and second to develop novel vasodilation strategies which can enhance the 
reliability of cardiac BOLD exams.  
1.5.1 Aim 1: To develop a time-efficient, confounder-corrected, free-breathing, 
quantitative, 3D myocardial BOLD MRI with full LV coverage at 3T and validate 
the approach against simultaneously acquired quantitative PET perfusion.  
A Fast free breathing T2 mapping sequence tailored for BOLD CMR was developed and is 
described in n chapter 3. Chapter 3.1 presents the highly efficient T2 mapping platform. This 
technique utilizes motion-correction algorithm with contrast integration to achieve high imaging 
efficiency whole heart T2 mapping. The T2 accuracy and feasibility of the technique were tested 
with an animal model with acute MI. In chapter 3.2, a saturation-recovery pulse was added to 
further reduce scan time and eliminate confounding effects caused by heart rate changes leading 
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to bias in T2 estimation. The BOLD response from the proposed sequence is validated with 
simultaneously acquired 13N-ammonia PET perfusion imaging.  
1.5.2 Aim 2: To develop and test innovative vasodilation strategies that combine imaging, 
post-processing, and analysis methods for reliably and safely measuring myocardial 
BOLD response.  
Chapter 4 and 5 summarize two different novel vasodilation strategies to improve imaging 
reliability and stress safety. Chapter 4 explores the use of Regadenoson (a newer and safer 
vasodilator) for cardiac BOLD exam. The delayed vasodilation effect of regadenoson was tested 
for more reliable stress imaging while enabling further insights into coronary dynamics 
(vasodilation and relaxation).  
Chapter 5 explores the use of precisely targeted hypercapnia as a safer and repeatable vasodilator. 
The vasodilation effect was validated with quantitative PET perfusion and BOLD CMR. The 
study serves as a foundation for a more sophisticated paradigm design using repetitive 
hypercapnic stimulations.  
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2  Chapter 2: Background 
2.1  Coronary Artery Disease  
Coronary artery disease is the leading cause of death in the United States in both men and 
women. It is estimated that in excess of 16 million people are living with CAD in the US and 
more than one in three deaths are due to CAD and more than 1 million people are hospitalized 
each year. The most common form of CAD leads to the narrowing of the coronary arteries 
(stenosis) resulting in reduced blood flow and oxygen supplied to the heart muscle, causing 
myocardial ischemia – a condition where the oxygen demand of the myocardium is far in excess 
of the available supply (35). The presence of myocardial ischemia is an important risk factor for 
major adverse cardiac events (MACE: stroke, myocardial infarction, and death) (36,37). 
Appropriate early interventions (pharmacological, or medical therapy (OMT), angioplasty (PCI), 
coronary bypass (CABG)) that are guided by the extent and severity of ischemic burden 
associated with stable CAD may be instrumental in reducing the risk of MACE (4-6) .  Hence a 
reliable, non-invasive, and repeatable method for determining the extent and severity of ischemia 
is invaluable in managing patients with CAD. 
2.2  Assessment of CAD on the Basis of Coronary Function 
Current CAD assessments evaluate either anatomy or function of the coronary arteries. Although 
coronary anatomy is an important indicator of CAD and is associated with coronary function 
under controlled conditions (Fig.2.1), the coronary function is a more direct way of probing the 
actual oxygen supply to the myocardium.  Coronary function can also be disassociated with 
coronary anatomy in the presence of diffuse stenosis and arterial remodeling. (38) 
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Figure 2.1  Relationship between coronary flow reserve and coronary stenosis level. The figure showed 
the effect of coronary narrowing on coronary flow reserve. The maximum flow is degraded when the 
stenosis level is higher than 50%. Adopted from (38) 
In addition, measuring only anatomical stenosis in large coronary arteries is not sufficient to 
detect ischemia in the presents of coronary microvascular disease and limits the accuracy for 
evaluating myocardial ischemia.  Recent studies have shown improved clinical outcome from 
functional assessments (Fig. 2.2) (8,9,39,40) and indicate functional measures offer superior 
guidance in the management of CAD.  
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Fig2.2 Treatment outcome difference between Angiography-guided and FFR-guided PCI. FFR guided 
PCI showed significantly reduced ratio of major adverse events compare to anatomical angiography 
guided procedures.  Adopted from (9)  
The current gold standard of evaluating coronary function (FFR, XCA) are still invasive and the 
extra operational risk, patient discomfort and cost from the invasive procedures make it less 
suitable for patients with modest symptoms and lower CAD risk. The imaging-based ischemia 
tests serve as an effective noninvasive alternative for the patient population suspected of having 
CAD.  
2.3  Imaging-based Ischemic Testing 
Imaging-based ischemic testing investigates the vasodilatory capacity of coronary arteries using 
noninvasive imaging modalities and identify the coronary vessels that are affected by disease.  
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One of the most direct measurements of coronary vasodilation is through the monitoring of 
myocardial perfusion. Under vasodilatory stress, the normal coronary circulation will increase 
blood flow and oxygen supply to the myocardium.  However, in the stenotic coronary arteries, 
the vessels lose the ability to dilate, which will lead to hypoperfusion or even ischemia. Imaging 
the difference of myocardial perfusion between rest and stress can identify the myocardial 
supplied by the affected arteries, which has significant diagnostic and prognostic values.  In the 
past 20 years, considerable growth in Imaging-based cardiac stress testing because of the 
advancement in technology and the proven diagnostic values. The incidence of imaging based 
stress testing has increased to more than 85% in all stress exams and is considered a critical 
diagnostic tool in CAD management (41). Imaging-based ischemic testing can generally be 
defined in two steps: Step 1. Induction of cardiac stress resulting in coronary vasodilation. Step 
2.  Imaging myocardial perfusion changes induced by the stimulation and identifies the ischemic 
territories. Details of each step are discussed in the following sections. 
2.3.1 Myocardial Perfusion Reserve (MPR) and Coronary Vasodilation  
Coronary perfusion is a well-regulated physiologic phenomenon. Modulating myocardial blood 
flow is extremely important in balancing myocardial oxygenation. Because of the high (60~80%) 
myocardial oxygen extraction fraction in the left ventricle under regular condition (42), it is not 
possible to significantly increase O2 consumption by increasing O2 extraction. Consequently, 
increased oxygen demand is mainly met by the elevation of coronary blood flow (43). Healthy 
coronary arteries are capable of modulating the myocardial perfusion by 3-5 folds during 
maximal vasodilation. This myocardial perfusion reserve (MPR) provides a large buffer for extra 
oxygen demand. The vasodilation process is illustrated in the upper panel in fig 2.3. However, in 
coronary arteries affected by disease, such as with epicardial stenosis arising from 
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atherosclerosis, increase the coronary resistance and leads to the reduction of the vasodilation 
capability. This effect decreases the maximum myocardial blood flow during peak vasodilation 
and reduces the myocardial perfusion reserve (MPR) in the affected myocardium. (43) The 
property makes MPR a valuable feature of probing coronary health condition. 
 
Fig. 2.3 Normal and diseased blood flow between rest and stress. Healthy and stenotic artery reaction to 
the increased oxygen demand during exercise. Artery stenosis reduce the maximum blood flow during 
exercise and reduce the blood flow reserve. Adopted from (44). 
To probe MPR, various methods, including exercise, pharmacological agents and blood gas 
modulation are used to induce coronary vasodilation. In imaging studies, pharmacological stress 
is the most common way to induce peak vasodilation due to the ease of administration. Recent 
studies have used controlled hypercapnia and breathing maneuver to induce vasodilation for 
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identifying coronary arteries with significant stenosis (45,46). While each vasodilation approach 
has its own strengths and weaknesses, suitable stimulations should be selected to best 
accommodate the features of the applied ischemic testing modality. Comparisons of various 
methods used to induce coronary vasodilation are listed in table 2.1 
Stress 
Methods 
Mechanism 
Oxygen 
Consumption 
During Stress  
Cardiac Activity 
During Peak 
Vasodilation 
Repeat 
Stimulation 
Capability 
Exercise 
Non- 
Pharmacological 
Intrinsic 
Significantly 
Elevated 
Very Unstable 
(Increased contractility) 
Difficult to repeat  
(Patient condition)  
Dobutamine 
Pharmacological 
Inotropic 
Significantly 
Elevated 
Very Unstable 
(Increased contractility) 
Unrepeatable  
(Dose Limitation) 
Dipyridamole 
Pharmacological 
Chronotropic+ 
Unhanged or 
slightly elevated 
Unstable  
(Heart rate variation) 
Unrepeatable 
(Long Half-Life) 
Adenosine 
Pharmacological 
Chronotropic+ 
Unhanged or 
slightly elevated 
Unstable  
(Heart rate variation) 
Unrepeatable  
(Dose Limitation) 
Regadenoson 
Pharmacological 
Chronotropic+ 
Unhanged or 
slightly elevated 
Very Unstable 
(Heart rate variation) 
Unrepeatable 
(Long Half-Life) 
Hypercapnia 
Non-
Pharmacological 
Intrinsic 
Unhanged or 
slightly elevated 
Stable with small heart 
rate variation 
Repeat stimulation 
with controlled 
hypercapnia 
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Table 2.1 Stress property comparisons between vasodilation methods. Different levels of oxygen 
consumption elevation, imaging stability and repeat stimulation capability during stress imaging makes 
the methods suitable for different imaging modalities.  
2.3.2 Myocardial Perfusion Imaging (MPI) 
After inducing vasodilation, measuring myocardial perfusion is the important next step for MPR 
evaluation. Myocardial perfusion can be imaged with several modalities, such as SPECT, PET, 
CT, ultrasound, and MRI, noninvasively. The imaging properties and contrast mechanisms are 
summarized in table 2.2 and each modality has its own strength and weakness and can be chosen 
to accommodate different clinical needs. Despite the differences between modalities, the 
majority of current MPI techniques utilize ionizing radiation and use exogenous contrast agents 
as surrogates of the blood and measure myocardial perfusion by monitoring contrast agent 
dynamics. These features induce extra risks besides the catheterization procedure and make MPI 
contraindicated in certain patient population; on the other hand, BOLD CMR is one of the new 
imaging modalities, which does not require the use of ionizing radiation and exogenous contrast 
agent. This provide BOLD CMR a preferable risk profile compare to the standard MPI 
approaches and make it suitable for the patients that need repeat measurements or are 
contraindicated to contrast agents. 
MPI 
Modalities 
Ionizing 
Radiation 
Contrast Agent Contrast Mechanism 
Spatial 
Resolution 
SPECT Yes Radioactive Isotopes 
Myocardial tracer 
uptake 
6-8 mm 
PET Yes Radioactive Isotopes 
Myocardial tracer 
uptake 
3-5 mm 
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CTP Yes Iodinated Contrast first passage <1 mm 
MCE No Microspheres 
Microspheres 
replenishment 
3-5 mm 
FFP MRI No Gd-based Contrast first passage 1-3 mm 
BOLD MRI No No Blood oxygenation level 1-3 mm 
ASL MRI No No Arterial Spin labeling 1-3 mm 
Table 2.2 Summary of the MPI modalities.  
2.4  Fundamentals of Blood-Oxygenation-Level-Dependent (BOLD) MRI  
Image contrast permitting the detection of BOLD signal changes originate from nuclear 
relaxation of spins in a spatially heterogeneous magnetic fields that are determined by the 
oxygenation state of the red blood cells. The following sections summarize the key 
elements of nuclear magnetic relaxation theory and the foundations of BOLD image 
contrast. 
2.4.1 Nuclear Magnetic Relaxation 
Nuclear Magnetic Resonance (NMR) signal is generated from the interaction between unpaired 
protons (spins) in atoms and applied external magnetic fields. Among different elements, such as 
1H, 23Na, and 31P, hydrogen protons (1H) in the water is the most used element for medical MRI 
due to the high water content in human bodies. When an ensemble of hydrogen protons is placed 
into a static external magnetic field (B0), the spins will be aligned to the direction of B0 and split 
into two energy states (up-state and down-state). At thermal equilibrium, the exceeded spin 
population in the up-state lead to a non-zero magnetic dipole moment (M0) along the B0 
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direction. However, the existence of M0 is typically too small to be detected in steady magnetic 
systems. In order to generate measurable signal from M0, a time-varying orthogonal magnetic 
field (B1) with on resonance frequency 0 = B0 (is the Lamor frequency;42.7MHz/T for 1H) 
needs to be applied. The B1 field can apply a torque to M0 which can rotate the magnetization 
vector by a prescribed flip angle angle (depend on the amplitude and duration of the B1 field. 
This process is called excitationof the spins. The excited M0 will precess along the static field at 
0. The tilted magnetization vector creates a rotating magnetic moment in the transverse plane 
(Mxy), which can be detected with an on resonance antenna.  When B1 is turned off, the 
longitudinal (Mz) and transverse components (Mxy) of the excited magnetization vector will relax 
back to the thermal equilibrium at a rate of T1 and T2, respectively.  
 
Fig 2.4 A cartoon representation of the spin excitation and relaxation process. M0 is first excited with a B1 
field by in the first half of the coordinates. In the second half of the coordinates, the magnetization 
slowly relaxes back to the thermal equilibrium with a rate of T1 in the longitudinal direction (Mz) and T2 
in the transverse direction (Mxy). 
This process is known as spin relaxation and can be described by the phenomenological Bloch 
equations (112): 
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𝑑𝑀𝑥
𝑑𝑡
= ∆𝜔𝑜𝑓𝑓𝑀𝑦 −
𝑀𝑥
𝑇2
 
𝑑𝑀𝑦
𝑑𝑡
= ∆𝜔𝑜𝑓𝑓𝑀𝑥 −
𝑀𝑦
𝑇2
 
𝑑𝑀𝑧
𝑑𝑡
=
𝑀0 − 𝑀𝑧
𝑇1
  
Where off is the off resonance frequency of a spin and can be defined as ∆𝜔𝑜𝑓𝑓 = 𝜔0 − 𝜔 
In a perfect on resonance environment where ∆𝜔𝑜𝑓𝑓 = 0, we can derive the temporal 
representation of the relaxation process to be: 
𝑀𝑥(𝑡) = 𝑀𝑥(0)𝑒
−
𝑡
𝑇2 
𝑀𝑦(𝑡) = 𝑀𝑦(0)𝑒
−
𝑡
𝑇2 
𝑀𝑥(𝑡) = 𝑀𝑧(0)𝑒
−
𝑡
𝑇1 + 𝑀0(1 − 𝑒
−
𝑡
𝑇1 ) 
 This simplified representation provides a general picture of the MRI contrast mechanisms and is 
important because: 
 The measured MR signal is proportional to the transverse magnetization (Mxy= Mx 𝑖̂ + My 
𝑗̂; where 𝑖̂ and 𝑗̂ represent unit vectors in the x and y direction respectively), which is 
related to M0, , t, T1 and T2. By carefully choosing the imaging parameters (t), one 
will be able to generate MR signal and contrasts that is sensitive to specific MR 
parameters (M0, T1, and T2). 
 MR parameters, such as M0, T1 and T2, are closely correlated to the surrounding 
environment of the spins (details will be provided in the following sections), which is 
often connected with physiological conditions.  Probing the MR parameters can provide 
 18 
important information on the micro and macro environment around the water molecules, 
which can reflect in different pathological features. 
In practice, there are more complicated components that can influence the MR signal. Off 
resonance spins, modulations of the excitation and relaxation process can all impact the spins 
and generate different contrasts or artifacts. In this dissertation we will focus on the basic 
principles that are related to the blood oxygenation level sensitive parameters and discuss its 
application in the ischemic stress testing.   
2.4.1.1 Longitudinal Relaxation 
As mentioned earlier, the post-excitation longitudinal magnetization recovers to thermal 
equilibrium with a time constant T1. The longitudinal relaxation is established by two processes, 
which are spontaneous emission and stimulated emission.  In the biological environment, 
spontaneous emission is typically very slower, which makes the stimulated emission the 
dominant effect for longitudinal magnetization recovery.  Stimulated emission occurs as the 
nuclei experience rapid changing magnetic fields that is close to the resonance frequency. In 
MRI, the origin of the fluctuating magnetic fields is typically caused by the rotation, translation 
and collision of the hydrogen nuclei to surrounding molecules. This effect makes T1 sensitive to 
the magnetic property of the surrounding molecules and the mobility of the hydrogen itself.    
2.4.1.2 Transverse Relaxation 
The transverse component of the magnetization relaxes to the thermal equilibrium state with a 
relaxation constant T2. Unlike the longitudinal magnetization, the transverse relaxation decays to 
zero in time.  As discussed in the previous section, the transverse magnetizations are precessing 
against the B0 direction in the x-y plane. This means the magnetization can be decomposed into 
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an amplitude term and a phase term and the total Mxy can be think of a complex superposition of 
the individual spins. When the bulk magnetic field is homogeneous, transverse relaxation is 
mainly composed from two mechanisms. (i) The energy transformation from spin-lattice 
relaxation as mentioned in the last section. The effect brings a spin back to the low energy state 
and reduce the transverse component; and (ii) the magnetization cancelation between the local 
incoherent spins caused by phase accumulation and dipolar interaction. Because of the second 
mechanism, T2 is always shorter than T1. The phase accumulation is strongly dependent on the 
local molecular environment and the spin mobility during the relaxation period. In this 
dissertation, we define the T2 that is not affected by imperfect field perturbation as the intrinsic 
T2 (T2
Intr) of the spins. In the presents of field inhomogeneity; on the other hand, the local spins 
will be exposed to a range of different B0 (B = B0 max-B0 min) and be precessing at a different 
frequency. This effect accelerates the dephasing process of the transvers magnetizations and 
shorten the transverse relaxation time. It is common practice in MRI literature to define the 
shorten relaxation constant as T2* where 
1
𝑇2
∗ =
1
𝑇2
𝐼𝑛𝑡𝑟 + 𝛾∆𝐵 
Fortunately, the magnetization dephasing caused by a slowly spatial varying static field 
inhomogeneity is possible to be recovered with the use of 180o refocusing pulses. {ref Hahn; 
1950; spin echo} The signal generated by reversing the accumulated phase from the 
inhomogeneous field is called spin echo (SE) and the refocusing process is demonstrated in 
figure 2.5.  
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Fig 2.5 Spin echo formation and T2 relaxation. (a) A 90° RF excitation pulse is followed by a 180° RF 
pulse that is applied at a time of 180 after the 90° RF pulse. (b) Shows a schematic of spins losing 
coherence due to T2 * effects following the 90° RF pulse over the time period of 180. The 180° RF pulse 
reverses the direction of phase evolution to increase coherence over the next 180, forming an echo which 
peaks at time of 2180 after the 90° RF pulse. (c) Shows the exponential decay of the echo peaks (blue 
curve) occurring over the period of 2180, the time constant of which is T2, also shown is the T2* decay 
curve (orange line). Note that spin-echo extends the time over which the transverse magnetization 
persists, without which T2 * decay would more rapidly dephase the transverse magnetization. 
As plotted in the figure, a 180o pulse can reverse the phase accumulation by flipping the spin to 
precess in the opposite direction. In a slowly spatial varying field where spins do not move 
through different field offsets during the refocusing period (180), the spins will experience 
identical field perturbation before and after the 180o pulse and generates a perfect refocused 
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spins at t =2180. This condition makes the spin echo T2 equals to the intrinsic T2 (T2SE = T2Intr). 
Nonetheless, in MRI, there are often sources of local magnetic field variations that produce fast 
spatial varying inhomogeneous fields. When spins diffuse through such inhomogeneous 
environment, the random phase accumulation leads to an enhanced spin dephasing. Even with 
the application of a refocusing pulse, due to the random motion of diffusion, the phase 
perturbation through the process is difficult to reproduce during the refocusing period. The 
effect, therefore, results in a further reduced apparent T2 value compare to T2
intr.  The apparent T2 
under the influence of diffusion can be expressed by   
1
𝑇2
𝑆𝐸 =
1
𝑇2
𝐼𝑛𝑡𝑟 +
1
𝑇2
𝐷𝑖𝑓𝑓
 
Where T2
Diff is a function of refocusing time (180), field variation components, molecular 
mobility resonance frequency and diffusion path. Substances with susceptibility shift from the 
water molecules are often the source of inducing local field variation. In the case of BOLD 
imaging, the susceptibility change of the deoxygenated hemoglobin makes a perfect source for 
local field perturbation and creates transvers relaxation differences in both refocused and non-
refocused scenarios.    
2.4.2 BOLD Contrast 
Hemoglobin is the main component for oxygen transportation in the blood.  It is composed of 
four heme groups surrounding a globin group. Each heme group contains an iron atom to bind 
with oxygen. When heme is not bound to oxygen, the iron(II) in the heme group is paramagnetic 
with 4 unpaired electrons in the 3D orbit. When a heme becomes oxygenated, oxygen molecules 
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bind to the iron and change the confirmation of the protein and rendering them diamagnetic 
(47,48).  The process is plotted in figure 2.4. 
 
Fig.2.6 Molecule structure of deoxygenated and oxygenated hemoglobin. Binding oxygen to the heme 
group induces structural change of the molecules and turn transform the magnetization.  Adopted from 
(48)    
The capacity of the hemoglobin to alter magnetic susceptibility makes blood a magnetically 
inhomogeneous medium in which the susceptibility is strongly depend on the blood oxygen 
saturation (%O2). The susceptibility variation from deoxygenated hemoglobin creates local 
magnetic field inhomogeneity which cause a loss of phase-coherence among spins following 
radio-frequency (RF) excitation and reduce the capability of refocusing the transverse 
magnetization (in excess of spin-spin relaxation in the absence of field inhomogeneity), which 
leads to a shorter T2* and apparent T2 in the blood (49). 
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.  
Fig. 2.7 BOLD signal changes from neural stimulations. Neural stimulation increases oxygen 
consumption, which reduce the blood oxygenation level in the local vessels and induce the increase in the 
blood flow. The blood oxygenation level affects the spin refocusing property and lead to BOLD signal 
changes.   Adopted from (49) 
The MR signal variation correspond to the blood oxygenation level, also known as Blood-
Oxygenation-Level-Dependent (BOLD) signal, was first discovered by Dr. Ogawa in 1990 (50). 
Two years later, the effect was applied to human brains for the first time by two independent 
groups led by Dr. Ogawa (51) and Dr. Kwong (52). These studies built the foundation of 
functional MRI (fMRI) and opened the door for the modern cognitive and behavioral 
neuroscience.  In the Brain, blood supply changes during neural stimulations and, as a secondary 
effect, modulates blood oxygenation (Fig.2.5). This phenomenon provides neuroscientist an in-
direct tool to probe regional neuron activity through monitoring BOLD signal changes. On the 
other hand, the application of BOLD contrast in the heart provides an opportunity to assess the 
myocardial oxygenation directly. As mentioned in the previous chapters, myocardial ischemia is 
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an important indicator for CAD, which makes BOLD CMR a viable approach for CAD 
assessment. 
2.5  BOLD contrast in the Myocardium 
In the heart, nearly 90% of the blood volume is within the capillaries.(53) In the 
microcirculation, similar to the BOLD mechanism in the blood, field inhomogeneity induced by 
deoxygenated hemoglobin also influences the water molecules in the capillary bed with the 
interaction between the red blood cells and plasma and between the intravascular and 
extravascular spaces. Consequently, myocardial BOLD signal reflects the oxygenation level of 
the microcirculation and makes the BOLD signal sensitive to both the supply and demand of 
myocardial oxygen. During stress testing, vasodilators induced hyperemia in the healthy 
myocardium and the increased blood flow boosts oxygen supply in the capillary bed. When 
myocardial oxygen consumption stays the same, blood oxygenation level elevates substantially 
in the microcirculation (~30% (resting) vs. ~80% (hyperemic)); (54) on the other hand, 
myocardial blood flow in the myocardium subtended by stenotic coronary arteries do not 
respond to the stress agent results in unchanged or reduced oxygenation level and BOLD signal 
(Fig 2.6.).  This difference allows for detecting coronary stenosis on the basis of regional 
myocardial BOLD signal variations. 
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Fig. 2.8 Healthy and diseased coronary microcirculation under rest and stress. In healthy coronary 
arteries, vasodilation capability is reserved under rest condition and maintain the blood oxygenation 
level according to the myocardial oxygen demand. On the contrary, the vasodilation reserve is exhausted 
in the diseased arteries under rest condition to accommodate the impaired blood supply and loss the 
capability of further dilate the vessels under stress condition. This effect makes the oxygenation level 
difference between healthy and diseased myocardial territories and lead to the change in BOLD signal. 
Adopted from (54) 
Although the BOLD contrast was originally developed for brain and became a game changer in 
neuroscience, imaging BOLD signal in brain is always a challenging task due to the limited 
BOLD contrast (1-3% signal elevation in the active regions) (50,52). To overcome the effect, 
various statistical algorithms have been developed to extract meaningful values from the signal 
that is buried in the noise level (35). Even with the success from sophisticated statistical testing, 
higher BOLD contrast is always desired in the BOLD experiments.    Fortunately, important 
biophysical differences between the microcirculation in heart and brain enhance the applicability 
for BOLD ischemic testing. Specifically, the heart has a larger blood volume fraction than the 
brain (~10% vs. ~4%) and lower venous blood oxygen saturation (30% Vs. 60%)(55). This 
allows for a wider range of signal change with vasodilator-induced hyperemia in the 
myocardium compared to the brain, which provides greater BOLD sensitivity in the heart. 
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However, the challenge for myocardial BOLD CMR has been identifying oxygenation changes 
from confounding effects of imaging artifacts from motion (cardiac, respiratory and pulsatile 
blood flow), as well as, susceptibility difference between heart and lung interface. 
2.5.1 Biophysics of BOLD Contrast 
  As BOLD contrast is originated from susceptibility changes of the red blood cells, susceptibility 
sensitive (T2*-based) sequences are the most straightforward choices for BOLD imaging (56).  
Although T2* yield high sensitivity against blood oxygenation level, it is also sensitive to bulk 
susceptibility artifacts (57), field inhomogeneity, and frequency shift from off resonance spins. 
These shortcomings are particularly prominent in the heart due to the heart-lung interface at high 
field scanners. The effects significantly reduce the intra- and inter-subject reproducibility and 
reliability of T2*-based sequences. T2-based imaging is also sensitive to susceptibility variations 
as described in the previous sections. Because of the refocusing property, T2 is less sensitive to 
the slow varying field variation generated from large vessels. Although this effect sacrifices the 
BOLD sensitivity and make T2
  less sensitive to blood oxygenation compare to T2*, it also makes 
the T2
 contrast more specific to the oxygenation level of the capillary blood and microcirculation 
(Fig.2.7) (58). 
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Fig.2.9 T2(SE) and T2*(GE) BOLD sensitivity against vessel radius. T2 signal peaks for 
microvessels(5m) and 2*signal peaks for macrovessels. Although T2* signal exceeds T2 signal at 
all radii, the targeted sensitivity for the capillary vessels makes T2 more physiological relevant to 
myocardial ischemic testing. Adopted from (58)  
This effect makes T2 more physiologically relevant to ischemic testing, especially because ~90% 
of the blood in the myocardium is in the capillaries.  In addition, T2 is also less sensitive to 
confounders such as temperature, and bulk field inhomogeneity, which makes it more reliable in 
the challenging cardiac enviroment (59).  
More recently, a new approach utilizing the T2-based contrast with balanced steady state signal 
free precession (bSSFP) was proposed to generate cardiac phase resolved BOLD images (60). 
Fine parameter selection of bSSFP sequence can increase T2 contrast in the signal and create 
BOLD sensitivity. bSSFP sequences also provide a better tolerance to the inhomogeneous main 
magnetic field compared to T2* images. However, strong bulk shift in B0 in the myocardium, 
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which is not uncommon in high field scanners, can still lead to imaging artifacts and degrade 
image reliability.  
2.5.2 Main Magnetic Field Strength 
BOLD sensitivity is highly correlated with the field strength (B0) because the field perturbation 
generated from paramagnetic hemoglobin (B=B0) increases proportionally with the B0 (61).  
The effect increases BOLD sensitivity in the high field scanners and is prominent in both T2* 
and T2 BOLD contrasts(61,62) .  
 
 
Fig 2.10 Simulated T2 signal with different blood oxygenation level under 1.5T and 3T.  Larger BOLD 
response is observed under 3T compare to 1.5T. adopted from (62) 
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However, the increased susceptibility difference also magnifies the imaging artifacts caused by 
tissue-air interface and main field inhomogeneity. T2-based images, benefiting from the spin 
refocusing process, yield (20) more robust against to the off resonance spins compared to the T2* 
sequences, which makes T2 BOLD imaging more robust at higher magnetic fields. Moreover, in 
addition to the susceptibility disturbance, the higher field strength also influences the B1 field 
homogeneity and T1 of the tissue, which can induce additional confounders complicating the 
interpretation of BOLD signal changes.(20) 
2.5.3 Quantitative BOLD  
Given the image quality, fast image acquisition and short breath-hold duration (31,63), T2 
weighted- images, such as T2-prepared bSSFP and T2-prepared GRE, have become popular 
among the choice of myocardial BOLD approaches that are available (20,64-67).  Although the 
studies showed promising results in detecting CAD, confounders and imaging artifacts still limit 
the reliability and clinical applicability of the techniques, especially at 3T. Confounders, such as 
coil sensitivity, heart rate dependency and T1 contamination, from the weighted images can 
disturb the limited BOLD signal changes and diminish the acquisition reliability and accuracy. In 
contrast, quantitative T2 mapping can eliminate the confounders by acquiring absolute T2 
values. Despite the advantages the current T2 mapping approaches offer, they are mostly limited 
by imaging speed, resolution, coverage and accuracy. Further technical advances and systematic 
evaluation are needed to enable robust clinical imaging. 
2.5.4 Physiological Consequences of Vasodilatory Stress and its Relevance to BOLD CMR 
Imaging under peak vasodilatory stress is particularly challenging for cardiac BOLD MR. 
Although FPP MRI is capable of acquiring single-shot images under cardiac stress using parallel 
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imaging and other acceleration methods, the use of gadolinium contrast ensures high CNR.  In 
contrary, BOLD CMR has limited CNR, cannot easily adopt image acceleration strategies and 
thus requires long acquisitions. The current stress methods and protocols are mostly designed for 
the conventional imaging modalities, which can be problematic when applied to BOLD CMR for 
the following reasons:  
 Elevated oxygen consumption and unpredictable cardiac activity during imaging 
acquisition. 
Certain inotropic vasodilators, such as dobutamine, increase oxygen consumption with elevated 
myocardial contractility under vasodilation, which can degrade blood oxygenation changes and 
diminish the myocardial BOLD response.  Chonotropic vasodilators, such as dyprimadole, 
adenosine and regadenoson, although ensure that myocardial oxygen consumption stays 
unchanged, are often accompanied by physiological modulations particularly at the initial phase 
of the stress (irregular cardiac motion, rapidly changing heart rate during acquisition, 
significantly shorter quiescent period available for data acquisition). These effects lead to motion 
artifacts and confound image contrast both of which can mask the BOLD response from the 
stress images.   In addition, BOLD signal is also sensitive to the acquired cardiac phase 
(68)because of the differences in blood volume between systolic and diastolic states. Unstable 
cardiac activity often leads to cardiac phase mismatch between rest and stress images, which 
limit accurate estimation of BOLD response between rest and stress.  
 2D methods with multiple breath holds induce patient discomfort, slice mismatch and 
through-plane motion. 
Majority of the current BOLD imaging sequences are 2D sequence that requires multiple breath 
holds. However, performing multiple breath holds under vasodilating stress condition is 
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challenging especially for patients with CAD. The physiological response during stress can also 
aggravate irregular breathing and cardiac motion, which can induce slice mismatch and through-
plane motion in 2D acquisitions. These effects can cause regional signal variations and reduce 
the reliability of BOLD exams. 
 Restricted duration for imaging during vasodilator stress. 
Given the inherently lower CNR, BOLD imaging is more susceptible to noise and imaging 
artifacts. Since peak vasodilation is typically restricted to within 4 minutes, current BOLD 
approaches are not suitable for acquiring images at sufficient spatial resolution and spatial 
coverage with desireable SNR. In addition, unlike other perfusion imaging modalities, BOLD 
CMR does not require monitoring the temporal dynamics of contrast agents to derive arterial 
input function. The intrinsic contrast of deoxygenated hemoglobin, provides a unique 
opportunity to perform multiple acquisitions and achieve more reliable results. However, the 
short acquisition windows from the conventional stress methods only utilize images at single 
time point and makes cardiac BOLD imaging vulnerable for failure. 
A stress method that is tailored for BOLD CMR can significantly improve the imaging 
reliability, applicability and safety for the BOLD ischemic exam and benefit patients by realizing 
a truly noninvasive, non-contrast, ionizing radiation free, rendering it highlight desirable because 
it is reliable and safe for one or multiple ischemia testing.   
    This dissertation aims to overcome the current limitations in cardiac BOLD MRI so that it can 
become a reliable diagnostic method in the characterization of ischemic heart disease.  
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3  Chapter 3  Technical Development for BOLD CMR 
3.1  Fast, Free-Breathing, 3D Whole-Heart T2 Mapping at 3T with 
Application of Myocardial Edema Imaging in Acute Myocardial 
Infarction. 
3.1.1 INTRODUCTION 
Over the past decade, T2-based cardiac MRI has evolved as an important tool for characterizing 
myocardial tissue. To date, numerous clinical and preclinical studies have shown that 
hyperintensity in T2 cardiac MRI is associated with myocardial edema, which can be used to 
stage myocardial infarction (69), detect myocarditis (70), acute ischemia (71) and early 
transplant rejection (72). Conversely, hypointensity in T2 MRI has been instrumental in 
examining intramyocardial hemorrhage (73), chronic iron overloading from ferritin 
cardiomyopathies (74) (75) and Blood-Oxygen-Level-Dependent (BOLD) MRI (31) (76). 
Early approaches typically relied on T2-weighted imaging (T2-STIR(69), T2-prep-SSFP (63,77), 
etc.), but these approaches have well recognized image artifacts from motion, stagnant/slow 
moving blood and coil bias (78). As T2 mapping techniques with high SNR readouts have 
overcome many of the limitations (71,79,80) and an interest in quantitative tissue 
characterization became viable and of clinical interest, T2 mapping has become the preferred 
means for examining myocardial T2 changes. (81,82). Nonetheless, to date, T2 mapping is 
typically prescribed as 2D breath-held acquisitions to cover the full left ventricle (LV), which 
takes approximately 10-15 minutes. While respiratory navigator-gated approaches have 
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overcome the discomfort associated with multiple breath holds, the concomitant reduction in 
scanning efficiency has been a limitation in decreasing the overall scan time to below 10 min 
(83,84).  
In practice, long acquisition time and multiple breath holds impose significant limitations where 
whole-heart T2 mapping could be of great value. For instance, in cases where myocardial edema 
may serve as a marker of acute ischemia in the management of chest pain in the emergency 
department (85,86), target patients find it difficult to tolerate multiple breath holds and long 
acquisition times within the scanner. Moreover, in cases where contrast-agent free cardiac stress 
testing with myocardial BOLD MRI may be valuable, long acquisition times (> 6minuts) do not 
permit whole heart T2 mapping within the standard duration of adenosine infusion (87). The 
growing interest in T2-based cardiac MRI for both of these applications could potentially be 
empowered by a fast, free-breathing T2 mapping strategy.    
Moreover, most T2 mapping approaches are limited to 1.5T and prescribed with balanced steady-
state free precession (bSSFP). Their robustness to image artifacts at 3.0T (banding, B1 
inhomogeneity, etc) continues to be problematic (88). A more pragmatic cardiac T2 mapping 
approach should be time efficient (preferably < 6minutes) to accommodate cardiac stress testing 
with BOLD MRI; enable rapid edema assessment in a clinical environment without suspending 
breathing; and should enable reliable acquisitions at 3T with minimal or no image artifacts, while 
providing full LV coverage. A T2 mapping technique that conforms to these desirable attributes 
could enhance rapid assimilation of T2 imaging as part of time-sensitive and time-efficient 
clinical cardiac MRI protocols. 
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We hypothesized that a robust, time-efficient, 3D free-breathing T2 mapping technique at 3.0T 
can be obtained through the combined use of (a) adiabatic RF pulses for B1 insensitive T2 
preparation; (b) near 100% efficient navigator gating with affine motion correction to maximize 
efficiency of acquisition under free-breathing; and (c) stack-of-stars gradient-echo (GRE) 
readouts to eliminate banding artifacts associated with bSSFP readouts, without significant loss 
of SNR. We validated our approach in ex-vivo canine hearts and kidneys, in healthy human 
volunteers, and in canines subjected to reperfused acute myocardial infarction.    
3.1.2 METHODS 
Pulse sequence details and data acquisition, motion estimation and correction, and parameter 
estimation and heart rate corrections pertaining to the proposed imaging approach are described. 
The motion registration program was written in C using the Insight Toolkit. Image reconstruction 
and parameter fitting were performed offline using MATLAB (Mathworks, R2009a, MA, USA). 
All studies were performed on a 3.0 T clinical MRI system (MAGNETOM Verio®, Siemens 
Healthcare, Erlangen, Germany) and 32 channel matrix coils (16 anterior and 16 posterior) were 
used for data acquisition.  
3.1.2.1 Pulse Sequence Details and Data Acquisition 
A T2 prepared GRE sequence was adapted for 3D T2 mapping at 3.0 T. To minimize image 
artifacts from increased B0 and B1 inhomogeneities at 3T (89) and cardiac motion, an adiabatic 
T2 preparation (2x BIREF-1) (90) was used. A schematic of the timing diagram is shown in Fig. 
3.1 and imaging parameters for each experiment are described in the following section.  Images 
were acquired every other heart beat for longitudinal magnetization recovery.  
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Fig. 3.1 Pulse sequence timing diagram 
For the GRE readout, we used a stack of slices (along the long axis of the heart) with 144 evenly 
distributed radial lines to cover the 3D field of view. In each acquisition window (heart beat), a 
subset of 2-3 in-plane lines from all slices was acquired depending on the length of the quiescent 
period. In each subset, k-space lines were acquired in a slice-by-slice fashion. Centric reordering 
along the long axis of the heart was used to minimize T1 recovery following T2 preparation and 
the in-plane radial trajectory was ordered in an interleaved fashion to reduce the possibility of 
unevenly distributed data in each bin (details on bins below). For example, in a case where two 
in-plane radial lines A and B are acquired in each subset (A, B), the identity of the pair of radial 
lines conform to the sequence {(i, i+72)}, where i=1,72 and i is an integer.  A representative 
acquisition scheme with 5 slices and 2 in-plane lines per heartbeat is shown in Fig. 3.1. GRE 
readout was trigged at the mid diastolic phase with appropriate trigger delay. A respiratory 
navigator signal at the lung-liver interface was continually acquired during the free breathing 
acquisitions without rejecting any data (91). The navigator module was played out before T2 
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preparation to (a) avoid potential errors in binning from T2 weighting of navigator signals at the 
different TEs; and (b) preserve the T2 weighting by minimizing T1 recovery prior to signal 
readout. In order to derive T2 maps, the sequence was prescribed with three different T2 
preparation times (TE = 0, 24 and 55 ms).  
3.1.2.2 Motion Estimation and Correction  
Motion correction with 3D affine transforms, derived from the respiratory navigator signals, has 
been shown to reliably correct respiration-mediated motion of the heart (92,93). To maximize 
imaging efficiency (i.e., utilize all the data acquired during free breathing) the following steps 
were applied for motion-corrected T2 mapping:  
Motion Estimation: 
Binning: k-space lines were sorted into 4 bins based on the diaphragm position in which the end 
expiratory bin was assigned as the reference and the others were labeled as the target bins.  
Data composition and respiratory phase-resolved image reconstruction: To reduce streaking 
artifact from undersampling of k-space, composite images were reconstructed by combining the 
data from all three TEs (within the same respiratory bin) followed by Gaussian smoothing. 
Representative images acquired at the different TEs for one of the respiratory bins and the effect 
of combining the images across the different TEs within the same bin are shown in Fig. 3.2A.  
Motion Registration: A contour isolating the heart from rest of the anatomy was drawn manually 
using the 3D image set from the reference bin. The contours were then converted into a mask and 
applied to images in all respiratory bins. Processed 3D images from each target bin were 
iteratively registered to the reference bin using Insight Tool Kit (ww.itk.org) (94). Affine 
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transform matrices of each target bin were generated and stored for motion correction. Details of 
the registration process were previously described by Bhat et al (92).  
Motion Correction and Image Reconstruction: k-space data in each respiratory bin were sorted 
back into independent TEs. After gridding, affine transform matrices were applied to the 
corresponding images in each respiratory bin and motion-corrected images were reconstructed 
independently for each TE by combining complex images from all bins. Motion estimation, 
correction and image reconstruction steps are summarized in Fig. 3.2B. 
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Fig. 3.2 Image reconstruction steps. Panel A shows a representative case of combining undersampled 
low-resolution images from a common respiratory phase from different TEs to arrive at composite data 
sets for each bin. This is shown for Bin 3 here. Similar steps are taken to arrive at data for Bins 1, 2 and 
reference bin (Ref Bin, end expiratory phase). Panel B shows the steps associated with motion correction 
(binning based on navigator signal, estimation of motion and image reconstruction) and parameter 
fitting. In essence, the k-space data is first combined with different TEs and separated into different 
respiratory bins based on the navigator signal. From each bin, a low-resolution composite image 
 40 
representing different respiratory position was reconstructed. On the basis of the reference bin, the affine 
motion parameters of all other bins (target bins) were estimated with ITK and stored for motion 
correction. Finally, k-space data with different T2 preparations were gridded independently and applied 
with corresponding affine transformation to yield motion-corrected images. Subsequently the pixel-wise 
fitting is performed using the images at different TEs to estimate T2. 
 
 
3.1.2.3 Parameter Fitting and Heart Rate Correction 
Pixel-wise fitting of signal intensities at the 3 TEs to a exp(-b/TE) were performed with log-
transformed linear least-squares fit , where a and b are fit parameters with a= M0 (which includes 
proton density, coil sensitivity etc.) and b = 1/T2. After the fitting for T2, a heart rate correction 
was applied to compensate for imperfect T1 recovery between magnetization preparations. To 
estimate true T2, the T2 estimates from mono-exponential fit (T2
†) were multiplied by (1 + α) 
(Refer to the heart rate correction derivation).  was estimated from known values of T1 (1100 
ms) and T2 (40 ms) of myocardium, data acquisition in every other heart beat, and ∆TE =
27.5 ms (the midpoint of TEs). Subsequently, heart rate corrected T2 was calculated as T2
† ∙
(1 + α). If we estimate  assuming T2 = 40 ms and T1 = 1200 ms at 3T, then the estimated 
errors in  and the corresponding T2 would be 0.08 ms and 3.2 ms (in cases of significant edema 
when the actual T2 = 60 ms and T1 = 1400 ms) (83,95).  
Heart Rate Correction Derivation 
In the centric encoding scheme, the longitudinal magnetization immediately following T2 
preparation of each heart beat can be written iteratively as 
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MT2+ = (M0 + (MT2− − M0)E1) E2TE ,      (1) 
where MT2+ and MT2- are longitudinal magnetizations following the T2 preparations in the recent 
(MT2+) and previous (MT2-) heart beats, M0 is magnetization at thermal equilibrium, E1=exp(- 
RT/T1) with RT = recovery time, and E2TE= exp(-TE/T2). Assuming heart rate is constant 
throughout the acquisition, MT2 term will reach a steady state after a few heart beats (i.e. MT2+ =
MT2− =  MT2) and (1) can be rearranged to get 
MT2 =
E2TEM0(1 − E1) 
(1 − E1E2TE)
    (2) 
and the acquired signal can be expressed as 
STE = GMT2  (3) 
G accounts for readout scheme, coil sensitivity, etc. 
When RT >> T1, E1 ~ 0, R2 (or 1/T2) can be derived with 2 measurements with different TEs 
using 
log (
STE1
STE2
) = ∆TE R2, (4)  
where ∆TE = TE1 − TE2. However when RT is comparable to T1, E1 is not negligible and (2) 
has to be rewritten as 
log (
STE1
STE2
) = ∆TE ∙ R2
†  ,   (5) 
where R2
† = R2(1 + α) , with α =
log (
1 − E1E2TE2
1 − E1E2TE1
)
R2∆TE
   (6) 
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STE1, STE2 are Image intensities corresponding to the first and second TE and αR2 is the bias in 
R2 estimated from fitting to a mono-exponential under the assumption of perfect T1 recovery 
(R2
†
). Hence the appropriate correction factor to estimate true T2 is (1 + α); that is T2 = T2
† (1 +
α), where T2
† is 1/R2
†  .  
 
3.1.2.4 Validation Studies 
Ex-vivo Studies 
Three freshly excised canine hearts and kidneys were immersed in saline solution and imaged 
with the proposed method, 2D spin-echo and 2D T2-prepared bSSFP sequences (with the same 
adiabatic T2 preparation as in the proposed method) to assess T2 accuracy. Proposed 3D sequence 
was prescribed covering the whole organ and 2D sequences were prescribed to match 3 separated 
partitions in the organs. Sequences were randomized with regard to order. Imaging parameters of 
the different sequences were as follows: 
2D spin echo - TR = 5000 ms, TE = 6, 24, 58 ms, readout bandwidth (BW) = 300Hz/pixel and 
voxel size = 2.0 x 2.0 x 6.0 mm3 interpolated to 1.0 x 1.0 x 3.0 mm3.  
Proposed 3D T2 map - GRE readout with stack-of-stars trajectory, TR/TE = 3.4 ms/1.7 ms, flip 
angle (FA) = 15°, BW = 694 Hz/ pixel, 40 lines per heartbeat (simulated heart rate=60 
beats/min), trigger pulse = 2, total projections = 144/slice, field-of-view (FOV) = 380x380 mm2, 
matrix size =192x192x16, and voxel size = 2.0 x 2.0 x 6.0 mm3 interpolated to 1.0 x 1.0 x 3.0 
mm3, T2 preparation (as TEs) = 0, 24, 55ms. Gaussian apodization was used to increase SNR 
(96) .  
 43 
2D T2 maps with bSSFP readouts with Cartesian trajectory - TR/TE = 2.9 ms/1.1 ms, iPAT=2, 
partial Fourier = 3/4, FA = 35°, BW = 1184 Hz/ pixel, 86 lines per heartbeat (simulated rate 
60/s), trigger pulse = 4, FOV = 288x360 mm2, matrix size =154x192, and voxel size = 2.5 x 1.7 
x 6.0 mm3, T2 preparation (as TEs) = 0, 24, 55ms.  
 
3.1.2.5 Healthy Volunteer Studies 
Healthy volunteers (n=10, 3 men, average age 30± 5) were recruited in accordance with the 
protocol that was reviewed and approved by the Institutional Review Board. Every participant 
was competent and provided written informed consent and had no history of coronary artery 
disease, abnormal cardiac rhythm and rate, kidney/liver disease, and were not contraindicated for 
cardiac MR exams (completed a detailed cardiac MRI questionnaire). All studies were 
performed on the same clinical MRI system used for ex vivo studies with subjects placed on the 
supine position. After whole heart shimming and localization, proposed free-breathing 3D T2-
prepared acquisitions were prescribed with whole LV coverage using 25% slice over-sampling 
and 32-48 radial lines per heartbeat triggered at approximately mid-diastole within a data 
acquisition window of 110-160 ms. A four-chamber cine scan was used to determine the 
quiescent period of the cardiac cycle. Navigator pulses were placed on the dome of the right 
hemidiaphragm. The data was reconstructed as described earlier to generate T2 maps. For 
comparison purposes, images were also reconstructed without motion correction. Also, the 
standard 2D breath-held T2-prepared bSSFP acquisitions were prescribed along representative 
short-axis slices that were matched to three slices centered at the level of mid ventricle within the 
3D partitions. Imaging parameters and T2-preparation schemes were the same as those used for 
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ex-vivo imaging. To minimize bias with respect to acquisition order, the acquisitions were 
randomized.  
3.1.2.6 Canine Model of Acute Myocardial Infarction 
Dogs (n= 10, 18–26 kg) were studied according to the protocols approved by the Institutional 
Animal Care and Use Committee. Animals were anesthetized, intubated and mechanically 
ventilated with 100% O2 mixed with isoflurane (1.0-2.5%). Subsequently, the dogs underwent 
left thoracotomies and the left anterior descending artery was ligated at 1.0–1.5 cm from the 
bifurcation of the left main coronary artery for 3 hours followed by reperfusion. The dogs were 
allowed to recover for 4 days before imaging studies. 
Prior to imaging, animals were fasted, sedated, anesthetized, intubated, and transferred to the 
scanner table and were mechanically ventilated via a pneumatic anesthesia ventilator. 
Subsequently, they were placed on the scanner table in the feet-first right-lateral position. The 
imaging protocol (localizations, cardiac shimming, and T2-weighted acquisitions) and the scan 
parameters of proposed free-breathing 3D T2-prepared acquisitions were the same as those used 
for the human studies except for the FOV, number of slices acquired, and acquisition window 
(95-140 ms) reduced to adjust for differences in cardiac dimension and heart rate. 2D breath-held 
T2-prepared bSSFP acquisitions and phase-sensitive inversion recovery (PSIR) late-gadolinium-
enhancement (LGE) acquisitions were prescribed with full left ventricle coverage comprising 
slices matched to the 3D partitions. PSIR LGE images were acquired 10 minutes after Gd-DTPA 
infusion (0.2 mmol/kg, gadoversetamide/Optimark, Mallinckrodt Inc., Hazelwood, MO), using 
non-selective inversion recovery preparation with GRE readout (TR/TE = 3.2/1.5 ms, FA = 20°, 
BW = 586 Hz/pixel, matrix = 96 × 192, in-plane resolution = 1.3 × 1.3 mm2; and slice thickness 
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= 6.0 mm). A TI-scout sequence was used to find the optimal TI for nulling the healthy 
myocardium (240–270 ms). 
3.1.2.7 Image Analysis and Statistics 
All reconstructed T2 maps were analyzed in cvi
42 (Circle Cardiovascular Imaging Inc., Calgary, 
AB, Canada). Images were imported into cvi42 and endo- and epi-cardial contours were drawn to 
segment the myocardium for further T2 analysis. In addition, all statistical analyses were 
performed in IBM SPSS (V21.0, NY, USA). 
Ex vivo Studies:  
After segmenting the myocardium and parenchyma of the kidney, mean T2 values of the organs 
determined from images acquired using 2D spin echo, 2D T2-prepared bSSFP and 3D T2-
prepared (proposed) sequences were compared. Repeated measurements ANOVA tests were 
performed to examine whether the T2 values were different between different sequences. Post-
hoc comparison with Bonferroni correction was used if the null hypothesis was rejected. 
Human Studies:   
The mean and coefficient-of-variation (COV) of myocardial T2, as well as overall image quality 
scores of the T2 maps generated using images from the (i) proposed 3D sequence with motion 
correction (3D FB MoCo), (ii) proposed 3D sequence without motion correction (3D FB Non-
MoCo, using all respiratory phases), and (iii) 2D breath-held sequence (2D BH) were measured. 
Two independent, experienced observers who were blinded to the acquisition details evaluated 
image quality. All image quality assessments were based on the T2 maps. Mean myocardial T2 
values were measured from the segmented myocardium and the COV of T2 was calculated as the 
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quotient of the mean T2 and the corresponding standard deviation. Image quality was graded as 
1, poor (non assessable); 2, fair (mild to moderate artifacts); 3, good (minimal to mild artifacts); 
4, excellent (minimal or no artifacts). Repeated measurements ANOVA tests (mean T2 and COV 
in T2) and Friedman test (image quality scores) were performed to examine whether the 
measures were different between the three techniques. Post-hoc comparison with Bonferroni 
correction was used if the null hypothesis was rejected. 
Canine Studies:  
Following segmentation of the myocardium (as described earlier), remote myocardium was 
defined as the region showing no hyperintensity on LGE images. A reference region of interest 
was drawn in remote myocardium on both LGE images and copied onto the corresponding slice 
positions of 2D and 3D T2 maps. Affected myocardium was defined as the hyperintense region 
with mean signal intensity at least 2 standard deviations (SDs) above that of the reference region 
of interest on both 2D and 3D T2 maps (79).  Only LGE positive imaging slices were included in 
the analysis. Regression analysis was performed between slice-matched 2D and 3D acquisitions 
for (a) mean T2 values of remote and affected (edematous) myocardium; and (b) % edema 
volume, defined as the relative volume of affected myocardium to the total volume of the 
myocardium on a per-slice basis, for all animals. Bland-Altman analysis was performed to 
examine the limits of agreement and bias in mean T2 and % edema volume between the proposed 
3D approach and the 2D approach. 
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3.1.3 RESULTS 
3.1.3.1 Ex vivo Studies  
Representative T2 maps obtained using 2D spin-echo and T2-prep bSSFP acquisitions along with 
the proposed 3D acquisition (matched to the 2D slice) are shown in Fig. 3.3A. Mean T2 values 
derived from each sequences are shown in Fig. 3.3B (2D spin-echo T2 = 40.8±2.4 ms (heart), 
52.4±0.5 ms (kidney) ms; 2D T2-prep bSSFP T2 = 42.4±1.6 (heart), 52.9±1.1 (kidney) ms; and 
proposed 3D sequence T2 = 40.2±2.5 (Heart), 51.3±0.7 (kidney) ms). Relative to the “gold 
standard” T2 values (2D spin-echo), T2 values obtained with 2D T2-prep bSSFP and 3D T2-prep 
GRE were not different (p = 0.7 and p=0.2, respectively).  
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Fig. 3.3 Representative short-axis T2 maps and box-plot of mean myocardial T2 from explanted pig hearts 
obtained with 2D spin echo, 2D T2-prep SSFP and 3D T2-prep GRE acquisitions. (A)Slice-matched T2 
maps obtained at the level of mid ventricle from an explanted pig heart using the different T2 approaches 
are shown. Mean T2 values (B) between the approaches were not different.    
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3.1.3.2 Healthy Volunteers 
Figure 3.4 shows representative slice-matched T2-weighted images (Fig. 3.4A) and T2 maps (Fig. 
3.4B) obtained using 3D FB MoCo, 3D FB Non-MoCo, and 2D BH approaches. 2D BH and 3D 
FB MoCo images at the different TEs appeared to have comparable image quality, while image 
blurring from respiratory motion was evident in 3D FB Non-MoCo images and maps (arrows).  
 
Fig. 3.4 Representative short-axis images and T2 maps acquired from a healthy volunteer using 2D BH, 
3D FB MoCo and 3D FB Non-MoCo approaches. T2 maps reconstructed using weighted images from the 
different TEs at the basal, mid ventricle (Mid) and apical sections are shown. Note the loss of detail and 
variation in signal intensity in 3D FB Non-MoCo images (arrows), which is absent in 3D FB MoCo and 
2D BH T2 maps.  
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Quantitative measures of agreement between the methods are shown in Fig. 3.5 and collected in 
Table 1. 3D FB Non-MoCo showed significantly greater COV (p<0.05), longer T2 values 
(p<0.05), and lower IQ (p<0.05) compared to 3D FB MoCo and 2D BH images and maps. 
Conversely, 2D BH and 3D FB MoCo approaches did not show differences in mean T2 (p=0.99), 
COV T2 (p=0.74), and IQ (p=0.14).  
Fig. 3.5 Quantitative measures of mean T2 (A), COV T2 (B) and Image Quality scores (C) between 2D 
BH, 3D FB MoCo and 3D FB Non-MoCo approaches obtained from healthy volunteers. Across all 
measures, 2D BH and 3D FB MoCo approaches were not different but both were significantly different (* 
represents p<0.05) from 3D FB Non-MoCo approach. 
3.1.3.3 Canines with Reperfused Acute Myocardial Infarction 
Representative slice-matched images (Fig. 3.6A) and T2-maps (Fig. 3.6B) obtained with the 
proposed 3D FB MoCo and 2D BH obtained on day 4 post-MI are shown. Corresponding LGE 
images are also shown for visual confirmation for the presence of infarction in the LAD territory. 
Edema (and infarction) was identified in 2-4 short-axis slices in each of the animals. Close 
correspondence between edematous territories in the slice-matched 2D BH and 3D FB T2 maps, 
and the enhanced territories in LGE images was observed. T2 values were significantly elevated 
in regions positive for LGE in both 2D BH and 3D FB T2 maps. Linear regression analysis 
showed that the T2 estimates (edematous and remote territories) and the % edema volume 
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measured from 2D BH and 3D FB MoCo T2 maps were closely correlated (R
2 = 0.88,and 0.96, 
respectively. Both p<0.05). Bland-Altman plots of mean T2 measures from edematous territories 
and remote myocardium and % Edema Volume were within the limits of agreement (bias in T2 = 
0.4 ms; bias in % Edema Volume = 0.9%). The edema and LGE positive territories (on per slices 
basis) agreed well (R2 = 0.8, p<0.05) with the edema volume have a positive bias of 8% over 
LGE volume.  
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Fig. 3.6 Representative short-axis images obtained from a canine on day 4 post-MI and the statistical 
relations between 2D BH and 3D MoCo for T2 and Edema volume across all animals.  (A) Slice-matched 
T2 maps from 2D BH and 3D FB MoCo, as well as LGE images obtained from a canine at the basal, mid 
ventricle (Mid) and apical sections are shown. Note the close correspondence between hyperintense 
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regions identified on 2D BH and 3D FB MoCo T2 maps (black arrows) and their relation to hyperintense 
regions in LGE images (yellow arrows). Also note that the 2D BH images are blurrier due to cardiac 
motion (due to single-shot acquisitions in the presence of high heart rates in canines with recent 
infarction), which is not the case with the proposed approach. (B) Linear regression analysis between T2 
values (edematous territories and remote myocardium) of slice-matched 3D FB MoCo and 2D BH 
acquisitions and the corresponding Bland-Altman analysis are shown in panels B and C, respectively. 
Linear regression: y = 0.9 x – 3.4, where y = T2 from 3D FB MoCo and x = T2 from 2D BH acquisitions, 
with R2 = 0.88, p<0.05. Linear regression analysis between slice-matched 3D FB MoCo and 2D BH 
acquisitions for Edema volume and the corresponding Bland-Altman analysis are shown in panels D and 
E, respectively. Linear regression: y1 = 1.1 x1 -2.4, where y1 = Edema volume from 3D FB MoCo and x1 
= Edema volume from 2D BH acquisitions, with R2 = 0.96, p<0.05. 
3.1.4 DISCUSSION  
In this study we successfully developed and tested a motion-corrected, free-breathing 3D T2 
mapping technique using GRE-based stack-of-stars acquisition at 3T that can be completed 
within 5 minutes. The accuracy of T2 measures from motion-corrected reconstruction was 
examined in ex-vivo canine hearts and kidneys, healthy human volunteers, and controlled canine 
model of acute myocardial infarction, respectively. The results showed that compared to the 
commonly used T2 mapping approach (2D acquisitions with multiple breath holds), the proposed 
3D T2 mapping strategy can reliably estimate T2 values of the myocardium in health and disease. 
The proposed method is expected to be beneficial in patients who cannot tolerate suspension of 
breathing and in cases where the imaging exam needs to be completed with whole heart coverage 
within a short period of time. Hence the key features of the proposed approach (free-breathing, 
full LV coverage coverage and fast acquisitions) are expected to be particularly valuable in the 
management of chest pain in emergency department where myocardial edema may be used as a 
marker of ongoing ischemia (71) and for contrast-free cardiac stress testing using myocardial 
BOLD MRI(31,76) .  
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While the benefits of fast, free-breathing T2 mapping of whole LV over the conventional 
multiple-breath-held T2 mapping are clear, it is useful to contrast the proposed approach against 
previously proposed 3D T2 mapping approaches. While navigator gated methods have shown 
low imaging efficiency and residual motion artifacts, different methods have been proposed to 
correct for respiratory motion and accelerate acquisition(83,97). In particular, the recent 
development by Heeswijk, et al.(97) has markedly reduced acquisition time. However, since 
their T2 mapping approach is founded upon 3D high-resolution isotropic imaging, acquisition 
time continues to be near 20 minutes, which imposes limitations on its use for time sensitive 
applications discussed above.  
In this study we utilized a 3D stack-of-stars sampling scheme for T2 mapping, which lends some 
key benefits. First, at a heart rate of 60 beats/minute, with 48 projections acquired every other 
heartbeat, the total acquisition time for whole LV coverage is less than 5 minutes. Since the 
proposed approach does not restrict one to isotropic resolution, it provides the flexibility to 
control the resolution along the long axis, and hence imaging time, depending on the needs of the 
study. Second, the proposed approach allows for centric encoding, which reduces the T1 
dependency in T2 maps (83). Finally, the proposed T2 mapping strategy offers robust image 
quality at 3T since the proposed approach uses adiabatic T2 preparation combined with GRE 
readouts to overcome image artifacts from B1 and B0 inhomogeneities at 3T. Although bSSFP 
readouts can provide significant signal-to-noise benefits over GRE, previous studies have shown 
insignificant differences in myocardial T2 between the two readout sequences at 1.5T (98). 
Consistent with these studies, in the current study at 3T we observed comparable COV in 
myocardial T2 between bSSFP and GRE readout schemes. Nonetheless both readout schemes 
have their limitations in extreme cases - GRE acquisitions can suffer from lower SNR and have 
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less homogeneous signal in large patients; and bSSFP readouts are prone to unavoidable banding 
artifacts.  
  The T2 values measured under conditions of health in this study were comparable to the 
values previously reported in humans. Specifically, we found that the T2 value of the healthy 
myocardium to be 37.7±2.0 ms vs. 38.5 ± 4.5 ms (83). Similar observations were made in 
animals with acute myocardial infarction as well (T2 in the infarct zone from our study was 
55.2±7.1 ms vs. 58.1 ± 6.9 ms (99) and T2 in remote zone from our study was 36.7±3.5 ms vs. 
41.1 ± 5.2 ms (99) ). These favorable comparisons between our results and those reported in the 
literature further confirm that the proposed technique is a reliable method for measuring 
myocardial T2 under conditions of health and disease.    
Although not explored here, we anticipate that further shortening of scan time may be possible 
using parallel imaging techniques (100,101) and/or compressed sensing (102) schemes. 
However, to avoid potential “smoothing” artifacts observed in certain accelerated approaches 
and also to strictly examine the capability of motion correction, we did not consider any imaging 
acceleration techniques in the current study. Additional studies are necessary to examine the 
limits of imaging acceleration strategies within the constraints of reliable measurements of 
myocardial T2.  
There were some limitations in this study. First, while this study employed ex-vivo and in-vivo 
preparations of animals and healthy volunteers and showed that the proposed 3D approach can 
yield similar values of T2 as 2D breath-held acquisitions, the sample size of the study is limited. 
Additional studies are required to assess the robustness of the method under various 
physiological conditions, particularly in human subjects with disease. Second, based on the 
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mono exponential model, 3 TEs are the minimum requirement for a least-squares linear-
regression fitting of the logarithmically transformed data. To map the T2 of the remote and 
affected myocardium, we set the latest TE to be 55ms, so as to achieve a reasonable dynamic 
range in signal intensities for the affected territory (which tends to have T2~ 60ms) and still have 
sufficient in the remote myocardium (T2 ~ 40 ms). Although additional TEs may improve 
robustness of T2 fits (103), extra acquisition time associated with greater number of TEs can 
extend the study time beyond the demands of the key applications outlined earlier. Based on 
comparable results we obtained here in relation to past work (72,79,80,83,104), we expect that 
three TEs to be a good tradeoff between imaging speed and fidelity of myocardial T2 fits under 
conditions of health and disease. Third, in this study we assumed that the prescribed slice 
positions between 2D and 3D acquisition are the same, which may not be the case. To minimize 
this error, the data in the reference bin was always acquired at end expiration. Also, given that 
2D slice thickness and 3D partitions are similar (6 mm), we anticipate that any contributions 
from potential differences to be small. Moreover, we used only 4 bins to derive and correct for 
respiration-induced motion. Previous studies that employed affine motion correction on the raw 
data (92,105) used 6 bins to estimate respiration-mediated motion for coronary MR angiography. 
Finally, we estimated the correction term ( ) based on known T1 and T2 values of the 
myocardium at 3T in health. Since T1 and T2 of the edematous myocardium can be greater than 
30% and 50% of the normal myocardium (83,95), respectively, it is conceivable that  may not 
be accurately estimated on the basis of healthy myocardial T1 and T2 values. However, our 
calculations showed that even in the presence of significant edema (T1 =1400ms, T2=60ms), the 
estimated error in  determined using healthy T1=1200ms and T2=40ms values is within 8%, 
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which corresponds to a deviation in T2 of 3.2 ms, which is comparable to the standard deviation 
of myocardial T2.  
Nonetheless, the results here suggest that the quality of motion correction based on the empirical 
binning at reduced resolution is adequate for reliable estimation of myocardial T2 values under 
conditions of health and disease.  
3.1.5 CONCLUSION 
We developed and tested a free-breathing 3D T2 mapping approach at 3T with respiratory motion 
correction, which can be performed within 5 minutes. The proposed approach yielded accurate 
estimates of myocardial T2 in explanted canine hearts and kidneys, healthy human volunteers, 
and canines with reperfused acute myocardial infarction. Clinical studies are needed to validate 
the robustness of the proposed approach in patients.  
 
3.2   Fast, Confounder-Corrected, Quantitative BOLD CMR at 3T with 
Simultaneous 13N-Ammonia PET Validation in Canines 
 
3.2.1 INTRODUCTION 
Detection of impaired myocardial perfusion reserve is valuable in the clinical management of 
coronary artery disease (CAD) (106).  While SPECT/PET imaging methods are the established 
standards for determining myocardial perfusion, the requisite need for ionizing radiation with 
these approaches have long instilled a desire for an alternate method that can be performed 
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without subjecting patients suspected of CAD to ionizing radiation. To this end, first-pass 
perfusion methods, particularly comprising of recent technical advances (107), have provided 
compelling evidence that it is possible to evaluate myocardial perfusion without radiotracers. 
However, first-pass perfusion requires gadolinium-based contrast agents, which is 
contraindicated in patients with late-stage chronic kidney disease. Moreover, there is a growing 
concern that GBCA can lead to chronic deposition of gadolinium within the myelin sheaths with 
unknown outcomes even in patients without renal insufficiency. Enabled by nearly two decades 
of technical advancements, growing body of clinical evidence now supports the notion that 
blood-oxygen-level-dependent CMR, a method which can aid in the assessment of myocardial 
perfusion without radiation and exogenous contrast agents, can be used to assess myocardial 
perfusion on the basis of differential changes in oxygen saturation between rest and vasodilator 
stress (18-20,76,108). Nonetheless further refinements of the BOLD CMR approach are 
necessary as the currently available variants are limited by (a) limited imaging speed and 
coverage to accommodate the stress protocols; (b) loss in BOLD sensitivity due to imaging 
confounders (T1 weighing, coil bias and heart rate dependency); (c) patient discomfort and 
inaccurate slice match between rest and stress from 2D acquisitions requiring multiple breath 
holds; and/or (d) imaging artifacts (cardiac and respiratory motion; B0 and B1 field 
inhomogeneity) particularly at 3T, where the myocardial BOLD sensitivity has been shown to be 
superior to that at 1.5T. These limitations can compromise diagnostic sensitivity of BOLD CMR 
resulting in inaccurate interpretation of myocardial perfusion between rest and stress.   
 To address these limitations, we developed a heart-rate independent, free-breathing 3D 
T2 mapping technique at 3T, which can be acquired with marked insensitivity to B0 and B1 
inhomogeneities, along with near perfect imaging efficiency, to facilitate imaging coverage of 
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whole LV within 4 minutes. The proposed BOLD CMR approach was developed, tested and 
validated through computer simulations, ex-vivo studies, and in-vivo studies in canines with and 
without coronary stenosis with simultaneous acquisition of BOLD CMR and 13N-ammonia PET 
in a clinical hybrid PET/MR system. A feasibility study was also performed to evaluate the 
capability of the proposed approach for examining myocardial BOLD response throughout the 
whole LV within the clinically accepted window of adenosine vasodilator stress in healthy 
human volunteers.  
 
3.2.2 METHODS 
All ex-vivo and in-vivo imaging studies in canines were performed in a whole-body PET/MR 
system (Biograph mMR, Siemens Healthcare, Erlangen, Germany). Human studies were 
performed in a 3T MRI system (Verio, Siemens Healthcare, Erlangen, Germany), which has 
similar MR imaging capabilities as the PET/MR system. 
3.2.2.1 CMR Pulse Sequence Design and Motion-Corrected T2 Mapping with Near-Perfect 
Imaging Efficiency 
An ECG-gated, heart-rate independent, free-breathing, 3D T2 mapping approach with whole-
heart LV coverage, which minimizes the sensitivity to B0 and B1 inhomogeneities was 
implemented the PET/MR system. Adiabatic T2 preparation with spoiled gradient-echo (GRE) 
readout was used to minimize B0 and B1 artifacts, which are otherwise prominent at 3T(83). To 
improve imaging efficiency and enable data acquisition under free-breathing conditions, a 
motion correction platform with a hybrid Cartesian-radial trajectory was applied(109) that 
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permits near perfect imaging efficiency was used.  To further increase acquisition speed and 
minimize the signal dependence on heart rate between rest and stress, a Saturation Recovery 
(SR) preparation was integrated with a constant saturation recovery time (TSR) time to reset 
longitudinal magnetization every heartbeat (110). To minimize any potential confounding effects 
associated with differences in T1 recovery following T2 preparation under rest and stress (111), 
data was collected and centrically encoded in the through-plane direction. Images were acquired 
with 3 incremental T2-prepation times (TE=0, 24, 55ms) and T2 maps were reconstructed using 
a custom-written Matlab (The Mathworks, Natick, Massachusetts) script. Sequence diagram and 
reconstruction flowchart are shown in Figure 3.7. 
 
Fig. 3.7: Heart-Rate Independent 3D T2 Mapping Based BOLD CMR: Timing diagram, data acquisition 
and motion-corrected image reconstruction.  The timing diagram and data encoding strategy are 
illustrated in Panels A and B. In Panel A, a standard T2 preparation scheme was replaced with a T2 
preparation scheme composed of composite adiabatic RF pulses and spoiled gradient echo readout (in 
place of the typical balanced steady-state free precession readout) to minimize B1 and B0 artifacts at 3T. 
A SR preparation was added to eliminate the signal dependence on heart rate between segmented 
readouts and navigator pulses were added to monitor the respiratory motion during acquisition. Panel B 
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shows the centric encoding scheme with hybrid trajectory, to ensure optimal T2 weighting. The sequence 
was designed to permit T2 mapping with 3 different T2 preparation times for T2 fitting. Panel C shows 
the motion correction algorithm used (109). Raw data with different T2 weightings are first combined and 
binned based on the navigator signal to generate anatomical images from different respiratory phases. 
The respiratory motion is estimated from the anatomical images and applied to the raw data to 
reconstruct motion-corrected T2 maps using a log-transformed linear least-squares fit as previously 
described used (109).  
  Raw data acquired during free breathing was separated into 4 respiratory bins with the 
navigator signal to estimate respiratory motion. Data acquired from all TEs (in each bin) was 
combined to generate composite anatomical images and reduce the streaking artifact from under-
sampling. Corresponding affine transform parameters from each respiratory bin were estimated 
using iterative registration of the composite images. These motion estimates were applied to data 
in each bin and motion-corrected images were reconstructed with different TEs. The signal 
intensities from the images were fitted pixel-wise to a mono-exponential model to derive motion 
corrected T2 values. The proposed sequence is designed to acquire a 2x2x6 mm3 3D whole heart 
images under 4 minutes.    
Computer Simulations and Ex-vivo study 
Computer simulations employing Bloch equations (112), with parameters corresponding to 
commercially available 2D T2 mapping sequence and the proposed 3D T2 mapping approach, 
with and without SR preparation were performed to assess the dependence of heart rate on T2. 
Simulation parameters included myocardial relaxation times T2 = 47.5 ms and T1 = 1157 ms 
(104)at 3 T.  The transverse magnetization (Mxy) of the center of the k-space was used as the 
image contrast for each image and was fitted for quantitative T2.  
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To validate the simulation findings and to experimentally determine the influence of heart rate on 
T2 maps, freshly excised canine hearts (n=3) were immersed in saline solution and individually 
scanned using a head coil with i) a commercially available 2D T2 mapping sequence(84), ii) the 
proposed 3D method without SR preparation and iii) proposed 3D sequence (which includes SR 
preparation) by artificially imposing heart rates of 40 – 110 beats/min (bpm) in increments of 10 
bpm. 3D sequences were prescribed with full LV coverage and 2D sequences were prescribed to 
the matched 3D partitions. Heart rates were chosen to capture the typically observed heart rate 
changes between conditions of rest and adenosine stress (113). To minimize bias, prescription the 
order of the sequences were randomized. Details of the sequences are provided as the following: 
BOLD CMR Imaging Parameters  
Proposed 3D T2 map: GRE readout with stack-of-stars trajectory, TR/TE = 3.0 ms/1.5 ms, flip 
angle (FA) = 15°, BW = 1100 Hz/ pixel, 32 lines per heartbeat, trigger pulse = 1, total 
projections = 144/slice, field-of-view (FOV) = 380x380x84 mm3, with 14% slice oversampling, 
matrix size =192x192x16, and voxel size = 2.0 x 2.0 x 6.0 mm3 interpolated to 1.0 x 1.0 x 3.0 
mm3, T2 preparation (as TEs) = 0, 24, 55ms, SR recovery time= 130ms. Gaussian apodization 
was used to increase SNR (114) .  
2D T2 maps with bSSFP readouts with Cartesian trajectory: TR/TE = 2.9 ms/1.1 ms, 
iPAT=2, partial Fourier = 3/4, FA = 35°, BW = 1184 Hz/ pixel, 86 lines per heartbeat (simulated 
rate 60/s), trigger pulse = 5, FOV = 288x360 mm2, matrix size =154x192, and voxel size = 2.5 x 
1.7 x 6.0 mm3, T2 preparation (as TEs) = 0, 24, 55ms.  
Cine bSSFP: Cine acquisitions were prescribed in short-axis before stenosis induction and post 
stenosis dispensation with the scan parameters: TR/TE = 3.0/1.5 ms, FA = 50°, BW = 1300 
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Hz/pixel, matrix = 96 × 192, in-plane resolution = 1.9 × 2.5 mm2; slice thickness = 6.0 mm; and 
2 fold tGRAPA). 
LGE: Phase-sensitive inversion recovery (PSIR) late-gadolinium-enhancement (LGE) 
acquisitions were prescribed rule out infarctions. PSIR LGE images were acquired 10 minutes 
after Gd-DTPA infusion (0.2 mmol/kg, gadoversetamide/Optimark, Mallinckrodt Inc., 
Hazelwood, MO), using non-selective inversion recovery preparation with GRE readout (TR/TE 
= 3.2/1.5 ms, FA = 20°, BW = 586 Hz/pixel, matrix = 96 × 192, in-plane resolution = 1.3 × 1.3 
mm2; and slice thickness = 6.0 mm). A TI-scout sequence was used to find the optimal TI for 
nulling the healthy myocardium (240–270 ms). 
3.2.2.2 Validation Studies in Animals: BOLD CMR with Simultaneous 13N Ammonia PET  
Animal Model & Preparation: 
Two groups of dogs were studied: (a) Healthy animals (Group Intact, n=10) and (b) animals with 
coronary stenosis (Group Stenosis, n=10). For the stenosis studies, animals were implanted with 
occluders to artifically induce LAD stenosis, as previously described(45). Prior to imaging, 
animals were fasted (18 hours), sedated, anesthetized with propofol (2.0-5.0 mg/kg,IV), 
intubated, moved to the scanner table and ventilated (Model 2002 Halowell EMC, MA, USA).  
ECG, heart rate and blood pressure were monitored throughout the studies. Anesthesia was 
maintained with a continuous infusion of low-dose propofol (0.03-0.1 mg/kg/min, IV) during 
imaging to minimize confounding effects of anesthesia on the heart. In Group Stenosis, imaging 
was performed after establishing non-flow limiting stenosis at rest (absence of visually evident 
ST-elevation at rest). Moreover, cine CMR was acquired to ensure that following the release of 
the LAD stenosis, wall motion abnormalities or edema (115) were absent. All studies were 
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terminated with LGE CMR to rule out myocardial infarction. Imaging parameters are presented 
as the following: 
Imaging Protocols:  
In all studies, 13N-ammonia PET and BOLD CMR images were acquired simultaneously in the 
same scanner. PET images were acquired in 3-dimensional (3D) list mode using 13N-ammonia 
(200 MBq, IV bolus (3-5 s) followed by 10 cc saline flush) as the blood flow tracer.  Prior to 
each PET scan, anatomical MR images were acquired to correct for photon attenuation.  
Attenuation correction was performed using segmentation of images obtained with a 2-point 
Dixon MR imaging pulse sequence, which has been shown to be effective for cardiac 
studies(116,117).  Data acquisition spanned over 10 minutes and began a few seconds before the 
13N-ammonia injection.  A time delay was introduced between the sequential PET acquisitions at 
each physiological condition to ensure sufficient decay of each 13N-ammonia dose (5 half lives, 
~50 minutes). BOLD CMR images were acquired with the proposed 3D sequence under each 
physiological condition immediately after the 13N-ammonia injection. BOLD images were 
acquired with the same parameters described in the ex-vivo studies. 3D whole-heart BOLD 
images were consistently acquired within 4 minutes depending on the heart rate. To investigate 
the influence of HR on BOLD sensitivity, conventional 2D T2 mapping was performed on a 
single mid-ventricular slice in the intact animals and was randomized with respect to the 
acquisition order (i.e., before or after 3D acquisitions).   In Group Intact, images were acquired 
during adenosine infusion (140 g/kg/min, IV) and at rest to investigate the Myocardial 
Perfusion Reserve (MPR) and Myocardial BOLD Response (MBR). Specifically, under 
adenosine, image acquisitions were prescribed following 2 minutes of adenosine infusion.  In 
Group Stenosis, images were acquired at rest and under adenosine after inducing LAD coronary 
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stenosis. Other aspects of the imaging protocol implemented in Group Stenosis were similar to 
that implemented in Group Intact. A schematic representation of the sequential execution of the 
study protocols is provided in Figure3.8. All stenosis scans were terminated with late gadolinium 
enhancement (LGE) imaging to rule out infarctions. Once the imaging studies were completed, 
animals were euthanized.  
 
 
 
Fig. 3.8 Chronological order of image acquisition in Group intact (A), and Group Stenosis (B). In all 
studies, simultaneous PET and BOLD CMR images were acquired under rest and stress with an at least 
50 minutes separation to avoid isotope cross talk. In group stenosis, Cine images were acquired before 
the stenosis induction and following the release of the stenosis to probe the motion abnormality and 
signal elevation and rule out myocardial edema. LGE images were also acquired after cine images to 
rule out myocardial infarction.    
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3.2.2.3 Whole Heart BOLD Response in Healthy Human Subjects During Adenosine-
Mediated Coronary Vasodilatation: A Feasibility Study 
10 Healthy volunteers (7 men, average age 35± 8) without any history of CAD and other 
cardiovascular abnormality were recruited in accordance with the protocol that was reviewed and 
approved by the Institutional Review Board of Cedars-Sinai Medical Center. Subjects were 
placed in the supine position, and after scouting and whole heart shimming, proposed sequence 
was prescribed under rest and 2 minutes after the start of adenosine infusion (140 g/kg/min, IV; 
total infusion time 6 minutes). Imaging parameters, including the SR and T2-preparation 
schemes, were the same as those used for animal studies. In subjects with significant fat 
deposition, water excitation pulses were used to suppress fat signal (118). 
Image Analysis  
All CMR images were analyzed with ImageJ (version 1.46, NIH, Bethesda, MA, USA). 
Ex-vivo Images 
Regions of interest (ROIs) drawn within the myocardium of mid ventricular slices (Figure 3.9A) 
were used to measure T2 from images acquired with the different sequences under variable heart 
rates. Mean T2 values at the various heart rates were used as the dependence of T2 on heart rate. 
Ammonia PET 
All 13N-ammonia PET images were processed by an experienced technologist as previously 
described (119). Myocardial perfusion (in units of ml/min/g) and Myocardial Perfusion Reserve 
(MPR) were quantified automatically from the PET data using the automated QPET software 
(Cedars-Sinai Medical Center, Los Angeles, CA, USA) (119). In Group Stenosis, myocardial 
segments with perfusion defects were identified on the basis of stress-rest change analysis in 
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QPET software (119,120). The segments identified with perfusion deficit were labeled as 
‘Affected’ and those without perfusion defects were labeled as ‘Remote’ segments.  
BOLD CMR 
Epicardial and endocardial contours were traced on T2 maps to delineate the myocardium and 
were subsequently segmented according to the AHA 16-segment model. Mean myocardial T2 
values under rest and stress were measured for each segment. Myocardial BOLD responses 
(MBR), defined as T2 at stress normalized by the T2 at rest (MBR= T2
Stress/T2
Rest) for each 
segment was computed. This was determined in both group of animals (Intact and Stenosis) and 
compared against segmental MPR from 13N-ammonia PET. In Group Intact, MBRs were 
computed from the T2 maps of mid-ventricular slices acquired using proposed (MBRPorp) 
matched to the conventional 2D T2 maps (MBRConv). To determine the influence of heart rate 
fluctuations between rest and stress (HR= HRStress - MBRRest) on BOLD contrast was computed 
as Loss of Apparent MBR = 100% x (MBRProp - MBRConv) and regressed against HR. For 
stenosis studies, MBR of the affected segments (identified on the basis of 13N-ammonia PET 
analysis (119,120)) were compared against the MPR of the remote segments. A similar analysis 
was performed in human subjects to determine MBR.  
Statistical Analysis 
For ex-vivo studies, the conventional 2D T2 maps at HR= 60 bpm were labeled as baseline. T2 
measurements at different fixed heart rates were compared to the baseline values using two-way 
measurements ANOVA for each sequence. A post-hoc comparison with Bonferroni correction 
was used if the null hypothesis was rejected. For the intact animal studies, paired student’s t-tests 
were used to compare myocardial perfusion and myocardial T2 values between rest and stress. 
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Linear mixed models were used to examine data trends between the MBR and MPR. Linear 
regression between Loss of Apparent BOLD Contrast and HR was performed to investigate the 
influence of heart rate changes on BOLD response. For the stenosis studies, MPR from the 
Affected and Remote segments from all animals were compared using student’s t-test with 
Bonferroni correction. The same test was used to examine the difference in the simultaneously 
acquired MBR. In human studies, segmental T2 values between rest and stress were compared 
using a paired student’s-t test; and a student’s t test was use to test whether MBR> 1. All values 
are reported as mean ± SD (unless stated otherwise) and statistical significance was established 
for p<0.05. All statistical analysis was performed in IBM SPSS (V21.0, NY, USA). 
3.2.3 RESULTS 
3.2.3.1 Computer Simulations and Ex-vivo Study 
Figure 3.9 shows the results from computer simulations and the ex-vivo studies. Simulated and 
experimental mean myocardial T2 measured under artificially modulated heart rates are 
compared in panel A.  Simulations showed a clear trend of decreasing T2 values with increasing 
heart rates, which was not evident with the proposed sequence.  Experimental T2 values 
measured from ROIs placed within the mid-ventricular slices (Fig. 3.9B), confirmed the 
predictions of computer simulations. The dynamic range of the estimated T2s through out 
different heart rates are significantly reduced from the proposed sequences compare to the other 
methods (1.0ms (Proposed) vs. 2.9ms (without SR) vs. 3.9ms (2D) , all p<0.05) . A 
representative set of mid-ventricular short-axis T2 maps acquired with the different T2 mapping 
strategies at different fixed heart rates is presented in panel C.  Images acquired with 
conventional 2D T2 mapping and proposed T2 mapping without SR preparation showed a trend 
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with decreasing T2 as heart rates increases. Among these two T2 mapping methods, significantly 
lower T2 values were observed at HR= 100 bpm (45.1±1.7 ms (2D) vs 42.2±1.7 ms (without 
SR), both p<0.05) and 110 bpm (44.2±1.6 (2D) vs 41.6±1.7 (without SR), both p<0.05), 
compared to at HR=60bpm (2D: 47.6±2.1; without SR: 43.9±2.0). In contrary, images acquired 
with the proposed T2 mapping (with SR preparation) showed practically no sensitivity to HR.  In 
particular, the T2 values acquired with the proposed approach did not differ from T2 estimates 
obtained using conventional 2D T2 and 3D T2 maps without SR preparation at a HR of 60 
mmHg (p=1, for all). 
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Fig. 3.9: T2 dependence on heart rate as determined from computer simulations and ex-vivo studies. In 
Panel A, the theoretically expected dependence of T2 on heart rate for the conventional 2D, 3D T2 
mapping without (proposed w/o SR) and with SR preparation (proposed) are shown as solid lines. In 
addition, experimentally measured T2 values from ex-vivo hearts at the different artificially modulated 
heart rates are also shown. In Panel B, T2 maps acquired using the different T2 mapping approaches of a 
representative mid-ventricular slice image is shown. In Panel C, representative ROIs used for the 
analysis are identified for reference. Diminishing T2 values with increasing heart rates, as observed in 
conventional 2D T2 maps and 3D T2 maps without SR preparation were markedly reduced with the 
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proposed 3D T2 mapping approach. All images showed consistent image quality and similar T2 
distribution. * denotes p<0.05 
 
3.2.3.2 Animal Studies 
The dependence of Loss of Apparent MBR on HR is shown in Figure 3.10. Panel A shows a 
representative set of slice-matched rest and stress mid-ventricular images obtained with the 
proposed and conventional 2D sequences. In this particular example, a HR increase of 26 bpm 
under adenosine stress led to a 9% increase in MBR with the proposed approach, while a 1% 
decrease in MBR with the conventional 2D T2 mapping approach. PET measurements of the 
MBF in the same animal are shown in panel B. The corresponding global MPR in this animal 
was 2.45, which demonstrates the presence of marked vasodilation that is detected by the 
proposed method but not captured by conventional 2D T2 mapping approach. Panel C shows 
significant correlation between the Loss of Apparent MBR and HR (R=0.7; p<0.05), which 
indicates that the larger the heart rate change under vasodilator stress (compared to at rest), the 
greater the Loss of Apparent MBR in T2 maps that are uncorrected for heart rates. 
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Fig. 3.10 Dependence of MBR Sensitivity on Heart Rate Differences Between Rest and Vasodilator Stress. 
Representative rest and stress T2 maps of a mid-ventricular slice obtained with conventional and 
proposed T2 mapping methods are shown in panel A. Myocardial T2 under stress with the proposed T2 
mapping approach is much higher than the T2 at rest, but T2 under stress is reduced in the conventional 
images compared to rest. Panel B shows the experimentally observed relationship between Loss of 
Apparent MBR in conventional images and HR increases under vasodilator stress. A strong correlation 
was observed between Loss of Apparent MBR and HR.  
MBR and MPR in dogs without coronary stenosis following adenosine administration were 
consistently higher than at rest. Figure 3.11 shows representative sets of short-axis T2 maps 
depicting BOLD response (Fig 3.11A) and 13N-ammonia PET perfusion (Fig 3.11C) acquired 
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under rest and adenosine stress. Corresponding bull’s eye plots derived from segmental 
intensities are shown in Fig 3.11B and 3.11D, for BOLD CMR and 13N-ammonia PET. Mean 
myocardial BOLD responses from segmental intensities were: 19±8% (BOLD CMR) and 
2.5±0.4 (13N-ammonia PET MPR). 
 
 
Fig. 3.11 3D T2 maps and 13N-ammonia PET at rest and under adenosine stress in canines without 
coronary stenosis. Representative basal, mid, and apical short-axis images of BOLD CMR with the 
proposed 3D T2 mapping approach and PET perfusion images with 13N-ammonia are shown in Panel A. 
From images acquired using both modalities, significant signal elevation can be observed in the stress 
 74 
images compare to the corresponding rest images. Corresponding bull’s eye plots are shown in Panels B 
and C, respectively. For this representative case, mean BOLD response of 16% and PET MPR of 2.3 
were evident. 
 Absolute mean myocardial T2 and 13N-ammonia PET perfusion values at rest and adenosine 
stress are shown in figure 3.12A and 3.12B, respectively. BOLD response and MPR from each 
segment are compared in Fig. 3.12C. 13N-ammonia PET perfusion values were significantly 
higher under adenosine stress than at rest (0.8±0.1 ml/mg/min (rest) vs. 2.0±0.9 ml/mg/min 
(stress); p<0.05). The corresponding mean MPR was significantly larger than 2.0 (MPR: 
2.6±0.3;refer to Fig. 3.12B). A similar trend was observed with T2 measurements, where 
myocardial T2 was significantly higher during adenosine stress (38.5±1.0 ms (rest) vs. 44.4±3.1 
ms (stress), p<0.05; refer Fig. 3.12A) with a mean myocardial BOLD response of 19±8%.   The 
segmental correlation between myocardial BOLD response and 13N-ammonia PET MP was good 
(R=0.7; p<0.05).      
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Fig. 3.12: Mean BOLD Response and 13N-Ammonia PET Perfusion in Canines without Coronary 
Stenosis. Panel A shows a box plot with higher mean myocardial T2 values under adenosine adenosine 
stress compared to rest. Similar trend is observed with 13N-Ammonia PET perfusion measurements in 
Panel B. Panel C shows a scatter plot showing between BOLD response and 13N-Ammonia PET MPR. 
Linear regression analysis (line of best fit in red) shows good correlation between BOLD response and 
13N-Ammonia PET MPR. * denotes p<0.05 
In Group Stenosis, a representative set of short-axis T2 maps depicting BOLD response and the 
corresponding rest and stress 13N-ammonia PET perfusion in a dog with LAD stenosis are shown 
in Fig. 3.13 A and D, respectively. T2 maps acquired under adenosine showed a significant 
reduction in T2 is in the LAD territories of mid ventricular and apical slices, which is consistent 
with the reduced MBF in the 13N-ammonia PET. Polar plots of MBR and MPR are shown in in 
Fig. 3.13 B and Fig. 3.13 E, respectively, which show reduced MBR and MPR consistent with a 
LAD coronary stenosis. Box plots of MBR and MPR in the remote and affected segments are 
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shown in Fig. 3.13 C and Fig. 3.13 F, respectively. Mean MBR and MPR of the affected 
territories were significantly lower than the remote territories ((MBR: 1.09 ± 0.04 (remote) vs. 
1.00±0.03 (affected), p<0.05); and MPR: 2.5±1.7 (remote) vs. 1.4±1.0 (affected), p<0.05).  
 
Fig. 3.13: 3D T2 maps and 13N-ammonia PET at rest and under adenosine stress in canines with LAD 
coronary stenosis. Panel A shows representative basal, mid, and apical short-axis T2 maps at rest and 
under stress from a canine with LAD coronary stenosis. Panel D shows the corresponding quantitative 
myocardial blood flow (MBF) maps determined from 13N-ammonia PET. Note the close correspondence 
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in the MBF distribution and T2 maps, particularly under adenosine stress. Specifically, the remote 
territories on PET images showed increased T2 values on T2 maps acquired under adenosine. 
Conversely, the affected territories on PET images (anterior wall corresponding to LAD territory; white 
arrows in zoomed-in images) showed markedly diminished increase in T2 (black arrows in zoomed-in 
images) compared to remote segments. Corresponding polar maps for BOLD and PET are shown in 
Panels B and E, respectively. Affected segments identified with change analysis from QPET are labeled 
with ‘+’ in the polar maps. Both BOLD Response and PET MPR showed significantly lower values in the 
affected territories compare to the remote segments (Panels C and F, respectively). * denotes p<0.05. 
3.2.3.3 Human Studies 
Every stress and rest scans were completed within 4 minutes. Consistent with canine studies, 
significant increases in myocardial T2 was observed during stress compared to rest (44.5±2.8ms 
(rest) vs. 49.1±5.8ms (stress); p<0.05). Mean MBR across subjects was significantly larger than 
1 (mean MBR=1.10± 0.08; p<0.05). Representative short axis-images from a healthy volunteer 
along with a corresponding polar map representation of MBR are shown in Figs. 3.14A and 
3.14B, respectively. All three images showed visually discernable increases in T2 during stress 
compared to at rest.  
 78 
 
Fig.3.14 Heart-Rate Independent 3D T2 mapping at Rest and Under Adenosine Stress in Healthy Human 
Subjects. Panel A shows representative short-axis T2 maps from rest and stress. An increased myocardial 
T2 corresponding to hyperemia can be observed across all slices. Panel B shows box plots of myocardial 
T2 values across animals at rest and under stress. Panel C shows a polar map of MBR for the case in 
panel A, which show a relatively homogenous MBR across the segments that are greater than 1.      
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3.2.4 DISCUSSION 
A non-contrast-enhanced, radiation-free, imaging approach which can be used to reliably detect 
the presence of hypoperfused myocardial territories could be valuable in ischemia testing in 
patients with compromised kidney function. Over the past two decades BOLD CMR has made 
substantial advancements towards filling this role. However, the most commonly employed T2-
based BOLD CMR methods have well-known limitations. Specifically, they offer limited spatial 
coverage during vasodilator stress, are confounded by heart-rate variations between rest and 
stress acquisitions, and have not yet been directly validated against gold-standard PET-perfusion 
measurements under identical physiological conditions. Our work developed, tested and 
validated a new T2-based BOLD CMR approach at 3T to overcome these key imitations. This 
led us to demonstrate for the first time a quantitative BOLD CMR approach which (a) permits 
full LV coverage within the duration of adenosine stress under free-breathing conditions; (b) 
ensures preservation of BOLD sensitivity independent of heart-rate variations between rest and 
stress; and (c) is validated in vivo against 13N-ammonia PET-based myocardial perfusion under 
identical physiological conditions.     
Our studies relied on computer simulations, ex-vivo imaging, in-vivo imaging in canines with 
and without coronary stenosis and early demonstration of feasibility in healthy human subjects. 
The proposed method was compared against established (84) 2D T2 mapping approach and the 
proposed method without the SR preparation. Computer simulations and ex-vivo studies 
demonstrated a clear dependence of T2 on artificially modulated heart rates that were not evident 
with the proposed approach. By using a SR preparation, the proposed method ensured that the 
longitudinal signal recovery begins from zero during each of the segmented readouts, hence 
removing the variability associated with longitudinal signal recovery, which is highly dependent 
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on heart rates. This dependence of HR on T2 has important implications for BOLD CMR. As 
shown in Fig. 3.10, T2 mapping methods that are sensitive to HR can underestimate the expected 
BOLD response and the magnitude of this underestimation is proportional to HR. Effectively, 
this underestimation in T2 counters the vasodilator mediated increase in T2 leading to a 
diminished and unreliable apparent BOLD response, which may partly account for the large 
scatter typically observed between T2-based BOLD CMR and perfusion studies in the literature.  
These variations might also lead to incorrect estimation of myocardial oxygen extraction fraction 
(OEF) (33) and confound the BOLD interpretations. The proposed T2 method helps to overcome 
these limitations. Previous studies have recognized these limitations and have attempted to 
correct for signal measurements using fixed model parameters that are often variable between 
subjects and imaging conditions (19), which can lead to further misinterpretations. BOLD 
sensitive balanced steady state freee precessing (bSSFP) sequence is another way of reducing the 
heart rate dependency by reaching the steady state(121,122). However, other limitations, such as 
off resonance artifacts, long breath hold duration and single slice 2D acquisitions, still limited its 
applicability. The proposed method provides fast 3D free breathing acquisition capability while 
eliminating the HR and T1 dependency. Although SR preparation methods are often limited by 
SNR, in our 3D implementation, we did not find this to be the case as the proposed approach 
showed comparable standard deviation in T2 in the myocardium (1.16±0.12 ms (proposed) vs. 
1.25±0.35 ms (conventional approach), p=0.3).  
We were able to consistently acquire complete data sets within 4 minutes during adenosine 
infusion for whole-heart T2 mapping with similar spatial resolution of 2D T2 maps. Our data 
showed that the T2 values of the healthy myocardium measured at rest using the proposed 
approach were in good agreement with previous reports in the literature (123,124).  
 81 
Simultaneously acquired T2 and 13N-ammonia PET data, which were used to estimate MBR and 
MPR, respectively, were highly correlated. In the presence of LAD stenosis, consistent with the 
findings from 13N-ammonia PET MPR, we observed marked reduction in MBR in the affected 
territories compared to remote territories. Collectively these findings support that the measures 
of MBR based on the proposed approach and MPR provide similar information with respect to 
myocardial perfusion and can be used to improve the identification of myocardial territories 
subtended by coronary arteries with non-flow limiting stenosis. Further, our studies in healthy 
human subjects demonstrated the feasibility of the proposed approach for consistently generating 
artifact-minimized, whole-heart T2 maps from free-breathing acquisitions at rest and standard 
duration of peak adenosine stress (i.e., within 4 minutes). Although the MBR estimates in human 
subjects were not validated with PET MPR, the observed mean MBR of 10% in human subjects 
is comparable to that observed in animals. 
Study Limitations 
The present study was performed in animal models and healthy human subjects, which offer 
well-controlled environments compared to the clinical setting.  While we were able to 
consistently acquire whole-heart T2 maps within acceptable window of adenosine stress and 
eliminate heart-rate dependency, along with marked reductions in B0 and B1 inhomogeneities, 
rapid heart rate changes during the acquisition may be challenging. Although this may be 
addressed using strategies similar to arrhythmia rejection approaches previously employed in 
other settings, this was not investigated here. These investigations would require patient studies.  
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3.2.5 CONCLUSION  
To overcome the key limitations in cardiac BOLD CMR, we developed, tested, and validated a 
new 3D T2 mapping approach. The proposed approach offers the capability to acquire artifact-
minimized, quantitative, whole-heart, BOLD images under free-breathing conditions during peak 
adenosine stress with no loss in sensitivity from heart rate changes between rest and stress. 
Patient studies are necessary for clinical translation.  
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4  Chapter 4 BOLD CMR Based on Pharmacokinetics of 
Regadenoson  
4.1  Towards Reliable BOLD CMR Using Late Effects of Regadenoson  
4.1.1 INTRODUCTION 
The number of cardiac patients with chronic kidney disease is on the rise. Assessment of 
ischemic heart disease in these patients requires a non-contrast-enhanced, high-resolution, 
imaging approaches to evaluate the presence of perfusion anomalies. Myocardial BOLD MRI 
has the capacity to fill that unmet need. Over the past two decades myocardial BOLD MRI has 
seen major technical advancements and a number of clinical validation studies. However, the 
reliability of BOLD MRI remains a key weakness for its widespread adoption for routine clinical 
use. To date, most of the technical developments have addressed improvements in imaging 
speed, coverage and reducing image artifacts at rest. However, image artifacts from 
unpredictable cardiac motion during stress can lead to significant deterioration of image quality, 
which can confound/mask the BOLD signal changes during stress. Since the FDA approval in 
2008, Regadenoson (Gilead Sciences Inc) has become a popular stress agent and is currently 
used in ~70% of the pharmacological stress in the US owing to its improving patient tolerability 
and ease of administration. Studies have also shown that regadenoson can prolong the coronary 
vasodilation to 8-10 minutes, but to date no studies have quantified the myocardial blood flow 
(MBF) during the late phase of vasodilation. We hypothesized that (a) stress BOLD MRI 
performed at ~10 minutes can markedly improve the reliability for detecting myocardial 
hyperemia; and (b) that myocardial perfusion reserve remains significantly greater than 2.0 (a 
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meaningful hyperemic state for ischemic testing) following regadenoson injection. We studied 
this using a canine model in a hybrid PET/MR system, which is capable of reporting BOLD 
signal changes (from MRI) and quantitative blood flow changes (from 13N-ammonia PET) in the 
heart.    
4.1.2 METHODS  
Healthy mongrel dogs (n=7) were studied in a state-of-the-art PET-MR system (Biograph mMR, 
Siemens Healthcare, Germany). After scouting and whole-heart shimming, BOLD images were 
acquired with 2D T2 maps at rest simultaneously with dynamic 
13N-ammonia PET. Following a 
40-min gap to ensure sufficient decay of radiotracer, a bolus injection of regadenoson (2.5 μg/kg) 
was administrated. T2 maps were acquired 2 mins and 10 mins post regadenoson administration 
(p.r.a) to investigate the mean BOLD response and reliability of the BOLD response. To quantify 
the extent of myocardial hyperemia 10 mins p.r.a, another dynamic 13N-ammonia PET was also 
acquired. Mean and standard deviation () of myocardial T2 were measured from images 
acquired at rest and at 2 mins and 10 mins p.r.a.. Myocardial BOLD Response (indexed as 
T2(stress)/T2(rest)) and Myocardial BOLD Variability (indexed as T2(stress)/T2(rest)) and 
were computed at 2 mins and 10 mins p.r.a, respectively to assess mean BOLD response and the 
reliability of BOLD response. MR-based attenuation corrected PET images were analyzed in 
standard fashion with commercially available qPET software and were matched to the 
corresponding BOLD imaging slices to determine myocardial perfusion reserve (MPR) at 10 
minutes p.r.a and regressed against Myocardial BOLD Response.   
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4.1.3 RESULTS 
A box-plot of observed Myocardial BOLD Variability at 2-mins and 10-mins p.r.a (and at rest, 
for reference), along with representative mid-ventricular, short-axis, T2 maps corresponding to 
the different conditions are shown in Fig. 4.1. Note the extensive image artifacts present in the 
representative T2 map at 2 min (from the intense heart-rate variability during acquisition), which 
is absent in the T2 maps acquired at rest and 10-mins p.r.a. Relative to 2-min p.r.a, Myocardial 
BOLD Variability was significantly larger at 2-min p.r.a (1.6±0.9) compared to 10-mins p.r.a 
(1.0±0.3) and at rest (1.0); p<0.05 for both. Average reduction in Myocardial BOLD Variability 
between 2-min and 10-mins p.r.a was 0.6±1.2.  
 
Figure 4.1. Myocardial BOLD Variability at Stress Relative to Rest. Box-plot of Myocardial BOLD 
Variability and representative images at rest and from 2 and 10 min p.r.a are shown. Large Myocardial 
BOLD Variability is observed at 2 mins p.r.a. compared to rest and is markedly reduced at 10 mins p.r.a.  
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Representative 13N-ammonia PET images of MBF at rest and 10-mins p.r.a are shown in Fig. 
4.2A. MBF at 10 min (1.8±0.9 ml/g/min) was significantly higher than at rest (0.6±0.3ml/g/min), 
p<0.05 (Fig. 4.2B). Mean MPR from PET at 10-min p.r.a was significantly larger than 2.0 
(3.0±0.6, p<0.05). BOLD images corresponding to the PET images in Fig. 4.2A are shown in 
Fig. 4.2C. Myocardial T2 at 10-min p.r.a (40.4±1.7ms) was significantly higher than at rest 
(37.1±2.0ms), p<0.05 (Fig. 4.2D). Mean Myocardial BOLD Response at 10-min p.r.a was 
significantly higher than 1.0 (1.09±0.04<0.05). Strong correlation between PET MPR and 
Myocardial BOLD Response was observed (R=0.7, p<0.05); Refer to Fig. 4.2E.   
 
Figure 4.2. 13N-Ammonia PET Myocardial Blood Flow and BOLD. Both PET and BOLD images showed 
significant increase in MBF and BOLD response, at 10 mins p.r.a. compared to rest (A-D). Results from 
regression analysis showed good correlation between PET myocardial perfusion reserve 
(MBF(stress)/MBF(rest)) and Myocardial BOLD Response(R=0.7, p<0.05; panel E).  
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4.1.4 CONCLUSIONS 
 Myocardial BOLD images acquired at 10-mins p.r.a were free of image artifacts typically 
observed in images acquired at 2-min p.r.a. MPR values at 10-mins p.r.a were significantly 
higher than 2.0 and were strongly correlated with the Myocardial BOLD Response. These data 
suggest that delayed BOLD acquisition following regadenoson administration can be a practical 
strategy for increasing the reliability of cardiac BOLD MRI for cardiac stress testing. The 
clinical utility of this approach remains to be evaluated in human subjects.  
4.2  Improving the Reliability of Myocardial BOLD CMR through 
Characterization of Coronary Relaxation Following Regadenoson 
Injection  
4.2.1  INTRODUCTION: 
Over the past two decades BOLD CMR has seen major progress in technical developments and 
advanced by a number of clinical validation studies. However, the reliability of BOLD CMR 
remains a key weakness for its widespread adoption for routine clinical use. Although technical 
developments as presented in our previous work have significantly improved imaging speed, 
coverage and helped to reduce imaging confounders, the unstable physiological conditions 
during vasodilator stress leads to significant variations in the BOLD measurements. Specifically, 
irregular cardiac motion, rapidly changing heart rate during acquisition and significantly shorter 
quiescent period contribute to motion artifacts, cardiac phase mismatch between rest and stress 
image, all of which lead to deterioration of BOLD images. This invariably masks the observed 
BOLD responses during stress and can diminish the reliability of the data interpretation.    
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Coronary Relaxation Dynamics in the Presence of Regadenoson: 
Since the FDA approval in 2008, Regadenoson (Lexiscan,Gilead Sciences Inc.) has become a 
popular stress agent and rapidly grown to capture  nearly 70% (125) of the pharmacological 
stress market in the US owing to its specificity to A2A adenosine receptor (improving patient 
tolerability) and ease of administration (bolus injection rather than continuous infusion). 
However, a rapidly changing cardiac motion (fig 4.3 A) post regadenoson administration can 
affect the conventional single time point BOLD imaging strategy in 2 ways: (i). irregular motion 
can leading to motion artifacts, can degrade image quality and result inb cardiac phase mismatch 
(fig4.3 B),(126); and (ii). heart rate differences between rest to stress can confound the measured 
BOLD signal and mask the BOLD response. 
 
Fig 4.3 Heat-rate response and the BOLD image quality influence by different imaging time points. 
Significant heartrate variation is observed in an animal for the first 5 minutes after regadenosine 
administration(A). The affected BOLD image quality due to imperfect imaging condition(B). 
Although advanced MR technical development as mentioned in chapter 3 can overcome part of 
the challenges, the unpredictable cardiac motion can still undermine the robustness of the image 
quality and prolong the scan time. An alternative method is proposed in chapter 4.1 to acquire 
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stress images at a delayed time point, which can provide a stable imaging condition and improve 
the scan reliability (126). However, it can also potentially decrease the sensitivity of detecting 
disease as the imaging is performed well after peak vasodilation.   
In this study, we hypothesize that continuous monitoring of the myocardial BOLD signal after 
regadenoson administration can improve the robustness of BOLD response extraction while 
preserving the sensitivity of peak vasodilation. To achieve this, we propose a multiple 
measurement strategy to investigate the coronary dynamic after regadenoson administration and 
reduce the influence on the BOLD response from artifacts in a single image. We applied a mono-
exponential decay model to extract the coronary dynamic parameters (CDPs), and derive the 
maximum BOLD response to compare with the conventional single time point method.  
We studied healthy human volunteers, intact dogs and dogs with chronic myocardial infarction to 
evaluate the capability of BOLD CMR for characterizing the coronary dynamics. In the healthy 
subjects, global CDPs were extracted to show the feasibility of the method and the increased 
BOLD sensitivity. In the pathologic cases, CDPs were compared between remote and affected 
territories in segmental and pixel wise fashions to evaluate the capability of detecting abnormal 
myocardial territories.    
 
4.2.2 METHODS 
BOLD images were acquired at different time points before and after regadenoson administration 
to sample the rest and stress images, respectively. After bolus regadenoson injection, multiple 
stress images were acquired to sample the coronary dynamics curve for 30 minutes.  All stress 
images were registered to the rest images with a non-rigid motion correction algorithm (127) to 
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correct for motion-induced miss match between acquisitions. Motion corrected images were used 
to extract the CDPs throughout the stress period using a mono-exponential model (128) (T2(t)= 
T2o+T2max exp(-t/)). A flow chart of the experimental setup is depicted in Fig4.4  
 
Fig4.4 Experimental flow chart. Rest BOLD images were acquired before Regadenoson administration 
and repeat BOLD acquisitions starting from 2 minutes post the bolus regadenoson injection were 
performed. Images were acquired every 1-5 minutes for 30 minutes. The stress images were registered to 
the rest image using a non-rigid motion correction algorithm (127). The motion corrected images were 
used to fit the coronary dynamics parameters with a mono-exponential model. 
In healthy volunteers and intact dogs, global CDPs were extracted from the myocardium. 
Maximum BOLD response was derived with CDPs (MBRCDP=T2max / T2o x 100%) and 
compared with conventional myocardial BOLD response (MBR), which was derived as the T2 
elevation from rest to 2 minutes after regadenoson administration (MBRconv= [ (StressT2
2min /Rest 
T2) -1) x 100%]. In the animals with coronary impairment, CDPs were measured in segmental 
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and pixel-wise manner. Pixel-wised CDPs between remote and affected territories were 
segmented using SVMs to investigate the capability of separating diseased myocardium from the 
remote regions. In addition, CDPs were derived from subsets of BOLD images with different 
starting time points to probe the optimized setup of detecting affected territories. Details of each 
step are described in the following sections    
Experimental Subjects and animal preparation: 
We studied healthy human volunteers (n=6), intact dogs (n=7) and dogs with chronic infarctions 
(n=1). During imaging studies in animals, all animals were mechanically ventilated and 
anesthetized with propofol. In the dog with chronic infarction, the animal underwent an open 
chest ischemia reperfusion protocol (3 hours of ischemia followed by reperfusion), followed by 
8-week recovery prior to imaging.  
Image acquisition: 
Human studies were performed on a 3.0 T clinical MRI system (MAGNETOM Verio®, Siemens 
Healthcare, Erlangen, Germany) and the animals were studied on a 3T whole body PET MR 
system (Biograph mMR, Siemens Healthcare, Erlangen, Germany). In all subjects, BOLD 
images were acquired with a commercially available 2D T2 mapping sequence {Giri, 2009 
#820}. In all studies, after localization and shimming, rest BOLD images were acquired under 
baseline followed by a bolus regadenoson injection. Post regadenoson administration, BOLD 
CMR images were acquired between 2 to 30 minutes after regadenoson injection with an interval 
of 1-5 minutes depend on the physiological and imaging condition. In the animal with chronic 
infarction, simultaneous 13N ammonia PET images were acquired at 2 minutes post regadenoson 
administration to validate the hyperemic response from regadenoson. In addition, LGE images 
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were acquired to identify the infarcted territories after all BOLD acquisitions were completed.  
Block representations of imaging protocols are illustrated in figure 4.5. Imaging parameters are 
listed as the following: 
T2 mapping: TR/TE = 2.9 ms/1.1 ms, iPAT=2, partial Fourier = 3/4, FA = 35°, BW = 1184 Hz/ 
pixel, 86 lines per heartbeat (simulated rate 60/s), trigger pulse = 4, FOV = 288x360 mm2, matrix 
size =154x192, and voxel size = 2.5 x 1.7 x 6.0 mm3, T2 preparation (as TEs) = 0, 24, 55ms.  
 
 
Fig. 4.5 Chronical order of image acquisition for each imaging group.  
Late Gadolinium Enhancement (LGE): PSIR LGE images were acquired 10 minutes after Gd-
DTPA infusion (0.2 mmol/kg, gadoversetamide/Optimark, Mallinckrodt Inc., Hazelwood, MO), 
using non-selective inversion recovery preparation with GRE readout (TR/TE = 3.2/1.5 ms, FA 
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= 20°, BW = 586 Hz/pixel, matrix = 96 × 192, in-plane resolution = 1.3 × 1.3 mm2; and slice 
thickness = 6.0 mm). A TI-scout sequence was used to find the optimal TI for nulling the healthy 
myocardium (240–270 ms). 
Image Processing: 
The series of BOLD images acquired post regadenoson administration were aligned using the 
advanced normalization tools (ANTS: http://www.picsl.upenn.edu/ANTS) software. Rest images 
were used as the reference for registration. For each subject, ANTS utilized a cross-correlation-
based symmetric diffeomorphic transformation between the reference image and the target 
images to minimize image differences. The representative effect of image registration is 
presented in fig. 4.6.  
 
Fig. 4.6 Effect of the non-rigid motion correction algorithm. Contour mismatch (black arrows) from the 
original images are successfully registered to the rest image after motion correction.  
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Aligned images were used to fit CDPs on a pixel-by-pixel basis in the myocardial ROI. In all 
studies, a mono exponential model T2(t)= T2o+T2max exp(-t/) (128) was used to represent the 
BOLD signal modulation post regadenoson injection and extract CDP maps from BOLD images 
of the whole period(T2o  = baseline T2, ms; T2max = Maximum BOLD stimulation amplitude, 
ms; = coronary relaxation time constant, min). The rest images were set to be the fully decayed 
to baseline BOLD signal at 2 hours after regadenoson injection in the dynamic curve fitting 
(129). In the diseased animal, CDPs were fitted with different starting time points (2mins, 5mins 
and 10 mins) to investigate the influence decreased sampling of data points close to the peak 
vasodilation. 
Image analysis: 
In the studies performed in healthy volunteers and animals, global myocardial CDPs were 
extracted to investigate the feasibility of probing BOLD response. Myocardium was segmented 
with epi- and endocardial contours. Global myocardial CDPs were measured and compared with 
the conventional single time point T2 response between Rest and Stress. In the studies with 
coronary impairment, infarcted territories were identified using LGE images with remote + 5 SD 
criteria as previously described (fig. 4.7). 
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Fig. 4.7 Infarcted territories identified from LGE images. Pixel-wise and segmental masks of infarcted 
territories identified with +5SD standard are presented. Remote territories are labeled with green and 
affected territories are labeled with red.   
The capability of identifying the affected myocardium on the CDPs was examined using cross 
validation of support vector machines (SVMs) (fig. 4.8) and compared with the conventional 
single time point T2 based classification. The analysis was first performed in a pixel-wised 
fashion and compared in on the basis of standard AHA segmentation (fig. 4.7).  
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Fig.4.8 Flow chart of the SVM cross validation process for evaluating the disease separation capability 
of the CDPs. The myocardial pixels were labeled using LGE images before the SVM training.   
Myocardial CDPs are separated into 10 subgroups in which 9 groups will be used to train an SVM. The 
SMV is used to segment the last group to test the segmentation accuracy and examine the disease 
identification capability from the CDPs. The process is repeated for 10 times to cross validate the whole 
dataset.  
In addition, simultaneously acquired quantitative PET images were used to derive myocardial 
perfusion reserve (MPR) with a clinical validated software (QPET, Cedars-Sinai Medical Center, 
Los Angeles) and to validate the reduced MPR in the infarcted myocardium. 
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4.2.3 RESULTS 
4.2.3.1 Coronary Dynamics in Health 
 
Fig. 4.9 Representative CDP curves of a human volunteer and a healthy dog. High R values present the 
good representation from the CDP model.  
A representative set of temporal resolved BOLD signal and the fitted CDP curve from a healthy 
human subject and an intact dog is presented in Figure 4.9. Representative data showed high 
Pearson correlation (R) values to the exponential fit (Human: R=0.97, Dog: R=0.93). Fitted 
CDPs of the healthy studies are presented in table 1.  
 
Table 4 1 CDPs from humans and healthy animals. The fitted parameters are comparable between human 
and animal and are in the physiological range compare to the values reported in the literatures. 
High R-values demonstrated the model is suitable to reports on the dynamics of the BOLD 
signal. CDPs are comparable between human and dogs and are in reasonable physiological 
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ranges (79,129).  In addition, the mean MBRCDP (T2max / T2o x 100%) was significantly larger 
than the mean MBRcon, which indicates the recovered (magnified) BOLD sensitivity from the 
CDP extraction. The MBRCDP correlated with the conventional single time point MBR with a 
linear regression model is shown in figure 10. 
 
Fig. 4.10 Linear regression between MBRCDP and MBRcon. The regression shows MBRCDP is significantly 
correlated with the conventional MBR but the MBRCDP shows significantly larger amplitude compared to 
MBRcon.  
The MBRCDP was strongly correlated with MBRcon (R=0.93; p<0.05). The regression also shows 
a slope significantly larger than 1 (Y=2.83X-0.27), which indicates the increased BOLD 
sensitivity with the extracted CDPs compared to the conventional approach. 
4.2.3.2 Coronary Dynamics in an Animal with Myocardial Infarction  
The masks of infarcted territories are first compared with 13N -Ammonia PET to validate the 
perfusion deficit in the affected region.    
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Fig. 4.11. Mask of the infarcted territory identified by LGE (red) and the corresponding 13N -ammonia 
PET images.  Excellent agreement between the infarcted territories and the perfusion deficit shows the 
reduced blood supply in the affected myocardium. 
Fig. 4.11 presents strong spatial correspondence between infarcted territories from LGE and 
perfusion deficit from 13N -Ammonia PET images. Both rest and stress myocardial blood flow 
were significantly reduced in the affected region and significant lower myocardial perfusion 
reserve was derived in the infarcted territories (MPR=1.9) compared to the remote myocardium 
(MPR=3.7).  BOLD signal from the remote and affected regions were separated using the 
affected mask and fitted with the CDP model. The BOLD signal dynamic curve correspond to 
the remote and affected myocardium are presented in fig. 4.12.  
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Fig 4.12 Representative BOLD signal dynamics curves extracted from the infarcted animal. Fitted curves 
are significantly different from remote and affected regions. Obvious reduction on T2max in the affected 
curve reflected the reduced perfusion reserve in the infarcted territory.  
Remote and affected area showed significant differences in BOLD signal dynamics, particularly 
in the maximum T2 response (T2max ) and coronary relaxation time constant () (Remote: 
T2max =5.4ms, =29.6min vs. affected: T2max =1.6ms, =54.09min). Significantly lower 
maximal amplitude of vasodilation and longer relaxation time in the affected region 
demonstrated the abnormal coronary dynamics in the infarcted region.  
CDPs were fitted with different starting time points to assess the effect of sampling after peak 
vasodilation and to optimize the capability to accurately assess disease. Representative curves 
fitted from 2, 5 and 10 minutes post-regadenoson injection are presented in fig 4.13.  
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Fig. 4.13 Representative CDP curves fitted from different starting time points. Curves were fitted from 
BOLD sampled from remote (red) and affected (black) territories. The measured data are represented in 
circle and square and the fitted data are presented in lines.  
 
Fig. 4.13 shows the fitted curves with different starting time points. While the curves shifted 
among different fitting conditions, the remote and affected curves were clearly separated in all 
fitted curves. The capability of the derived CDPs in separating the affected and remote 
myocardium was evaluated in segmental (fig.4.14) and pixel-wise (fig 4.15) fashion. The linear 
supporting vectors were presented in the CDP scatter plots (panel A-C) to investigate the 
seperability of the parameters and compared with the conventional single time point T2 values 
(panel D). 
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Fig 4.14 Segmental evaluation of the remote and affected territories. CDPs derived from different 
starting time points are plotted in the scatter plots(A-C) and labeled as remote (blue dots) and affected 
segments (red dots). Infarcted segments were successfully identified from all CDPs and T2 values.  
Larger margins from the derived SVM are shown in CDPs from 2 and 5 minutes compare to the 10 
minutes and the conventional single time point approach.  
Figure 4. 14 shows the segmental CDPs from an infarcted dog. CDPs fitted from starting 
2min(A), 5min (B) and 10 min(C) post regadenoson administration are plotted with scatter plot 
and compared with conventional single time point BOLD signal (D). Affected segments 
identified from each parameter are labeled with polar plots and presented in the corresponding 
panel. All CDPs and conventional measures show the capability of separating the remote and 
affected segments. SVMs from each data sets were derived to investigate the separability 
between remote and affected segments. Post regadenoson measurement after 2min and 5 min 
CDPs showed greater margin from SVM compare to the conventional single time point 
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measurements. The effect demonstrated the possible increased sensitivity of disease 
identification with multiple measurement and coronary physiological information from the whole 
vasodilation period. Pixel-wise analysis from the same animal are presented in figure 4.15.  
 
Fig 4.15. Pixel-wised evaluation of the remote and affected myocardium. CDPs derived from different 
starting time points (A:2min, B:5min and C:10 min) are plotted in the scatter plots and compared with 
the conventional single time point T2 values (D). The pixels are labeled as remote (blue dots) and 
affected (red dots) with different colors. Affected pixels identified by the averaged SVMs were displayed 
in the corresponding panel and highlighted with green. Lowest error rate and best accuracy on disease 
identification was achieved with the 5min CDPs. 
Pixels from remote and affected area are clustered within each group in all CDP scatter plots. 
Averaged SVMs trained with 10-fold cross validation are presented in the plots and classification 
error rates were measured to assess the capability of classifying the affected pixels. The affected 
pixels detected by the averaged SVMs are also presented and highlighted (green) in each panel. 
CDPs fitted from 2 minutes and 5 minutes post regadenoson showed higher accuracy compared 
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to the conventional method while 10 minute CDPs presented slightly lower measures. Among all 
measurements, 5 mins CDPs showed the best classification property and lowest error rates in 
both segmental and pixel-wise analysis. In addition, acquiring stress images at a delayed time 
point is also favorable for providing more robust image quality as discussed in chapter 4.1, 
which enables a more sensitive and robust BOLD study.   
4.2.4 DISCUSSION 
In this study, coronary dynamics following regadenoson injection was assessed in dogs and 
humans with repeatedly acquired BOLD CMR. In healthy subjects, CDPs were extracted and the 
fitted parameters were closely correlated to the conventional single time point BOLD response. 
Maximum BOLD response extracted from CDPs showed the possible increased BOLD 
sensitivity relative to the conventional single time point MBR calculation. In the infracted dog, 
CDPs derived from 5 minutes post regadenoson showed the maximum capacity for classifying 
remote and affected myocardium in both segmental and pixel-wise analysis.  
 
4.2.4.1 Increased Robustness of BOLD CMR with CDP Estimation 
Reliability of BOLD images and the robustness of BOLD response are currently the key barriers 
for the clinical adoption of BOLD CMR. The capability to repeatedly sample the BOLD signal 
reduces the susceptibility to imaging and physiological noise compared to the standard single 
acquisition, which helps increase the robustness of the exams. This is enabled by the capability 
of regadenoson and is ideally suited for BOLD exam for two reasons: (A) due to the significant 
heart rate elevation and unstable cardiac motion at the initial phase (3-5min) (129) post injection, 
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imaging artifacts can significantly confound the BOLD signals. The capability of bypassing this 
unpredictable period with repeated measured BOLD CMR is ideal for extracting BOLD signal 
changes; and (B) The second phase of pharmacological half-life of regadenoson is ~30 minutes 
(130). The time scale is ideal for BOLD CMR acquisitions to sample the coronary activity post-
regadenoson administration.  
4.2.4.2 Valued-Added Benefits of Characterizing Coronary Dynamics 
In the conventional stress exams, due to the limitation of perfusion imaging methods (typically 
aimed to capture the first-passage of the contrast agent), coronary reactivity (response) is only 
evaluated at a single time point (i.e., at peak vasodilation). Notably, the conventional 
noninvasive perfusion exams, such as SPECT, PET and first pass perfusion MRI, are usually 
based on imaging contrast agent dynamics. These approaches are not suitable for repeat 
measurements due to the dose of contrast agent, radiation and contrast washout speed. Although, 
peak MPR assessed with these methods provide important information in evaluating coronary 
function, a noninvasive way of determining the complete dynamics of the coronary arteries 
following regadenoson has the capacity to provide more information. For example, it provides 
the temporal dimension to study the actual condition of the coronary arteries, which is currently 
not available. Such a method can offer opportunities to assess time-dependent coronary 
relaxation and myocardial perfusion in patients experiencing coronary vasospasms.  
 We used a mono-exponential model as a first-order approximation to model the 
pharmacodynamics (128) of regadenoson mediating coronary relaxation. The extracted CDPs 
from the healthy subjects are in accordance with previously reported values (79) (131). In the 
animal with chronic MI, the CDPs were significantly different in the infarcted segments from the 
normal values. The difference showed the abnormal coronary reactivity in the affected 
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myocardium compared to the remote myocardium to be consistent with the expectation that there 
would be no or little dynamical response in a regions supplied by a culprit artery that caused an 
infarction. 
4.2.4.3 Future directions 
In this proof-of-concept study, BOLD images were acquired with a commercially available 2D 
T2 map, which is susceptible to the confounders as mentioned in the previous chapters. The 3D 
free-breathing HR independent sequence that was developed in earlier (Chapter 3) would be a 
desirable tool to rapidly acquire whole-heart BOLD signals and eliminate confounders from the 
vasodilatory stress.  
Furthermore, the repeat measurement strategy can be used to further accelerate the imaging 
acquisition by exploring the temporal sparsity. While this study fitted the coronary dynamics 
with a mono-exponential model, a more sophisticated model (128) may provide an improved 
fitting for the BOLD signal dynamics. Although the current study showed the mono-exponential 
fit can capture sufficient differences in CDPs to differentiate remote and infarcted myocardial 
segments, the capability of the approach to identify non-flow limiting stensosis thatare clinically 
significant remains to be investigated. 
4.2.5 CONLUSION 
Repeatedly acquired BOLD CMR post regadenoson administration enables the extraction of 
coronary relaxation parameters and capture the BOLD response from peak vasodilation. CDP 
appear to have the capacity to reliably differentiate disease and healthy myocardium and have 
better tolerance for degraded image quality, hence improving the reliability of BOLD CMR. 
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5  Chapter 5 BOLD CMR with Hypercapnia 
 
5.1  Arterial CO2 as a Potent Coronary Vasodilator 
5.1.1 INTRODUCTION 
A large number of studies have investigated the effect of carbon dioxide tension in arterial blood 
(PaCO2) on myocardial blood flow (MBF) (132-141), but their conclusions on the sensitivity of 
CO2 to invoke an increase in MBF has been variable. Specifically, studies have reported that an 
increase in PaCO2 has marked (134,135), minimal (137,138) or no (133,139) effect on 
myocardial blood flow (MBF). These findings may be explained by one or more of the 
commonly shared aspects of these studies: (a) an indistinct stimulus due to the inability to 
independently, precisely and rapidly control PaCO2; (b) confounding physiologic effects 
resulting from the use of isolated heart-lung or in-situ preparations; and (c) uncertain measures of 
the outcome variable due to limitations of the surrogate metrics of MBF.  
If CO2 were to be a powerful coronary vasodilator, it would have important scientific and clinical 
implications. For instance, in the absence of controlled levels of PaCO2 the efficacy of novel 
experimental myocardial therapies may be confounded. Clinically, PaCO2 may affect the results 
of invasive and non-invasive cardiac stress tests, coronary revascularization, and other 
procedures that depend on or wish to regulate MBF during intervention (142).  
Our aim was to investigate the effects of PaCO2 on MBF while minimizing contributions from 
factors that can unintentionally reduce or inaccurately report on sensitivity of PaCO2 on MBF. To 
this end, we used a clinically relevant animal model along with (i) a validated strategy to 
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precisely and rapidly establish desired levels of PaCO2, while holding PaO2 constant; (ii) the 
gold-standard method for quantifying MBF in vivo; and (iii) validated image analysis platform to 
derive MBF values across the different coronary supply territories. We compared our findings to 
the effects of standard dose of adenosine in the same animal models with and without coronary 
stenosis to quantify MBF and flow deficit regions under peak tolerable PaCO2. To determine 
whether the potential change in MBF in response to PaCO2 overlaps the same mechanistic path 
as adenosine, we quantified MBF under hypercapnia and adenosine following caffeine 
administration – a substrate that is known to competitively inhibit the adenosine receptors 
affecting coronary artery resistance.  
5.1.2 MATERIALS AND METHODS 
5.1.3 Study Design 
The objective of this study was to test whether physiologically acceptable hypercapnia can 
increase MBF to the same extent as adenosine – a well-known potent coronary vasodilator, 
which is routinely used in clinical cardiac stress testing (125). Previous investigations that aimed 
to examine the effect of elevated levels PaCO2 on MBF have been limited by one or more 
methodological limitations. The current study overcomes these limitations through (a) 
prospective targeting of PETCO2 to reach precise levels of PaCO2 using a closed-loop gas-
delivery system within 2-3 breaths while keeping PaO2 fixed (143-145); (b) validated 
noninvasive imaging that is capable of reporting quantitative measures of MBF in vivo (146); (c) 
an accepted image analysis approach for quantifying MBF and related metrics (147); and (d) a 
clinically relevant animal model to investigate MBF under various physiological conditions (45). 
Prospectively targeted computerized control of end-tidal CO2 (PETCO2) method has evolved 
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into a reliable approach for fine, rapid and independent control of end-tidal partial pressures of 
CO2 (PETCO2) and O2 (PETO2) (143,144). Importantly, the PETCO2 attained with prospective 
end-tidal targeting, is equal to PaCO2 (144) —the independent variable with respect to 
vasoreactivity (143) which we investigated in this work. We used prospective end-tidal targeting 
to control PaCO2 and 
13N-ammonia Positron Emission Tomography (PET) to measure of MBF, 
in vivo (142,148).  We acquired cardiac images under rest, hypercapnia and following adenosine 
infusion in a clinically relevant canine model (149,150) with and without coronary stenosis. In 
the forthcoming text, we refer to PETCO2 when referring to what was measured and PaCO2 when 
referring to the vasoactive stimulus. We quantified MBF at each physiological condition using a 
validated image analysis approach (147). On the basis of changes in MBF in response to 
hypercapnia and adenosine, we quantified myocardial perfusion reserve (MPR, defined as ratio 
of MBF at stress (adenosine or hypercapnia) and MBF at rest). In canines with coronary stenosis, 
we quantified the relative volume of myocardial flow deficit under hypercapnia and adenosine. 
Specifically, first we examined whether the global and regional MBF and MPR are equivalent 
under conditions of hypercapnic stimulus (PETCO2 ~ 60 mmHg) (45) and clinical dose of 
adenosine routinely used for cardiac stress testing (140 g/kg/min) (125) in intact animals. Next, 
we examined regional changes in MBF and MPR under the same hypercapnic stimulus in 
animals subjected to coronary stenosis. Here we examined whether the total perfusion defects 
identified with hypercapnia are the same as with adenosine.  
The mechanism mediating the observed hypercapnia-induced myocardial hyperemia from the 
above studies is not clear. However, the cellular and molecular pathways involved in adenosine-
based coronary vasodilation are well understood (125). In the heart, increased levels of 
adenosine cause the extracellular A2A receptors to initiate a set of cascading events that 
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ultimately converge on ATP-dependent K+-dependent channels to relax vascular smooth muscles 
of the coronary arteries, thus leading to vasodilation. It is also known that caffeine is a potent 
nonselective competitive inhibitor of A2A receptor and counteracts the downstream effects of 
adenosine (151). To investigate whether the mechanism of action of adenosine and hypercapnia 
are the same, we tested whether a known inhibitor of adenosine-mediated myocardial hyperemia, 
caffeine, can also abolish hyperemic MBF under hypercapnia (152). The institutional Animal 
Care and Use Committee approved all animal studies.  
5.1.4 Animal Model & Preparation 
Study Groups: Three groups of animals were studied: (a) Intact animals (Group Intact, n=10): In 
preparation for imaging studies, animals were fasted for 18 hours, sedated and anesthetized with 
propofol (2.0-5.0 mg/kg, IV) and intubated. (b) Animals with Coronary Stenosis (Group 
Stenosis, n=10): In addition to the above preparation, each animal was implanted with an 
occluder to implement stenosis of the left-anterior descending coronary (LAD), as previously 
described (45). (c) Pre-treatment of intact animals with caffeine (Group Caffeine, n=5): Animals 
were prepared as described above (Group Intact) but imaging was performed before and 10 
minutes after caffeine administration (5 mg/kg, IV, chased by a 10 cc saline flush).  
Anesthesia and Ventilation: All animals were transferred to the scanner table and were initially 
mechanically ventilated (Model 2002 Halowell EMC, MA, USA) with tidal volume 7-10 ml/kg, 
frequency 12-15/min, and inspiration to expiration ratio 1:2. A secondary sequential gas delivery 
circuit, functionally similar to that used for spontaneous ventilation was interposed between the 
animal and the ventilator to enable end-tidal prospective gas control. During end-tidal gas 
control, tidal volume was increased to 10-15 ml/kg and frequency to 15-20 /min to assure end-
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tidal rebreathing. ECG, peripheral blood oxygenation (SpO2), heart rate and blood pressure 
(diastolic, systolic and mean) were monitored. During the imaging studies, anesthesia was 
maintained with a continuous infusion of low dose propofol (0.03-0.1 mg/kg/min, IV). 
Prospective Targeting of PaCO2 and PaO2: Prospective targeting of PaCO2 and PaO2 was 
accomplished using an algorithm-driven computerized gas blender administering gases to a 
sequential gas delivery breathing circuit (RespirAct™, Thornhill Research Inc., Toronto, 
Canada) as previously described (143).  At rest and during adenosine infusion, PETCO2 was 
targeted at ~35 mmHg and during hypercapnia PETCO2 was targeted at ~60 mmHg, all while 
targeting isoxia at PETO2 ~125mmHg.   
Stenosis Studies: In Group Stenosis, imaging was performed within 2 minutes of establishing 
non-flow limiting stenosis at rest by ensuring that that occlusion did not lead to any visually 
evident ST-elevation at rest. In addition (a) first-pass perfusion MRI (153) at rest prior to release 
of occlusion at the terminal point of the study to determine flow abnormalities; (b) cine MRI to 
A
DC
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ascertain any wall motion abnormalities or edema (115); and (c) late-gadolinium enhancement 
MRI to rule out myocardial infarction. Fig 5.1 shows a representative case from the animals 
included as part of the Group Stenosis for analysis in which there was no evidence of rest 
perfusion anomalies or myocardial damage at rest at the terminal point of the studies.  
Fig. 5.1 MRI-based validation of non-flow limiting stenosis. Balanced steady-state free-precession cine 
images were acquired in the presence of LAD stenosis at rest. End diastolic and systolic images from the 
cine series are shown in panels A and B. Note the absence of any wall motion or hyperintense regions 
(indicative of edema) in the anterior segments of the myocardial wall. Panels C and D show first-pass 
perfusion images at peak myocardial enhancement and late-gadolinium enhanced images obtained at 
rest, which show the absence of perfusion defects and infarction. 
Two out of the 10 animals subjected to coronary stenosis, showed evidence of rest perfusion 
defects and mild sub-endocardial evidence of late-gadolinium enhancement in the anterior lateral 
wall and were excluded from further analysis. Thus, a total of 8 animals from Group Stenosis 
were analyzed. 
5.1.5 Noninvasive Assessment of MBF with 13N PET  
All PET images were acquired using a whole body clinical Biograph mMR (Siemens Healthcare, 
Erlangen, Germany) in 3-dimensional (3D) list mode using 13N-ammonia (200 MBq, IV bolus 
(3-5 s) followed by 10 cc saline flush) as the blood flow tracer.  Prior to each PET scan, 
magnetic resonance images were acquired to correct for photon attenuation.  Attenuation 
correction was performed using segmentation of images obtained with a 2-point Dixon MR 
imaging pulse sequence, which has been shown to be effective for cardiac studies in both 
humans and canines (116,117).  Data acquisition spanned over 10 minutes and began a few 
seconds before the 13N-ammonia injection. In Group Intact, images were acquired during 
hypercapnia and adenosine infusion at rest to investigate the MBF response in the absence of 
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coronary stenosis. Specifically, under adenosine, PET acquisitions were prescribed following 2 
minutes of adenosine infusion; and under hypercapnia, 1 minute after the desired PETCO2 value 
was reached.  A time delay was introduced between the sequential PET acquisitions at each 
physiological condition to ensure sufficient decay of each 13N-ammonia dose (5 half-lives, ~50 
minutes). In Group Stenosis, images were acquired at rest, hypercapnia and adenosine before and 
after infliction of LAD coronary stenosis. In Group Caffeine, rest scans were acquired pre- and 
post-caffeine treatment. This was followed by post-caffeine treatment scans under hypercapnia 
and adenosine. Other aspects of the imaging protocols implemented in Group Stenosis and 
Group Caffeine were similar to that implemented in Group Intact. In all animal groups, the order 
of adenosine and hypercapnia stimulations was randomized and the animals were allowed to 
recover to baseline PETCO2 between the protocols.  A schematic representation of the sequential 
execution of the study protocols in the three different groups of animals is provided in Fig. 5.2. 
 
Fig. 5.2 Chronological order of 13N-ammonia PET data collection in Group intact (A), Group Stenosis 
(B) and Group Caffeine (C). PETCO2 at the different points of imaging are shown over the blocks. 
PETCO2 was held constant as described in text. In all studies, adenosine and hypercapnia were 
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randomized (“Adenosine (option)” denotes that PET images were acquired before or after hypercapnia, 
but only once). A 40-minutes delay was introduced between acquisitions to ensure sufficient decay of the 
radiotracer between acquisitions. In Group Stenosis, LAD stenosis was induced as described in text with 
additional MRI scans performed at the very end (not shown) to ensure absence of rest flow defects, 
myocardial stunning or infarction. In Group Caffeine, pre- and post-caffeine rest exams were performed 
in the order as described and the PET acquisitions under adenosine and hypercapnia were performed 
post-caffeine and the order was randomized.  
5.1.6 PET Reconstruction and Quantifications of MBF and MPR 
An experienced technologist verified the registration of the MRI attenuation map with the PET 
images visually, and alignment was corrected if necessary by manual 3D translation. Sixteen 
dynamic PET frames were reconstructed (twelve 10-s, two 30-s, one 1-min, and one 6-min 
frames, for a total of 10 min). Standard reconstruction (2-dimensional attenuation-weighted 
ordered-subsets expectation maximization) was used with 3 iterations and 14 subsets and 3D 
post filtering with a 5-mm Gaussian kernel (154). Transverse data were reformatted to a 168 x 
168 x 47 matrix with 2-mm pixels for each dynamic frame. Late perfusion images were 
reconstructed using 7 min of the acquisition after a 2-min delay to allow for blood-pool 
clearance. The reconstruction parameters were identical to the dynamic reconstruction. 
Global and regional myocardial blood flow (MBF) values in ml/min/g and myocardial perfusion 
reserve (MPR) values were derived automatically from the PET data using the automated QPET 
software (Cedars-Sinai Medical Center, Los Angeles, CA, USA), as described previously (154). 
Left ventricular contours were determined automatically from summed dynamic image data, 
discounting the first 2 min. The region for the left ventricular input function was derived 
automatically by placing a cylindrical region of interest (1-cm radius and 2-cm length) with its 
vertical-axis oriented along the long-axis of the heart and centered in the middle of the valve 
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plane. An expert reader reviewed the left ventricular contours and placement of region-of-
interest to determine the arterial input function. Dynamic myocardial samples were obtained 
from the polar map, by analyzing all time frames within the fixed left ventricular contour 
boundaries. Using a standard 2-compartment kinetic model for 13N-ammonia, stress and rest flow 
values in ml/min/g were computed for each sample on the polar map as previously described 
(119).  MPR was computed as a ratio, by dividing each stress polar map sample by the 
corresponding rest sample at each point. The MPR values were corrected by adjusting the resting 
flow by the resting rate-pressure product, following standard processing technique, in QPET. 
The global MBF at stress and rest was computed within the whole LV region bounded by the LV 
plane. The regional MPR was then obtained by dividing the polar map into three regions (left 
anterior descending artery (LAD), left circumflex coronary artery (LCx), and right coronary 
artery (RCA)) using the 17-segment model of the American Heart Association. Regional and 
global MPR values were extracted automatically for further analysis.  
 
5.1.7 Quantification of Total Reduction in Perfusion Volume  
Myocardial perfusion defect territory of Group Stenosis was measured using the stress-rest 
change analysis in QPET software (154,155). In the analysis, perfusion images from both 
provocative stresses were registered to the rest images using the short-axis images; a 2-pass 
registration algorithm was used to minimize the overcompensation between rest and stress (155). 
Subsequently, the “stress-rest” perfusion difference was derived from the voxels contained 
within the stress contour volume.  The count differences between the stimulations were then 
divided by the total rest counts, resulting in a relative count change measure, which was defined 
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as the measure of perfusion difference between stress and rest, as previously demonstrated (155). 
Total reduction in myocardial perfusion volume was derived as a fraction of the total LV 
myocardial volume (TRP, %LV). 
 
5.1.8 Statistical Analysis 
All statistical analyses were performed in IBM SPSS (V21.0, NY, USA). Statistical significance 
was established for p<0.05. All results are reported as mean ± standard deviation (SD). In all 
studies (Group Intact, Group Stenosis and Group Caffeine), two-way repeated measurement 
ANOVA tests were used to examine the regional MBF and MPR in response to hypercapnia and 
adenosine. Two factors were set to be the regional coronary territories (LAD, LCx and RCA) and 
the physiological states (MBF: rest, hypercapnia, adenosine; MPR: hypercapnia, adenosine). 
One-way repeated measurement ANOVA tests were used to examine the differences of Global 
MBF (rest, hypercapnia and adenosine) and hemodynamic indices (heart rate, blood pressure, 
and rate-pressure product). For both tests, post-hoc comparison with Bonferroni correction was 
used to examine if the null hypothesis was rejected. Global MPR from all studies and TRP 
between hypercapnia and adenosine were compared using paired t test. An equivalence test was 
performed with a confidence interval of 90% to determine whether the global MBF was different 
under adenosine and hypercapnia in Group Intact; the same was performed for global MPR. 
Linear correlation analyses were performed between hypercapnia and adenosine in all studies to 
compare regional MBF, regional MPR and TRP. Bland-Altman analysis was also performed to 
determine the limits of agreement and bias between hypercapnia and adenosine. All results are 
shown as mean ± SD. 
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5.1.9 RESULTS 
5.1.9.1 Hypercapnia can induce more than a 2-fold increase in myocardial blood flow  
We acquired cardiac PET images in intact canines (Group Intact, n=10) under rest (PETCO2 ~ 35 
mmHg), at peak hypercapnia (PETCO2 ~ 60 mmHg) (45,156) and 2-3 minutes following standard 
adenosine infusion (140 g/kg/min) (157) while holding PETO2 relatively constant (PETO2 ~ 
125 mmHg). We quantified global and regional MBF and MPR from the PET images. Table 1 
summarizes the measured mean arterial CO2, O2 and hemodynamic variables of interest in Group 
Intact. The results are shown in Fig. 5.3 and mean global and regional MBF and MPR are 
tabulated in Table 5.1. 
 
 
 
 
 
 
Group Intact 
(n=10) 
PETCO2 
(mmHg) 
PETO2 
(mmHg) 
SBP 
(mmHg) 
HR (per min) 
RPP 
(mmHg/minx103
) 
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Adenosine 37.5 ± 2.9 119.9±7.0 128.6 ± 16.8 99.6 ± 34.7* 12.3 ± 4.9* 
Hypercapnia 60.6 ± 1.4* 121.3±5.8 130.2 ± 14.3 81.8 ± 16.8 10.9 ± 2.4 
Rest 36.9 ± 1.6 118.3±5.2 121.2±12.1 65.4 ± 15.2 8.2 ± 2.3 
Group Stenosis 
(n=7) 
PaCO2 
(mmHg) 
PaO2 
(mmHg) 
SBP 
(mmHg) 
HR (per min) 
RPP 
(mmHg/minx103) 
Adenosine 37.3 ± 2.4 128.0 ± 4.9 111.8 ± 32.1 120.8 ± 26.9* 13.9 ± 6.1* 
Hypercapnia 60.6 ± 1.2* 123.7 ± 5.6 118.2 ± 25.3 101.2 ± 23.0 12.0 ± 5.2* 
Rest 35.9 ± 3.4 126.0 ± 4.5 118.1 ± 30.7 73.4 ± 17.0 8.9 ± 2.9 
Group Caffeine 
(n=5) 
PaCO2 
(mmHg) 
PaO2 
(mmHg) 
SBP 
(mmHg) 
HR (per min) 
RPP 
(mmHg/minx103) 
Adenosine 35.1 ± 0.6 123.7 ± 3.0 125.8 ± 8.0 65.4 ± 29.9 6.9 ± 1.7 
Hypercapnia 59.9 ± 2.3* 128.9 ± 6.8 128.3 ± 11.6 69.8 ± 10.8 9.3 ± 3.6 
Rest 34.5 ± 1.2 125 ± 3.6 124.0 ± 11.2 56.6 ± 23.2 7.1 ± 4.0 
Table 5.1 Targeted arterial blood gas estimates and hemodynamic parameters  
SBP: Systolic Arterial Blood Pressure; HR: Heart Rate; and RPP: Rate Pressure Product (MAP x HR). 
*denotes statistically significant difference within the hemodynamic or vital indexes compared to values 
at rest.  
 Representative peak myocardial uptake (short- and long-axis), dynamic myocardial 
uptake curves and polar maps of MBF under rest and stress (hypercapnia and adenosine) along 
with corresponding MPR are shown in Fig. 5.3 A, B and C. An increase in myocardial uptake of 
the tracer, MBF and MPR were evident between rest and hypercapnia and were similar to those 
observed with adenosine.  
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 Mean global and regional (classified according to supply territories of left-anterior 
descending (LAD), left-circumflex (LCx), and right (RCA) coronary arteries) MBF under 
hypercapnia and adenosine showed marked increases compared to rest (Fig. 5.3D). Global MBF 
under adenosine and hypercapnia were both significantly higher than at rest (p<0.05, for both) 
and were not different from one another (p=0.33). Global MBF increase in response to adenosine 
and hypercapnia were found to be equivalent with a margin of equivalence of 0.26 ml/min/g (1/3 
of the standard deviation of the difference in MBF, 0.8 ml/min/g) at  = 0.05. Global MBF 
normalized by rate-pressure-product under adenosine (1.16 x 10-5 ±0.80 x 10-5) and hypercapnia 
(1.26 x 10-5 ±0.56 x 10-5) were significantly different from rest (0.67 x 10-5 ±0.33 x 10-5, p<0.05 
for both), but were not different from one another (p=1.00). Regional MBF under adenosine and 
hypercapnia were significantly higher than at rest but were not different from one another (p>0.8, 
for all). Collective comparison of regional MBFs between hypercapnia and adenosine were 
positively correlated (R=0.73, p<0.05) and showed good agreement (bias of 0.19 ml/g/min, Fig. 
5.3E).  
 Mean global MPR with adenosine and hypercapnia were significantly greater than 2 and 
were found to be equivalent with a margin of equivalence of 0.50 (1/3 of the standard deviation 
of the difference in MPR, 1.54) at  = 0.05. Similar observations were evident for regional MPR 
with hypercapnia and adenosine with p<0.05 for all territories. The MPRs in the respective 
territories did not differ under hypercapnia and adenosine (p=1.00, for all comparisons; Fig. 
5.3F). Comparison between regional MPR under adenosine and hypercapnia showed significant 
correlation (R = 0.75, p<0.05) and good agreement with a bias of 0.35 (Fig. 5.3G).  
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Figure 5.3.Global and Regional Myocardial Blood Flow Response to Hypercapnia and Adenosine in 
Intact Canines. Panel A shows representative short- (Base, Mid, Apex) and long-axis (horizontal (HLA) 
and vertical (VLA)) PET images of peak myocardial uptake of 13N-ammonia during hypercapnia of 
PaCO2 ~ 60 mmHg (CO2), standard clinical dose of adenosine infusion (Adenosine) and under baseline 
conditions with PaCO2 ~ 35 mmHg (Rest). These visual results show the increase in myocardial uptake 
of radiotracer relative to rest under hypercapnia and adenosine. Panel B shows the corresponding 
dynamic radiotracer uptake curves, which further verify the increased myocardial uptake responses to 
hypercapnia and adenosine stresses relative to rest.  Panel C shows the corresponding Myocardial 
Perfusion Reserves (MPRs) under hypercapnia and adenosine (for the case in panels A and B) as well as 
myocardial blood flow (MBF) as polar maps. Panel D shows the global and regional mean MBF at rest 
and under hypercapnia and adenosine. In both cases, MBFs were significantly higher during hypercapnia 
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and adenosine compared to rest. No significant differences in regional MBFs were observed between the 
different coronary supply territories. Panel E shows the correlation (linear regression) and agreement 
(Bland-Altman plots) between regional MBF under adenosine and hypercapnia. Both regression and 
Bland-Altman analyses showed good correlation (R=0.73, p<0.05) and agreement (bias= -0.19 
ml/min/g) in regional MBFs under the two different stresses.  Panel F and G show similar analyses of 
MPR under hypercapnia and adenosine. No differences in global or regional MPR differences were 
observed between hypercapnia and adenosine. Good regional MPR correlations (R=0.75, p<0.05) and 
good agreement (bias = -0.35) were observed between respective regional responses to hypercapnia and 
adenosine. * denotes p<0.05. 
 
 The observed range of MBF at rest (0.44 ml/min/g to 1.93 ml/min/g) and adenosine (0.47 
ml/min/g to 5.10 ml/min/g) and range of MPR under adenosine (1.20 to 4.57) across the animals 
is consistent with previous reports (149,150). We conclude that an increase in arterial PaCO2 of 
25 mmHg can increase MBF more than 2-fold in all myocardial territories subtended by fully 
patent coronary arteries, which is a hallmark of all clinically meaningful vasodilators (158). 
Notably, we found that such an increase in MBF is not different from that is observed with 
intravenously administered adenosine and is not attributable to changes in myocardial oxygen 
consumption (work) indexed by rate-pressure product.   
5.1.9.2 Hypercapnia can be used to identify regional impairments in MBF and MPR due to 
coronary artery stenosis  
 To determine whether myocardial territories supplied by stenotic coronary arteries can be 
identified under hypercapnia, we studied canines (Group Stenosis, n=8) subjected to LAD 
coronary stenosis under hypercapnia and adenosine infusion with 13N-ammonia PET. Table 1 
summarizes the estimates of mean arterial CO2, O2 and hemodynamic variables of interest in 
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Group Stenosis. Results are shown in Fig. 5.4 and mean global and regional MBF and MPR are 
tabulated in Table 5.2. Global and regional MBF and MPR values obtained from 13N-ammonia 
PET images from the different groups of animals under various physiological statuses are shown 
in Table 5.2 (Group Intact), 5.3 (Group Stenosis) and 5.4 (Group Caffeine).  The results are 
shown as mean ± SD. 
 
 
 
  
MBF 
Regional (ml/min/g) 
LAD LCx RCA 
Adenosine 1.4±0.6 2.3±1.0 2.7±1.1 
Hypercapnia 1.4±0.3 2.2±1.0 2.5±1.1 
Rest 0.6±0.1 0.5±0.1 0.6±0.1 
MPR 
Regional 
LAD LCx RCA 
Adenosine 2.2±0.6 3.8±1.4 4.7±1.4 
Hypercapnia 2.1±0.5 3.8±1.3 4.2±1.6 
Table 5.2: Global and Regional MBF and MPR in Group Intact  
Representative short- and long-axis peak myocardial uptake images and polar maps of MBF and 
MPR from an animal with LAD stenosis obtained at rest (PETCO2 ~ 35 mmHg) and the two 
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different states of stress (hypercapnia (PETCO2 ~ 60 mmHg) and adenosine) are shown in Fig. 
5.4 A, B and C. Rest/stress images and MPR maps under hypercapnia and adenosine were 
visually highly concordant. Notably, decreased peak myocardial uptake and MPR were evident 
only in the anterior lateral wall of the myocardium (consistent with the supply territory of distal 
LAD coronary artery).  
 Mean regional MBF in LAD, LCx and RCA supply territories at rest, hypercapnia and 
adenosine are shown in Fig. 5.4D.  MBF values were not different at rest among the different 
supply territories (p>0.4, for all). MBF increased under hypercapnia and adenosine (p<0.05, for 
all territories), albeit the increase in the LAD territory was significantly lower than in the LCx 
and RCA territories (with hypercapnia and adenosine; both p<0.05). However, MBF under 
hypercapnia was not different between the LCx and RCA territories (hypercapnia: p=0.21); the 
same was true under adenosine (p= 0.50). For each myocardial supply territory, MBF under 
hypercapnia and adenosine were not different (p=1.00, for all). Collective comparisons of 
regional MBF between hypercapnia and adenosine showed significant correlation (R=0.69, 
p<0.05) and good agreement with a bias of 0.41 ml/min/g (Fig. 5.4E).   
 Mean regional MPR under hypercapnia and adenosine for LAD, LCx and RCA are 
shown in Fig. 5.4F. MPR values were not higher than 2.0 in LAD territories (hypercapnia: 
p=0.48 and adenosine: p=0.52) but were significantly higher than 2.0 in the LCx and RCA 
(p<0.05 for hypercapnia and adenosine) territories. MPR under hypercapnia was not different 
between the LCx and RCA territories (hypercapnia: p=0.59); the same was true under adenosine 
(p = 0.34). For each myocardial supply territory, MPR under hypercapnia and adenosine were 
not different (p>0.5 for all). Collective comparisons of regional MPR between hypercapnia and 
 124 
adenosine showed significant correlation (R=0.71, p<0.05) and good agreement with a bias of 
0.21 (Fig. 5.4G).     
 
 
Figure 5.4. Regional Myocardial Blood Flow Response to Hypercapnia and Adenosine in the Presence of 
Coronary Stenosis. Panel A shows representative short- (Base, Mid, Apex) and long-axis (HLA and VLA) 
PET images of peak myocardial uptake of 13N-ammonia during hypercapnia of PaCO2 ~ 60 mmHg 
(CO2), standard clinical dose of adenosine (Adenosine) and at rest with PaCO2 ~ 35 mmHg (Rest) in a 
canine with a coronary stenosis of the LAD. Note the differentially lower uptake of the radiotracer in the 
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anterior lateral wall (as evidenced by the lower signal in myocardial segments supplied by the distal 
LAD, yellow arrows) under hypercapnia and adenosine. For ease of visualization, reduced tracer uptake 
in the LAD territory during peak uptake in remote regions (i.e., those not impaired by coronary stenosis) 
is highlighted in the zoomed-in apical short-axis image under hypercapnia and adenosine in panel B.  
For the case in panel A, rest and stress MBF (under hypercapnia and adenosine) and corresponding 
MPR are shown as polar maps in panel C. These images show marked preferential reduction in MBF and 
MPR in the supply regions of the LAD, which are visually evident and spatially consistent under 
hypercapnia and adenosine. Panel D shows mean regional MBF at rest, hypercapnia and adenosine. 
MBF across all coronary supply territories were higher relative to rest under adenosine and hypercapnia 
but the MBF under hypercapnia and adenosine were significantly higher in the RCA and LCx territories 
relative to LAD. Regional MBF under hypercapnia and adenosine showed significant positive correlation 
(R=0.65, p<0.05) and agreement (0.41 ml/min/g). Panels F and G show similar analyses of regional 
MPR under hypercapnia and adenosine. No differences in regional MPR were observed between 
hypercapnia and adenosine but significant differences in MPR between LAD and other territories (RCA 
and LCx) were observed. Significant positive regional MPR correlations (R=0.71, p<0.05) and good 
agreement (bias = 0.21) were observed between respective regional responses to hypercapnia and 
adenosine. * denotes p<0.05 compared to conditions of rest; and +denotes p<0.05 compared to LAD 
under stress.  
Our findings here suggest that myocardial territories supplied by a stenotic coronary artery can 
be identified using a hypercapnic stimulus (PaCO2 ~ 60 mmHg) as well as adenosine on the basis 
of reduced MBF and MPR.  
MBF 
Global 
(ml/min/g) 
Regional (ml/min/g) 
LAD LCx RCA 
Adenosine 2.2±1.1 2.1±0.7 2.2±0.9 2.2±0.9 
Hypercapnia 2.1±0.9 1.9±1.3 2.1±1.4 2.2±1.4 
Rest 0.9±0.4 0.9±0.5 0.9±0.4 0.9±0.4 
MPR Global 
Regional 
LAD LCx RCA 
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Adenosine 2.3±1.0 2.3±0.9 2.4±0.9 2.3±0.9 
Hypercapnia 2.6±0.7 2.6±0.9 2.6±1.1 2.6±0.8 
Table 5.3: Global and Regional MBF and MPR in Group Stenosis 
5.1.9.3 Perfusion defect volumes determined with hypercapnia and adenosine are equivalent 
We examined whether hypercapnic stimulus of 25 mmHg can be used to accurately quantify the 
volume of perfusion defect on the basis of PET in the presence of a coronary stenosis. The total 
reduction in perfusion volume (TRP, %LV) as a percentage of total LV volume between stress 
and rest states using a validated approach (155) is shown in Fig. 5.5.  
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Figure 5.5. Total Myocardial Perfusion Defect Due to Coronary Stenosis Under Hypercapnia and 
Adenosine.  Panel A shows representative short- (Base, Mid, Apex) and long-axis (HLA, VLA) PET 
images with perfusion defects from the Change Analysis (left) estimated from time-averaged myocardial 
uptake images (middle) at rest and stress (hypercapnia and adenosine), along with polar images 
highlighting total perfusion defects (right), for the representative case in Figure 5.4. Note the near 
identical correspondence in the perfusion defect territories identified in the slices and the whole heart 
identified under conditions of hypercapnia and adenosine stress. Panel B shows the mean TRP (%LV) 
under hypercapnia and adenosine. No significant difference in TRP (%LV) was observed under 
hypercapnia and adenosine. Panel C shows results from linear regression and Bland-Altman analyses. 
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Significantly high positive correlation (R=0.85, p<0.05) and minor bias (-2.11%) in TRP (%LV) was 
observed between hypercapnia and adenosine.   
Representative images from the change analysis for the LAD stenosis case in Fig. 5.4A is shown 
in Fig. 5.5A. Perfusion defect regions visually identifiable in the short- and long-axis images 
along with total perfusion defect regions captured by the polar maps show that the perfusion 
defect is confined to the lateral wall, which is consistent with LAD stenosis. Mean TRP obtained 
under hypercapnia and adenosine were not different: 25±19% (hypercapnia) vs. 27±15 % 
(adenosine); p = 0.12. Direct comparison of TRP within the same subjects under hypercapnia and 
adenosine were significantly correlated (R=0.85, p<0.05) and were in good agreement with a 
bias in TRP of 2% (Fig. 5.5C). These findings demonstrate that a hypercapnic stimulus (PETCO2 
~ 60 mmHg) can be used to determine the same spatial extent of myocardial perfusion defect 
typically assessed with adenosine stress. 
 
 
 
 
 
5.1.9.4 Caffeine treatment abolishes myocardial hyperemia under adenosine but not 
hypercapnia 
The results are shown in Fig. 5.6 and mean global and regional MBF and MPR tabulated in 
Table 5.4. 
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MBF 
Global 
(ml/min/g) 
Regional (ml/min/g) 
LAD LCx RCA 
Adenosine 0.6±0.2 0.5±0.1 0.6±0.2 0.6±0.2 
Hypercapnia 0.9±0.2 0.8±0.2 0.9±0.3 1.0±0.2 
Rest (post treatment) 0.6±0.2 0.5±0.2 0.6±0.3 0.6±0.3 
Rest (pre treatment) 0.8±0.4 0.8±0.4 0.8±0.4 0.9±0.4 
MPR 
Global 
(ml/min/g) 
Regional (ml/min/g) 
LAD LCx RCA 
Adenosine 1.1±0.6 1.1±0.1 1.1±0.2 1.1±0.1 
Hypercapnia 1.8±0.2 1.7±0.6 1.8±0.8 1.8±0.7 
 
Table 5.4: Global and Regional MBF and MPR in Group Caffeine  
 
 Representative short- and long-axis peak myocardial uptake images at rest (PETCO2 ~ 35 
mmHg), hypercapnia (PETCO2 ~ 60 mmHg) and adenosine (140 g/kg/min) in a canine treated 
with caffeine (5 mg/kg) are shown in Fig. 5.6A. The corresponding MBF and MPR values are 
shown as polar maps (Fig. 5.6B). These results show that in this animal treated with caffeine, 
although there is no change in MBF between rest and adenosine, hypercapnia is still able to 
induce myocardial hyperemia.  
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Figure 5.6 Global and Regional Myocardial Blood Flow Response to Hypercapnia and Adenosine 
Following Caffeine Treatment. Panel A shows representative short- (Base, Mid, Apex) and long-axis 
(HLA, VLA) PET images acquired during peak myocardial uptake of 13N-ammonia under hypercapnia of 
PaCO2 ~ 60 mmHg (CO2), standard clinical dose of adenosine (Adenosine) and at baseline conditions 
with PaCO2 ~ 35 mmHg (Rest) following caffeine treatment. These visual results show that the increase 
in myocardial uptake of radiotracer relative to rest to occur only under hypercapnia; but not under 
adenosine. For the case in panel A, rest and stress MBF (under hypercapnia and adenosine) and 
corresponding MPR are shown as polar maps in panel B. Panel C shows the global and regional mean 
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MBF at rest and under hypercapnia and adenosine following caffeine infusion (Caff+). Significant global 
and regional myocardial hyperemia is observed under hypercapnia; however, the MBF response under 
adenosine was not different from rest. Panel D shows the results from linear regression analysis between 
regional MBF under adenosine and hypercapnia; no significant correlation between adenosine and 
hypercapnia was seen (R=0.02, p=0.59). Panel E shows the MBF at rest before (Caff(-)) and after 
(Caff(+)) caffeine treatment. Panels E and F show similar analyses of MPR under hypercapnia and 
adenosine. Both global and regional MPR were significantly higher with hypercapnia than with 
adenosine. Weak and non-significant correlation was observed between respective regional responses to 
hypercapnia and adenosine. * denotes p<0.05. 
Mean global MBF at rest (post caffeine) and under adenosine were not different (p=1.00) and 
were significantly lower than hypercapnia (p<0.05, for both). Mean regional MBF were not 
different between rest and adenosine (p>0.8, for all territories) but significantly higher with 
hypercapnia across all territories (all p<0.05). Regional MBF were not different among territories 
at the different conditions (rest, hypercapnia or adenosine); p>0.1, for all. Refer to Fig. 5.6C. 
Under caffeine, there was no correlation between MBF under adenosine and hypercapnia (R = 
0.02, p=0.59; Fig. 5.6D). There was a trend towards higher resting MBF prior to caffeine 
treatment but was not statistically significant (p=0.09; Fig. 5.6E). However, the resting MBF 
normalized by rate-pressure-product were significantly higher prior to caffeine (1.5x10-5 (pre-
treatment) vs 1.0x10-5 (post-treatment), p=0.03). These observations are consistent with reports 
in humans (152) and are likely related to the influence of caffeine on calcium cycling at rest, 
which is known to promote vascular smooth muscle contraction (159,160). 
Under caffeine, the global MPR under adenosine was lower than under hypercapnia (p<0.05). 
Regional MPR values across the different coronary territories were significantly lower than 2 
(p<0.05) with adenosine but were not significantly different from 2.0 with hypercapnia (p=0.17). 
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Refer to Fig. 5.6F.  Regional MPR regressed against adenosine and hypercapnia showed a weak 
and non-significant correlation (R=0.13, p=0.10). Refer to Fig. 5.6G. 
This study showed that under caffeine, hypercapnia increased MBF, albeit by a lower amount 
than in the absence of it, compared to the complete abolishment of hyperemic response to 
adenosine. The findings here suggest that the mechanistic underpinnings constituting hyperemic 
response to hypercapnia and adenosine are not identical.  
5.1.10 DISSCUSSION 
Measures of blood flow within the myocardium and its modulations in response to various 
vasoactive stimuli can provide important insights into the health of the heart. Functional status of 
the myocardium and its ability to rapidly respond with increased MBF to meet oxygen demand is 
routinely assessed in the clinical environment using artificially elevated levels of adenosine. To 
date, a number of endogenous vasodilators have been identified and studied with respect to their 
effect on the myocardium (42). However, the effect of arterial CO2 on MBF has been unclear.  
Even though the arterial tension of CO2 is known to be a fundamental regulator of many 
physiological processes, its direct influence on MBF has not been well characterized, especially 
in relation to adenosine. Previous investigations have not been able to rigorously isolate the 
effects of PaCO2 on MBF primarily because it has not been possible to independently and 
rapidly control PaCO2. This limitation, coupled with limited access to noninvasive quantification 
of MBF changes with PET under different levels of PaCO2, has made it difficult to determine 
whether hypercapnia can be a potent coronary vasodilator to the same extent as adenosine on the 
heart.  
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We used precise, independent and rapid control of PaCO2, 
13N-ammonia PET, a validated image 
analysis approach and a clinically relevant animal model to rigorously study whether a 
physiologically viable hypercapnic stimulus is a potent mediator of MBF. We found that when 
the PETCO2 is altered from rest (~35 mmHg) to ~ 60 mmHg under isoxic conditions, MBF 
increases to levels observed with the clinical dose of adenosine. Specifically, these changes in 
MBF and MPR were both globally and regionally not different from those observed with 
adenosine in the absence and presence of coronary stenosis. Pre-treatment with caffeine 
abolished myocardial hyperemia to adenosine, as expected, but not to hypercapnia. 
5.1.10.1 Translational Importance of Arterial CO2 Tension as a Potent Modulator of 
MBF 
Given our findings that MBF is strongly influenced by hypercapnia, both scientific and clinical 
studies that evaluate MBF or whose outcomes are influenced by MBF need to consider the effect 
of PaCO2 on their results. Specifically, ongoing studies aimed at therapeutic regeneration of the 
myocardium and interventional strategies that aim to mechanically regulate MBF may need to 
evaluate whether hypercapnia influences outcome. Similarly, the effect of PaCO2 on MBF, 
especially in patients with ischemic heart disease, during intraoperative procedures (e.g., 
laparoscopic / abdominal robotic surgeries where PaCO2 can be in excess of 70 mmHg) (161), 
post-operative recovery (when PaCO2 can be in excess of 50 mmHg), or “permissive 
hypercapnia” in intensive care units (when the PaCO2 is between 90-130 mmHg) (156) need to 
be reconsidered.  Specifically, in patients with critical coronary stenosis that encounter 
significant hypercapnia, it appears that hypercapnia could trigger severe myocardial ischemia 
due to coronary steal (20), which could be hazardous.  
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Canines have been the preclinical model of choice in the literature for examining the MBF 
response to various pharmacological agents (42)  that are now routinely used as part of cardiac 
stress testing, including dipyridamole , adenosine and regadenoson (162). Hence our finding of 
marked increase in MBF under isoxic hypercapnia has significant translational value especially 
within the framework of cardiac stress testing. Currently, over 10 million cardiac stress tests are 
performed in the US per year (125). Since many patients cannot tolerate exercise stress tests, 
more than half of all stress tests employ intravenously administered pharmacological stress 
agents, despite their well-known limitations (125). Since elevated levels of PaCO2 can introduce 
myocardial hyperemia to the same extent as adenosine, it has the potential to be an alternative to 
these pharmacological agents. A desirable feature of hypercapnia-based vasodilation compared 
to pharmacological stress agents is that the effects PaCO2 could be rapidly reversed within 2-3 
breaths with prospective gas control methods as used in the study (143). In comparison, the 
effects of pharmacological agents are only reversed with metabolic breakdown of the 
administered agent or following rapid delivery of antidote, such as aminophylline (125).  On the 
other hand, hypercapnia can induce respiratory acidosis. However, the duration (~ 4-6 mins) and 
extent of hypercapnia ( PaCO2 ~ 25 mmHg) and the associated drop in pH (~0.1) that is 
expected in the context of cardiac stress testing has been shown to be safe in humans (163) (164).  
Although, the safety and tolerance of physiologically meaningful levels of hypercapnic stimulus 
in patients suspected of having heart disease remains to be systematically investigated, the 
presence of coronary artery disease is not known to affect the tolerability to hypercapnic 
increases above 25 mmHg (165) (156) .  
Moreover, our findings of differential MBF response to hypercapnia and adenosine following 
caffeine treatment suggest that the mechanism of action mediating myocardial hyperemia by 
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these stimuli are at least partly different. Our findings that PaCO2 and adenosine appear to 
contribute to coronary vasodilation via different mechanisms suggests that it may be possible to 
synergistically combine increases in PaCO2 and a reduced dose of adenosine with an aim of 
reducing both of their side effects.  The rationale would be that both compounds act as direct 
coronary artery dilators and in addition, the hypercapnia increases the sympathetic drive, 
counteracting the hypotensive side effects of adenosine, and compensates for A2A receptor 
blockade by caffeine. 
As noted earlier, a large number of studies have investigated the effects of PaCO2 on MBF. 
However, the reported sensitivity to invoke myocardial hyperemia, especially within the 
physiologically tolerable range of PaCO2, from these studies has not indicated that PaCO2 is a 
potent coronary vasodilator. Among the studies that showed a positive MBF response to 
hypercapnia, Eberlin and colleagues (134) using closed-chest canines showed that when PaCO2 
was altered from 45 mmHg to 82 mmHg, the mean increase in MBF was 2.8% /mmHg increase 
in PaCO2. Using 
133Xe clearance Ledingham et al (135) showed that in response to a change in 
PaCO2 from 40 mmHg to 100 mmHg, MBF mean increase was 0.50% /mmHg increase in 
PaCO2 in closed-chest canines. Using 
131I aminopyrin, Scheuer et al. (136)  showed that when 
PaCO2 was increased from 38 to 91 mmHg, along with large bicarbonate infusion, the mean 
increase in MBF was 3.4% /mmHg increase in PaCO2 in canines. In comparison, our closed-
chest canine studies using 13N-ammonia PET, showed that when PaCO2 is changed from 35 
mmHg to 60 mmHg, the increase in MBF was 5.6% / mmHg increase in PaCO2 – nearly a two-
fold increase in sensitivity to hypercapnia than the highest reported sensitivity values in the 
literature. This observation may be explained on the basis of significant differences between our 
studies and those of others. Previous studies were relatively slow to establish, maintain and/or 
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modulate steady-state levels of hypercapnia before making the MBF measurements (typically 
tens of minutes). These time-consuming manipulations may have contributed to the reduced 
MBF response to hypercapnia as it has been shown that the onset and extent of MBF response to 
hypercapnia is fast and degrades with exposure time (135). In comparison, we established the 
target PaCO2 within a few seconds (2-3 breaths), initiating the MBF measurements within 1-2 
minutes and terminating the exposure to hypercapnia within 5-6 minutes. Next, most of the 
previous studies did not tightly control PaCO2 or PaO2. This is particularly important for the 
studies that were performed under hyperoxia, since hyperoxia is known to cause coronary 
vasoconstriction, which can counteract the vasodilatory response from hypercapnia (42) . In this 
study we maintained isoxia and independently altered PaCO2 with a precision of 1 mmHg. 
Moreover, our measurements, particularly those in intact animals, were made in the most 
noninvasive manner possible using state-of-the-art PET imaging and image processing 
approaches. These results remain to be extended into humans.   
A limitation of this study is that we used the 17-segment model of the AHA to define the 
perfusion territories, despite its inaccuracies in humans (166) and unintended use for canines. 
While it is known that the coronary anatomy between canines and humans are different, the 
overall mapping of the coronary arteries to perfusion territories is similar to humans but not 
strictly the same (167). In particular, canines are typically left dominant while humans are mostly 
right dominant (although ~ 20% are left dominant as well) (168). This could contribute to an 
overestimation of MBF and MPR in the LAD region in the presence of LAD stenosis. 
Notwithstanding this, we observed a significant MBF difference between the assigned LAD and 
other supply territories in Group Stenosis. Further, the MBF and MPR assigned to individual 
coronary territories in the absence of coronary stenosis may by slightly different from reality. 
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However, since there was no statistical difference between the regional territories in Groups 
Intact and Caffeine, the AHA segmentation appears to be a useful model to assign MBF values.   
We conclude that the arterial blood CO2 tension is an independent variable of MBF, which when 
increased by 25 mmHg can induce MBF to the same level as clinical dose of adenosine. Our 
studies also suggest that prospectively targeted arterial CO2 has the capacity to evolve as a potent 
vasodilator for clinical cardiac stress testing and that all research studies or clinical conditions 
which require control of MBF could benefit from regulating CO2 tension of the arterial blood.  
 
5.2   Assessment of Myocardial Reactivity to Targeted Hypercapnia with  
Free-breathing T2-prepared Cardiac Blood-Oxygen-Level-Dependent MR  
 
5.2.1 INTRODUCTION 
Cardiac stress testing is the standard of care for diagnosing ischemic heart disease (2 ). It is 
performed in nearly 10 million patients each year in the US alone. It is conventionally initiated 
with exercise to induce hyperemia and coupled with imaging to identify stress-induced failure to 
increase perfusion, or frank hypo-perfusion in myocardial territories. The approximately 50% of 
patients who find it difficult to perform sufficient exercise for an adequate test are administered 
coronary vasodilators such as adenosine, which carries a rare but serious risk of heart attack and 
death (169).  A limitation of this approach is that all drugs have complex pharmacology and 
pharmacokinetics making it difficult to achieve a consistent blood level across patients; there is a 
large individual variation in response--even to a given blood level.   
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It has been suggested that increases in the arterial partial pressure of CO2 (PaCO2), termed 
hypercapnia, long known as a vasodilator of cerebral vessels (170), may increase coronary blood 
flow in similar measure (42,135,140,171 ).  Hypercapnia as a myocardial vasodilator has some 
theoretical advantages over pharmacologic agents.  It is a natural intrinsic molecule and can be 
administered non-invasively through the respiratory system.  For the target application of cardiac 
stress testing it would only need to be applied for one or two minutes, with its effect terminating 
in seconds.   An increase of 10 mmHg, from resting values (about 40 mmHg) is well tolerated in 
a population similar to that requiring cardiac stress testing (172).  It has a favorable safety profile 
with sustained levels over 3-times resting with no adverse effect on organ function (156). The 
main technical drawback of the use of hypercapnia has been that precise targeting, modulation, 
and monitoring of PaCO2, particularly in spontaneously breathing humans.   
Recent advances in computerized control of gas delivery (144,173) have enabled the precise and 
independent control of end-tidal partial pressures of CO2 (PETCO2) and O2 (PETO2). 
Importantly, the PETCO2 attained with one of these methods, prospective end-tidal targeting, is 
equal to PaCO2 (144) —the independent variable with respect to vasoreactivity (143). A second 
advance exploited for this study is the refinement of non-invasive MRI-based approach for 
examining cardiac perfusion (31,68,76). Myocardial Blood-Oxygen-Level-Dependent (BOLD) 
MRI (174,175 ) is a noninvasive (radiation- and contrast-agent-free), high-resolution, imaging 
method that could provide details of myocardial blood flow based on the changes in oxidative 
state of hemoglobin (176) reflecting the balance between myocardial oxygen demand and 
supply.  
The first hypothesis of this study was that an increase in PaCO2 of up to 10 mmHg in healthy 
humans would result in changes in myocardial blood flow of the same order of magnitude as 
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adenosine.  To address this hypothesis we compared the effects of hypercapnia on myocardial 
blood flow in healthy volunteers to published values with adenosine. The second hypothesis of 
this study was that hypercapnia would result in coronary vasodilation and increase in myocardial 
blood flow to the same order of magnitude as adenosine, and would generate similar myocardial 
perfusion patterns on myocardial BOLD MRI in intact dogs and those with LAD stenosis. In 
addressing both hypotheses, we used myocardial BOLD MRI as a surrogate measure of 
myocardial blood flow. Hence the purpose of this study was to examine whether controlled and 
tolerable levels of hypercapnia may be an alterative to adenosine, a routinely used coronary 
vasodilator, in healthy human subjects and animals. 
5.2.2 METHODS 
5.2.2.1 Human Studies 
Healthy human volunteers (n=18, 9 female, age = 30±5 years, range = 21 – 40 years) were 
recruited in accordance with the protocol that was reviewed and approved by the Institutional 
Review Board. Every participant was competent and provided written informed consent and had 
no history of CAD, lung disease, abnormal cardiac rhythm and rate, kidney/liver disease, and 
were not contraindicated for cardiac MR exams (completed a detailed cardiac MRI 
questionnaire). Volunteers were required to be non-smokers, to fast for 12 hours and refrain from 
intake of caffeine or performance of vigorous exercise prior to the study.   
Control of end-tidal gases 
Prospective targeting of PETCO2 and PETO2 were implemented by an algorithm-driven 
computerized gas blender administering gases to a sequential gas delivery breathing circuit 
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(RespirAct™, Thornhill Research Inc., Toronto, Canada).  The principle of control of PETCO2 
by prospective gas targeting depends on the control of alveolar ventilation ( ) in the 
relationship PETCO2 =  /  where  is the measured CO2 production.  Part of the 
exhaled gas is retained by the breathing circuit in a reservoir.  The breathing circuit receives a 
controlled rate of gas flow.  The patient breathes this flow and makes up the balance of breathing 
with rebreathed gas.  As the exhaled gas has already equilibrated with the pulmonary capillary 
blood, it does not contribute to gas exchange, leaving the gas from the gas blender as the only 
source of alveolar gas exchange.  In other words, the gas blender flow is equal to the and can 
therefore be used according to the above equation to target PETCO2 independently of ventilation.  
As any CO2 in the inhaled gas can be considered an equivalent reduction in , a combination 
of gas flow and inspired PCO2 can generate any , independently of ventilation.  Similar 
considerations are invoked for the control of PETO2.  The underlying rationale for the method 
and its practical implementation are discussed in greater detail elsewhere (145).   
Prior to entering the scanner, the volunteers underwent a trial of an abbreviated targeted 
breathing sequence consisting of one minute each of PETCO2 targeted at 5 and 10 mmHg, above 
resting values (Plus 5 and Plus 10 respectively) to evaluate their tolerance to elevated levels of 
CO2 and to familiarize them to the variations in CO2 levels. In the scanner, subjects’ PETCO2 
was increased to Plus 5 and Plus 10 consecutively, each for 4 min.  All subjects tolerated the 
testing sequences and during MRI.   
 
Cardiac MR and CO2 Manipulation Protocols 
AV
2COV
 AV
2COV

AV
AV
AV
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All imaging studies were performed on a 3.0 T clinical MRI system (Siemens MAGNETOM 
Verio®, Erlangen, Germany). Subjects were placed on the scanner table and continuous 
monitoring of ECG, pulse oximetry and non-invasive blood pressure readings were established. 
A posterior spine array coil and a flexible phased-array coil (placed on the chest) were used for 
signal reception. Following whole-heart shimming and localization of true axes of the heart, 
ECG-triggered, motion-corrected, free-breathing T2-prepared SSFP acquisitions (as described 
previously by Kellman et al (77)) were prescribed over a mid-ventricular slice along the short-
axis at each targeted PaCO2 level (as described above). Images were acquired with following 
parameters: single-shot acquisitions with GRAPPA (rate 2) and 4 signal averages; T2-preparation 
time = 40 ms; TR/TE = 2.9/1.5 ms; flip angle = 45o; slice thickness = 6 mm; in-plane resolution 
= 1.7 x 1.7 mm2; trigger pulse of 2; and readout bandwidth (BW) = 1371 Hz/pixel.  Myocardial 
BOLD MR acquisitions were triggered at each PETCO2 level (baseline, Plus 5, and Plus 10) one 
minute following the stabilization of PETCO2 values.  PETO2 was maintained at resting values 
(i.e., while breathing room air).   
 
5.2.2.2 Canines Studies 
Canine Preparation  
Mongrel dogs (n=14, 20-25 kg) were studied according to the protocols approved by the 
Institutional Animal Care and Use Committee of Cedars-Sinai Medical Center. Each dog was 
sedated with acepromazine (0.5-1·0mg/kg SQ), induced with propofol (2.0-5.0 mg/kg IV), 
endotracheally intubated, and maintained on inhalational gas anesthesia (2·0-2·5% isoflurane, 1-
2 L/min of 100% oxygen). A left lateral thoracotomy was performed at the fifth intercostal space 
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to expose the heart.  Catheters were implanted into the descending aorta (for invasive pressure 
measurement) and left atrium (for blood sampling).  A 20 MHz Doppler probe was affixed on 
the outer surface of vessel immediately distal to the first branch of the left anterior descending 
coronary artery (LAD) to enable measurement of left anterior descending coronary artery artery 
flow velocity.  In half of the dogs (n=7), an externally actuated hydraulic occluder was affixed 
proximal to the Doppler flow probe to allow the induction of LAD stenosis. Subsequently, the 
chests were closed and the dogs were allowed to recover for at least 7 days prior to imaging 
studies.  
Prior to imaging, dogs were fasted for 18 hours, sedated using acepromazine (0.5-1.0mg/kg SQ) 
or midazolam (0.4mg/kg IM), anesthetized with propofol (2.0-5.0 mg/kg, IV) and intubated. 
During the imaging studies, anesthesia was maintained with a continuous infusion of propofol 
(0.03-0.1 mg/kg/min, IV).  Dogs were transferred to the MR scanner table and were initially 
mechanically ventilated (Model 2002 Halowell EMC, MA, USA) with tidal volume 7-10 ml/kg, 
frequency 12-15/min, and inspiration to expiration ratio 1:2.  A secondary sequential gas 
delivery circuit, functionally similar to that used for spontaneous ventilation (143,145), was 
interposed between the dog and the ventilator to enable end-tidal gas control by the RespirAct™ 
(Figure 5.7). During end-tidal gas control tidal volume was increased to 10-15 ml/kg and 
frequency to 15-20 /min to assure end-tidal rebreathing. ECG, SPO2, heart rate, invasive blood 
pressure (systolic, diastolic, and mean arterial), and temperature (Expression, Invivo, FL, USA) 
were monitored. 
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Fig. 5.7: A schematic diagram of the breathing circuit used to ventilate and control the end-tidal gas 
concentrations in ventilated canines. The gas control system (RespirAct; Thornhill Research) flows a gas 
mix of carbon dioxide, oxygen, and nitrogen into the circuit. During exhalation, the exhaled gas enters 
the expiratory limb of the circuit (lower limb in diagram). The expiratory valve opens passively, which 
allows gas to vent into the ventilatory circuit and then to atmosphere. Also during exhalation, the gas 
from the gas control system collects in the flexible bag. On the inspiratory cycle of the ventilator, the 
PEEP valve on the expiratory limb of the circuit directs the ventilator flow down the path of lesser 
resistance into the rigid container displacing gas from the flexible bag into the canine. When the bag is 
collapsed, the pressure in the circuit increases until the PEEP valve is overcome and the ventilator gas is 
directed down the expiratory limb, which results in rebreathing of previously exhaled gas. This results in 
the sequential delivery of the source gas (ie, fresh gas) followed by the previously exhaled gas. Changes 
in alveolar ventilation are affected by controlling the concentrations of carbon dioxide, oxygen, and 
nitrogen in a constant flow of inspired gas by the gas control system according to algorithms described 
by Slessarev et al (1). 
 
Cardiac MR and Coronary Artery Blood Flow Velocity Measurement Protocol 
As the relationship between PaCO2 and changes in coronary flow are unknown, we studied the 
flow response to a graded range of PETCO2 30 mmHg, 40 mmHg, 50 mmHg, and 60 mmHg, in 
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7 dogs.  This PETCO2 range is 10 mmHg below and 10 mmHg above our test protocol of target 
change from 40 mmHg to 50 mmHg and would indicate the available dynamic range of coronary 
blood flow in response to hypercapnia (Group Ramp Figure 5.8).  Coronary blood flow velocities 
were measured at the different PETCO2.   The protocol used to examine the effect of coronary 
stensosis on blood flow is summarized in Figure 5.8 (Group Occluder).   
  
Fig. 5.8: Chronological sequence of data collection. Two groups of canines (ramp [a] and occluder [b] 
groups) were studied and the data collection events are shown for each group. All canines were scouted 
and shimmed in the MR imaging system (Scouts and Shim) and the pressure values over the event blocks 
(or continuation arrows) point to the corresponding Petco2 associated with the event. In ramp group, 
during the adenosine block, adenosine infusion is started and myocardial BOLD MR acquisitions were 
performed. This event was randomized so as to induce pharmacological stress either at the beginning of 
the study or near the end of the study. Thus, if adenosine block is performed near the beginning of the 
study, the terminal adenosine block is not implemented, and vice versa Stenosis Induction refers to the 
inflation of the hydraulic occluder to induce LAD stenosis. Stenosis Removal + Recovery refers to 
deflation of the hydraulic occluder to remove the LAD stenosis. 
 
All imaging studies were performed on a 3.0 T clinical MRI system (Siemens MAGNETOM 
Verio®, Erlangen, Germany). Dogs, prepared in the manner described above, were placed on the 
scanner table in the feet-first right-lateral position.  The imaging protocol (localizations, cardiac 
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shimming, and BOLD MR) and the scan parameters were the same as that used for the human 
studies (listed above), except the in-plane resolution was 1.7 x 1.7 mm2. 
Adenosine and CO2 protocol order was randomized; BOLD MR was prescribed over identical 
imaging slices. In two dogs from Group Ramp, BOLD MR acquisitions were also performed in 
the long axis views (LVOT) for visualization purposes (not included in quantitative analysis), at 
baseline (PETCO2 ~ 40 mmHg) and at peak hypercapnia (PETCO2 ~ 60 mmHg). In both cases, 
the dogs were allowed to recover to baseline conditions between the protocols (verified by 
attaining PETCO2 ~ 40 mmHg and restoration of resting Doppler coronary blood flow velocity).  
Specifically, BOLD MR acquisitions were prescribed following 2 minutes of adenosine infusion 
(140 g/kg/min, IV) and approximately 1 minute after the desired PETCO2 values were reached. 
Prior to, or right after, the baseline (PETCO2 ~ 40 mmHg) and peak hypercapnia (PETCO2 ~ 60 
mmHg) BOLD acquisitions, the Doppler transducer (Triton Technology Inc, CA, USA) was 
connected to the wires originating from the surgically implanted Doppler probe and root-mean-
square Doppler flow velocity values were recorded.  In dogs where LAD stenosis was to be 
induced, peak hyperemic coronary blood flow velocity measured at PETCO2 ~ 60 mmHg was 
reduced to coronary blood flow velocity measured under PETCO2 ~ 40; and (c) after 3 minutes 
of adenosine infusion. Once the imaging studies were completed, dogs were euthanized. 
5.2.2.3 Image Analysis 
Two expert reviewers (H.Y, R.D.) evaluated the images in consensus, each with more than 4 
years of experience evaluating cardiac MR images. Reviewers were blinded to any other patient 
or canine data. 
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Myocardial BOLD MR images, obtained from humans and canines, were analyzed using ImageJ, 
(version 1.46, National Institutes of Health, MA, USA). Contours were traced to segment the 
myocardium (excluding the papillary muscles) and mean signal intensity of the myocardium was 
measured for each experimental condition. At each condition, % Hyperemic BOLD Response, 
and % coronary blood flow velocity were computed, relative to baseline and mean % Hyperemic 
BOLD Response was computed for each study group. For Group Occluder, the myocardium into 
AHA 6 segments and the % Hyperemic BOLD Response was computed for each segment at 
different experimental conditions (PETCO2 ~ 60 mmHg; and adenosine) by normalizing the 
BOLD intensity at hypercapnia and adenosine by BOLD intensities obtained under PETCO2 ~ 
40 mmHg. First-pass perfusion images (acquired with adenosine under LAD stenosis) were also 
segmented in the same fashion. The segments identified to have perfusion defects on the first-
pass perfusion images were labeled as Affected and matched to the segments on myocardial 
BOLD MR images acquired under hypercapnia and adenosine; all others were labeled Remote.  
5.2.2.4 Statistical Analysis 
In humans, multiple, repeated measurements ANOVA were performed to test whether the rate-
pressure product, and blood pressure (systolic, diastolic, and mean arterial) were different from 
baseline at the two different hypercapnic states. Repeated measurements ANOVA was 
performed on the mean % Hyperemic BOLD Response measured to determine whether the 
responses observed at Plus 5 and Plus 10 were different from the values reported by Arnold et al 
(175) for adenosine.  All values are reported as mean ± SD and statistical significance was 
established for p<0.05. Statistical analysis was performed in IBM SPSS (V21.0, NY, USA). 
 147 
 In dogs, repeated measurements ANOVA tests were performed to examine whether the 
rate-pressure product, heart rate, and blood pressure (systolic, diastolic, and mean arterial) were 
different between baseline, hypercapnia, and adenosine. Post-hoc comparison with Bonferroni 
correction was used if the null hypothesis was rejected. Correlation analysis was performed 
between measured values of PaCO2 and PETCO2 at different physiological states for dogs from 
Group Ramp. %Hyperemic BOLD Response from Group Ramp was fitted to PETCO2 using a 
sigmoidal model (170). The reproducibility of %Hyperemic BOLD Response, for a given 
PETCO2 was evaluated from repeat measurements obtained in dogs from repeat myocardial 
BOLD measurements in Group Ramp, was examined with a paired t-test. A paired t-test was also 
performed to evaluate whether %Hyperemic BOLD Response and % Hyperemic Coronary Blood 
Flow Velocity Response obtained at the highest PETCO2 from Group Ramp were different from 
% Hyperemic Responses obtained with adenosine.  A two-way repeated measurement ANOVA 
was used to test the effects of region (two categories: remote and affected) and type of 
vasodilator (two categories: hypercapnia and adenosine) and their interaction on % Hyperemic 
BOLD Response. Kappa (Cohen’s) statistic was used to determine the level of concordance 
between the perfusion defects observed with hypercapnia and adenosine.  For this purpose, the 
segments positive for perfusion defect were identified as those conforming to mean segmental 
intensities that are at least one SD below the mean intensity of the myocardium; all others were 
considered to be normal (no perfusion defect).  
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5.2.3 RESULTS 
5.2.3.1 Human Volunteer Studies 
Physiological parameters recorded from the volunteers at baseline and the two elevated PETCO2 
(Plus 5 and Plus 10) are summarized in Table 1.  Systolic, diastolic and mean arterial blood 
pressure and rate-pressure product did not differ between conditions (baseline, Plus 5, and Plus 
10). Myocardial BOLD MR images of a healthy human volunteer at baseline and hypercapnia 
(Plus 10) showed a marked increase in BOLD signal intensity in response to hypercapnia (Figure 
5.9A). The response at Plus 5 was not greater than that at baseline (102±3% (Plus 5) vs. 100% 
(baseline), p=0.64); the response at Plus 10 was greater than the one at baseline (111±10% (Plus 
10) vs. 100% (baseline), p<0.01) and Plus 5 (111±10% (Plus 10) vs. 102±3% (Plus 5), p < 0.01) 
(Figure 5.9B). The mean response at Plus 10 in our volunteers was not different (111±10% (Plus 
10) vs. 112±11% (adenosine), p=0.75) from adenosine (175).  
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Fig 5.9 Effect of changing arterial CO2 on Myocardial BOLD MR signal intensities in healthy humans. 
Representative short-axis Myocardial BOLD MR images collected from a human volunteer at baseline 
(PETCO2= 37 mmHg) and hypercapnia (PETCO2 = 47 mmHg) are shown in panel A. BOLD signal 
intensity increased during hypercapnia. For ease of visualization, color overlays of the left ventricle (with 
color bar showing BOLD signal intensity in arbitrary units (a.u.)) corresponding to the gray scale images 
are shown directly below. Box plot showing the dependence of % Hyperemic BOLD Response on 
PETCO2 and standard dose of adenosine is shown in panel B. % Hyperemic Response increased at 
higher PETCO2 values; response at Plus 10 did not differ from that due to standard adenosine infusion. 
%Hyperemic BOLD Response for adenosine is from reported values in the literature (175). *denotes 
statistically significant difference relative to Rest (p < 0.05). Top and bottom of boxes indicate (upper 
limit +1 SD and lower limit -1 SD, respectively; error bars (whiskers) are maximum and minimum of 
data.  The mean and median are represented as a point and a band within the box, respectively. For 
adenosine, the whiskers represent the boundaries of 1st and 99th percentile of the data.  
5.2.3.2 Canine Studies 
Figure 5.10 shows examples of raw data for PETCO2 for Group Ramp (Figure 10C) and Repeat 
Measurement (Figure 5.10D) and their respective ensemble flow responses (Figure 5.10A and 
5.10B, respectively).    Figure 5.10A shows the flattening out of the slope of BOLD response to 
changes in PETCO2 above and below the range 40-50 mmHg.  Figure 5.10B shows a more than 
6% change in BOLD signal in response to hypercapnia.  Mean % Hyperemic BOLD Responses 
between the two hyperemic and baseline states did not differ (7±3% (first cycle) vs. 10±4% 
(second cycle), p=0.74).  
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Figure 5.10 Relation between % Hyperemic BOLD Response and PETCO2 in canines. % Hyperemic 
BOLD Response (defined in text) is directly related to PaCO2 (30 to 60 mmHg) and shows a sigmoidal 
relation (data fitted to individual measurements) over the range of PETCO2 values studied (A). When the 
PETCO2 was modulated between 40 and 50 mmHg, % Hyperemic BOLD Response also showed 
equivalent changes, (B). For reference, average % Hyperemic BOLD Response at the different PETCO2 
levels is shown. Panels C and D show the dynamic and precisely targeted changes in PETCO2 
administered to the animals. 
Mean % Hyperemic BOLD Responses and % Hyperemic Coronary Blood Flow Velocity 
Response during peak hypercapnia (mean PETCO2 = 565 mmHg, Table 1) and adenosine 
infusion were not statistically different (BOLD: 117±14% (hypercapnia) vs. -
114±23%(adenosine), p=0.80, coronary blood flow velocity: 120±15% (hypercapnia) vs. 
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126±22%(adenosine), p=1.00, Figure 5.11). Physiologic responses to changes in PaCO2 are 
summarized in Table 2.   
 
Fig 5.11 Box and whisker plot of (a) percentage of hyperemic BOLD response and (b) percentage of 
hyperemic coronary blood flow velocity response because of peak hypercapnia (Paco2, 56 mm Hg  5) 
and adenosine infusion (clinical dose) in canines from ramp group. The mean percentage hyperemic 
BOLD response and percentage hyperemic coronary blood flow velocity response between the peak 
hypercapnic state and adenosine were not different (P = .80, P > .99, respectively).  
 Baseline Plus 5 Plus10 
PETCO2 (mmHg) 38  3 43  3* (p<0.01) 47  3* (p<0.01) 
PETO2 (mmHg) 110  6 111  3 (p=1) 116  4 (p=1) 
Heart Rate (beats/min) 65  10 69  12 (p=1) 72  11* (p<0.05) 
Systolic blood pressure (mmHg) 109  10 109  8 (p=1) 111  9 (p=1) 
Diastolic blood pressure (mmHg) 60  9 61  9 (p=1) 63  8 (p=1) 
Mean arterial pressure 85  8 85  8 (p=1) 87  8 (p=1) 
Rate-pressure product 7000  1572 7428  1686 (p=1) 7675  1737 (p=1) 
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Table 5.5: Physiological parameters measured in healthy human volunteers during cardiac MR studies 
p values provided in the parenthesis are relative to baseline and (*) denotes cases where statistical 
significance (p< 0.05) was evident. Plus 5 and Plus denote 5 and 10 mmHg of PETCO2 above baseline.  
 Baseline Hypocapnia Hypercapnia Adenosine 
Targeted PaCO2 (mmHg) 40  1 30  2*(p<0.01) 56  5*(p<0.01) - 
Actual PaCO2 (mmHg) 43  4 35  5*(p<0.01) 54  7* (p<0.01) 43  4(p=1) 
Targeted PaO2 (mmHg) 113  10 107 12 (p=1) 111  9 (p=1) - 
Actual PaO2 (mmHg) 101  14 102  19 (p=1) 102  16 (p=1) 101  14(p=1) 
Heart Rate (beats/min) 86  14 80  20 (p=1) 105  29*(p<0.01) 119  27*(p<0.01) 
Systolic blood pressure 
(mmHg) 
94  9 96  8 (p=1) 92  7 (p=0.7) 80  13*(p<0.01) 
Diastolic blood pressure 
(mmHg) 
58  11 57  12 (p=1) 54  11(p=1) 46  16 (p=0.41) 
Mean arterial pressure 
(mmHg) 
76  9 77  9 (p=1) 73  8 (p=1) 63  14 (p=0.2) 
Rate-pressure product 
(bpm x mmHg) 
8050  2472 7674  2011(p=1) 9567  2595 (p=0.8) 9015  2147(p=1) 
SPO2 (%) 95.7  0.5 95.1  0.4 (p=1) 94.9  1.4 (p=1) 95.7  0.5 (p=1) 
Temperature (oF) 99.7  1.2 100  1.4 (p=1) 99.8  1.2 (p=1) 101  1.4 (p=1) 
Table 5.6: Physiological parameters measured in Group Ramp during cardiac MR studies. p values 
provided in the parenthesis are relative to baseline and * denotes cases where statistical significance (p< 
0.05) was evident. 
 153 
The hypercapnia-induced hyperemic response in healthy canines was visualized as an increase in 
BOLD signal intensity relative to baseline (Figure 5.12).   
 
Figure 5.12: Images show effect of changing arterial carbon dioxide on myocardial BOLD MR signal 
intensities. Representative short (a) and long (b) axis myocardial BOLD MR images collected from a 
canine from ramp group under baseline (PETCO2, 42 mm Hg) and hypercapnia (PETCO2, 55 mm Hg) are 
shown. Note the increase in signal intensity in images under hypercapnia relative to baseline. For ease of 
visualization, color overlays of the left ventricle (with color bar showing BOLD signal intensity in 
arbitrary units [a.u.]) corresponding to the grayscale images are shown directly below. 
Myocardial BOLD images from Group Occluder showed diminished BOLD responses in the 
Affected (LAD) territory, but increased responses in the Remote (unaffected) territory in the 
presence of LAD stenosis (Figure 5.13).  
 154 
 
Fig 5.13 BOLD Response to adenosine versus hypercapnia in the presence of LAD stenosis in canines. 
(A) Representative color-overlaid BOLD MR images acquired during adenosine infusion, hypercapnia, 
and rest from a canine with a LAD stenosis. Color bar shows myocardial BOLD MR signal intensity. 
Images acquired under adenosine infusion and at rest were obtained under normocapnia. (B) Bull’s eye 
plots constructed from images in panel A; the raw rest image with segmentation details is shown for 
reference. The point of radial extension on the epicardial contour of the bull’s eye plots and rest BOLD 
MR image indicates the right-ventricular insertion point. Color base is shown to index the magnitude of 
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the BOLD response between rest and stress. Note the close correspondence in hypoperfused territories 
between hypercapnia and adenosine (arrows, panel A) and the normalized BOLD response of myocardial 
segments at both hyperemic states (adenosine and hypercapnia) relative to resting state in panel B. (C) 
Box plot showing % Hyperemic BOLD Response from Affected and Remote (unaffected) segments in the 
presence of LAD stenosis in canines. Box plot presentation is the same as before. * denotes statistically 
significant difference relative to Affected territories (p<0.05). Actual values in panel C are: For 
adenosine:  1.01 ± 0.04 (stenosis segments) and 1.06± 0.04 (remote segments); and for hypercapnia:  
0.94± 0.04 (stenosis segments) and 1.04± 0.04 (remote segments).  
 
%Hyperemic BOLD Response from animals from Group Occluder measured under hypercapnia 
(mean PETCO2 = 553 mmHg) and adenosine from the Affected and Remote segments in the 
presence of LAD stenosis showed no difference in the responses to the two vasodilatory stimuli 
(1±4% (hypercapnia) vs. -6±4%(adenosine), p=0.12) in canines with patent coronary arteries; 
there was, however, a significant (105±10% (remote) vs. 97±5%(affected), p=0.01) difference in 
%Hyperemic BOLD Response between Remote and Affected segments in canines with LAD 
stenosis. The concordance between the segments identified as ischemic with adenosine and 
hypercapnic stimuli was high ( =0.75, 95% CI=(0.48,1.00)), indicating that the region and 
extent of ischemic and non-ischemic territories identified with both forms of stimuli are not 
different. 
5.2.4 DISCUSSION 
The key finding of this study is that free-breathing T2-prepared myocardial BOLD MR responses 
under hypercapnia of 10 mmHg and adenosine are not different. In particular, we found that that 
in humans a modest, precisely controlled, increase in baseline PETCO2 of 10 mmHg was both 
tolerable and sufficient to elicit a measurable increase in myocardial BOLD signal intensity.   In 
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this pilot study, the extent of increase in myocardial BOLD response was not different from that 
of adenosine. The controlled studies in canines with and without coronary artery stenosis yielded 
additional important insights. First, canine studies showed a sigmoidal relationship between 
PaCO2 and BOLD response. This data also indicated that the mean increase in PaCO2 above 
baseline by 11 mmHg encompassed a substantial portion of this dynamic range and resulted in 
an increase in myocardial blood flow similar to that elicited in response to a standard clinical 
dose of adenosine.  Notably, the reproducible BOLD responses observed following repeat 
stimulation between baseline and equivalent hypercapnic states indicate that the response did not 
diminish or potentiate with repetition. This implies the possibility that hypercapnic stimulation is 
reversible and repeatable, and would therefore allow repeat testing at a single session. In 
addition, in canines with coronary artery stenosis, hypercapnia and adenosine resulted in similar 
BOLD responses. While we found the heart rate to increase during hypercapnia, we also found a 
concomitant decrease in blood pressure, with both contributions causing no statistical changes in 
the rate-pressure product, a metric that is commonly used to assess cardiac work (Tables 1 and 
2). Hence within the scope of this work (i.e. in limited subjects, both animals and humans) it 
appears that increased heart rate associated with hypercapnia may not lead to an increase in 
oxygen demand. Nonetheless, additional studies are necessary to explore the mechanism of 
action of CO2 mediating to coronary vasodilation and observed physiological changes, such as 
heart rate, in response to hypercapnia. Collectively, these findings warrant more direct 
investigation as to whether hypercapnia could result in data equivalent to that of pharmacologic 
vasodilators for cardiac stress testing.   
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5.2.4.1 Limitations of Previous Studies Relating PaCO2 to Myocardial Blood Flow 
A major limitation of previous studies has been the inadequate control of the PaCO2, the actual 
physiologic stimulus to the coronary arteries.  Tzou et al (138) found that even in the presence of 
mild hyperoxia (inspired O2 concentration of 40%), increasing the PETCO2 by 10 mmHg, 
increased the proximal LAD flow velocity by 37%.   In contrast, Momen et al (139) did not 
detect any increase in coronary blood flow velocity in response to 5% CO2 in oxygen.  However, 
their inspired gas was hyperoxic possibly resulting in coronary vasoconstriction, and it is well 
known that a constant inspired CO2 concentration does not have a consistent effect on the PaCO2 
(144,177-179); the authors did not measure PaCO2 or report PETCO2.  Yokoyama et al (141) 
administered 7% CO2 via a non-rebreathing mask, managing to increase the PaCO2 from 
40.2±2.4 mmHg to only 43.1±2.7 mmHg, a statistically significant increase, but a 
physiologically trivial one.  It is not surprising that they did not find CO2-attributable coronary 
vasodilation (180,181).  In our study, an increase in PETCO2 of 5 mmHg was also insufficient to 
generate a measurable change in myocardial blood flow, but differs from these studies in 
important ways.  First, we attained significantly greater hypercapnic stimulus of 10 mmHg.  
Second, in our study the PaCO2 was known from the PETCO2 (143).  This relationship has only 
been shown to hold for sequential rebreathing, as used by prospective targeting (143,182). Third, 
in our subjects, normoxia was maintained to avoid vasoconstriction.  
 The recent study by Beaudin et al (140) is particularly relevant to our study.  These 
investigators applied an euoxic hypercapnic stimulus of 9 mmHg in humans and measured the 
effect on coronary sinus blood flow with MRI.  They found that myocardial blood flow (indexed 
by coronary sinus flow) increased by 34±4.6% similar to that of cerebral blood flow.  After 
accounting for the increase in myocardial blood flow due to the work-induced increase in MVO2, 
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the increase in myocardial blood flow, representing that from vasodilation alone, was 
17.1±5.7%.  This study, with a few caveats, is comparable to ours. Beaudin et al (140)  
implemented a 14-second breath-hold to enable the cardiac MR-based coronary sinus blood flow 
measures.  Such breath-hold induces further substantial hypercapnia, and rapidly developing 
hypoxia (183), both potent coronary artery vasodilators. Although outside of the breath-hold, 
Beaudin et al (140)  accurately target PETCO2 and PETO2, unlike prospective targeting methods, 
these values do not reliably reflect the arterial values (184).  Finally, the flow data was derived as 
a product of the cross-sectional area of the coronary sinus (measured from MR images) and the 
through-plane velocity of the blood. Given the size of the coronary sinus and the spatial/temporal 
resolution of the imaging, there may be significant differences between the actual size of the 
coronary sinus and that designated. Nevertheless, both their study and ours support consideration 
of hypercapnia as a stimulus for cardiac stress test.   
5.2.4.2 Advantages and Disadvantages and Limitations of Hypercapnia and Myocardial 
BOLD MR 
 Hypercapnia of about 10 mmHg from baseline is benign since it is within the physiologic 
range and is commonly experienced in day-to-day living by most people ((185,186). With few 
exceptions (e.g., increased intracranial pressure) there is no known risk or contra-indication to an 
increase of PaCO2 of 10 mmHg.  The main effects of hypercapnia are dyspnea, and in some, 
stimulation of the sympathetic nervous system resulting in increase in heart rate and blood 
pressure.  In a study of 400 consecutive patients undergoing a 10 mmHg increase in PETCO2 for 
cerebral blood flow studies using BOLD MRI, over 90% of subjects tolerated the stimulus (172). 
While we expect this number to be lower than 10% in the cardiac setting, there will likely be 
patients who will not tolerate this procedure. While there are ways to identify such patient 
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population through a short screening test (examination of tolerance to short hypercapnic stimulus 
as we have done in this study) prior to undergoing imaging, we do not expect that hypercapnic 
stimulus will become an exclusive provocative agent for cardiac stress testing in all subjects. 
Those that cannot tolerate or are contraindicated for hypercapnic stimulus may need to resort to 
pharmacological stress test should that be a suitable option for them. In every case, the sensation 
of dyspnea, resolved within 2-4 breaths with restoration of normocapnia.   
 As BOLD contrast is based on the oxygen saturation of hemoglobin, it reflects the 
balance between oxygen supply and demand, a feature of value in the assessment of ischemic 
heart disease. This feature of myocardial BOLD MRI differs from standard perfusion imaging 
methods that provide information only on blood supply but not demand (187). In the healthy 
myocardium, adenosine infusion has been reported to elicit BOLD responses that are between 10 
– 25% 3T (62,175), with the individual amplitude of response determined by the specific 
imaging approach. Among the various imaging approaches, T2-prep scheme has been studied by 
a number of different investigators and have also been validated against microspheres (31 ). In 
particular, the T2-prep SSFP approaches at 3T (175) has shown mean hyperemic BOLD response 
from healthy myocardium between 15-17%. In this study we showed that the free-breathing 
BOLD response at 3T using the T2-prepared SSFP acquisition scheme is 14±24% with adenosine 
and 17±14% with hypercapnia in canines, which are consistent with previous reports. 
5.2.4.3 Study Limitations  
Healthy human subjects were exposed only to hypercapnia but not adenosine as we considered it 
necessary to compare available data before performing invasive tests.  We chose a 10 mmHg 
hypercapnic stimulus for the human studies because considerable experience exists with this 
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‘dose’ in an elderly population with cerebrovascular disease (172), presumably with similar 
comorbidities (including ventilatory limitations) to those in patients with coronary disease.   
 While the observed coronary blood flow velocity responses in canines were similar to 
previous reports, some groups have shown that coronary blood flow velocity reserves in excess 
of 2.0 in healthy subjects (138,188). These latter differences likely stem from the differences in 
coronary blood flow velocity measurement position along the coronary artery (188). Moreover, 
since our stenosis studies relied on knowing the peak blood flow velocity prior to creation of 
hypoperfusion, we were unable to randomize the PaCO2 levels. Given that the LAD constriction 
likely only introduced hypoperfusion and not ischemia, we do not anticipate the non-
randomization of PETCO2 between 40 mmHg and 60 mmHg to have any effect on our findings. 
However, additional studies are needed to confirm this.  
 In this study, we only evaluated one level of stenosis.  Stenosis was created by reducing 
the blood flow to baseline levels in LAD under hypercapnia of 60 mmHg; hence, the true 
reduction of coronary diameter was not available to us.  This aspect of the study was intended 
only as a proof of principle for identifying redistributions of blood flow and comparing the 
extent to that of adenosine for perspective.   
 To the best of our knowledge there are no validation studies in the literature for defining 
perfusion deficit territories based on signal thresholding of first-pass perfusion MR images. In 
this study with limited sample size, we observed that visual assessment of perfusion territories to 
correspond closely to 1SD decrease in segmental signal intensity relative to remote segments. 
However, the same analysis with 2SD criterion tended to underestimate the segments with 
perfusion defects, which may be explained on the basis of number of factors. Among these, 
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partial volume effects, extent of perfusion territory, and animal-to-animal variation in supply 
territory of the coronary arteries are some viable reasons. A more thorough analysis is expected 
to be necessary to establish a viable criterion, which is outside the scope of this study. 
 This was an exploratory study. We anticipate that additional studies are necessary before 
hypercapnia can be considered a suitable stimulus for cardiac stress testing.   
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6  Chapter 6 Summary and Future Directions 
6.1  SUMMARY 
Assessment of myocardial perfusion is critical in the functional characterization of CAD. FPP-
MRI is a high resolution and non-radioactive approach for probing myocardial perfusion. 
However, it requires administration of a Gadolinium based contrast agent, which is 
contraindicated in patients with end-stage chronic kidney disease (CKD). Myocardial blood-
oxygen-level-dependent (BOLD) CMR is a non-contrast and ionizing-radiation-free approach for 
examining myocardial perfusion. It has the capacity to fill the need to assess myocardial repeat 
assessment of myocardial perfusion in the CKD patients, who have high prevalence of coronary 
artery disease. Despite previous advancements, BOLD CMR is still limited by one or more of the 
following challenges: inadequate spatial coverage, imaging speed, imaging cofounders, need for 
multiple breath holds and imaging artifacts, particularly at 3T.  In chapter 3 of this dissertation, a 
3D whole-heart, fast quantitative BOLD sequence is developed and validated with 
simultaneously acquired quantitative N13-ammonia PET perfusion. The technique was developed 
to address the current limitations and build a reliable method to acquire fast, robust and reliable 
BOLD images. In chapter 3.1, a high efficiency imaging platform was developed to acquire free-
breathing, whole-heart T2 mapping under resting condition within 5 minutes at 3T.  The platform 
utilizes affine transforms to correct for respiratory motion and achieves near perfect imaging 
efficiency during free-breathing. It also addresses imaging artifacts at 3T with well-designed 
adiabatic T2 preparation and GRE readouts. The technique was validated with commercially 
available 2D techniques and showed the capability of detecting myocardial edema in animals 
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with acute myocardial infarction. This was recently published in Magnetic Resonance in 
Medicine.  
In chapter 3.2, the T2 mapping platform is extended and tailored for BOLD CMR ischemic 
testing by incorporating an SR preparation pulse and optimized imaging trajectory and 
parameters. The approach further reduces the acquisition time while eliminating a key 
confounder of the BOLD signal.  These improvements enable the technique to accommodate 
short and unstable imaging window under vasodilatory stress. The method was implemented and 
tested in canine models and human subjects. The BOLD effect was validated in a state of the art 
clinical PET/MR scanner with simultaneously acquired quantitative 13N-ammonia PET perfusion 
images. This is also the first demonstration of the correlation between cardiac BOLD signal and 
quantitative PET perfusion under identical physiological conditions. This work has been 
published in an abstract form in the 2016 SCMR annual meeting and a full manuscript is 
currently under review by JACC: Cardiovascular Imaging.    
Future studies should investigate the applicability of the proposed technique in patients. In 
addition, this fast and reliable BOLD CMR acquisition technique, when integrated the innovative 
vasodilation strategies developed in chapter 4 and 5, has the capacity to markedly improve the 
current state of BOLD CMR.  
Besides the MR technical developments, this dissertation also pushes forward the imaging 
reliability through the advancements of new strategies for examining coronary vasodilation. 
Chapter 4 and 5 explore innovative imaging prtocols with two newer vasodilators (Regadenoson 
and Hypercapnia) to enable more suitable imaging environments for BOLD CMR.  
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The current vasodilation strategies for ischemia testing are designed for other imaging 
modalities, which depend of first-passage of a contrast agent. Improved vasodilation methods 
that can take advantages of BOLD CMR, such as repeat measurements, while minimizing the 
shortcomings can significantly increase the reliability of the exam and assist in the reliable 
application of BOLD CMR in the clinical settings. In chapter 4, regadenoson, a clinically 
available vasodilator, is explored for BOLD CMR acquisition. The study in chapter 4.1 takes 
advantage of the longer physiological half-life of regadenoson and explores the delayed 
vasodilation effect by acquiring BOLD images at a time point with more stable cardiac 
conditions. The results show significantly improved robustness in image quality and reliability 
for evaluating BOLD signal changes compared to the standard approach. This effect was tested 
in animals and validated with 13N-ammonia PET perfusion. The study has been published in 
abstract form in the JCMR 2016 and was nominated for the early career award in the 2016 
SCMR annual Meeting.  
The study in chapter 4.2 takes the method one step further to explore the full time course of 
coronary vasodilation with repeatedly acquired BOLD images. The study explores post 
regadenoson coronary dynamics in animal models under conditions of health and disease by 
monitoring BOLD signal changes in the myocardium. Significant CDP differences between 
healthy and affected myocardial territories were observed in the study. CDPs showed high 
accuracy for detecting affected myocardium. The preliminary results from chapter 4 demonstrate 
the potential of improving reliability and sensitivity of cardiac BOLD exams with better 
designed vasodilation and imaging strategies. Further investigations are needed for the single 
time point regadenoson BOLD exam to determine the best imaging timing. It is expected that 
one needs to optimize the trade-off between imaging robustness and the level of vasodilation to 
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reliably detect CAD. In addition, the preliminary CDP studies in the dissertation are performed 
in animal models and healthy human volunteers. The connection between the CDPs and the 
coronary physiological condition in patients remains to be explored.   
Chapter 5 explores vasodilation effect with controlled arterial CO2 level and its applicability in 
cardiac BOLD MRI. Unlike the conventional pharmacological stress agents, CO2 is an intrinsic 
molecule that can be noninvasively modulated through respiratory system. Utilizing hypercapnia 
in cardiac BOLD exams can potentially reduce the risk of the adverse side effects from the 
conventional pharmacological stress agents and increases exam reliability with repeat 
stimulations.  The capability of inducing vasodilation with controlled hypercapnia is first 
examined in chapter 5.1 with PET.  Quantitative 13N-ammonia PET was used in animals with 
and without coronary stenosis to investigate the vasodilatory capacity of the coronary arteries 
during hypercapnia with a computerized gas control delivery system to precisely target the 
arterial CO2 level. This work showed that controlled iso-oxic hypercapnia can increase 
myocardial blood flow to a comparable extent of adenosine and provide similar capability in 
ischemic volume identification. This work has been published in an abstract form in the 2016 
AHA annual meeting and is currently under review by JACC: Basic to Translational Science.    
The efficacy of hypercapnic vasodilation in BOLD CMR exam is further explored in chapter 5.2. 
The study investigated the BOLD response induced by hypercapnia in human volunteers and 
animal models. The result showed the hypercapnic BOLD response is comparable to the standard 
clinical dose adenosine and has similar capability of identifying ischemic territories. In addition, 
the study established the reversible and repeatable BOLD responses following repeat 
hypercapnic stimulations, which would allow for repetitive rest and stress alternation at a single 
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session. This work has been published in the Radiology in 2014.  Future directions to extend 
BOLD CMR through the use of our findings here are discussed in the following section.  
6.2  Next Steps: Cardiac Functional MRI with CO2 Stimulation Paradigm 
The fundamental limitations of BOLD MRI associated with reliable detection of myocardial 
ischemia stems from its inherently low sensitivity and specificity due to low BOLD contrast-to-
noise ratio (CNR). In integrating the developments in this dissertation, we expect to overcome 
these barriers through: (i). Utilizing the developed technique in chapter 3 to acquire 3D images at 
3T (instead of 1.5T) to increase BOLD CNR and perform high-resolution, free-breathing, BOLD 
imaging to ensure rapid data collection, volumetric coverage, with free gas-exchange capability; 
and (ii). Employment of general linear model (GLM) data analysis to further improve sensitivity 
and specificity with repeat stimulation using the prospective CO2 targeting technique developed 
in chapter 5.  
GLM analysis is one of the primary reasons for the success of BOLD MRI in the brain, which 
was also limited by sensitivity and specificity in the early days (35). At the core of GLM is a 
regression analysis that determines the statistical significance between repeated stimuli and the 
associated (repeated) measured responses. In the brain, the stimulus is easily repeatable (i.e. they 
are visual or cognitive) and leads to vasodilation and a concomitant BOLD response. To date, 
myocardial BOLD responses are induced via intravenously injected stimulus, adenosine, and 
cannot be repeated due to its adverse side effects and costs. Based on our findings in chapter 5, 
we will anticipate that precisely targeted PaCO2 may evolve as a noninvasive alternative to 
adenosine to repeatedly stimulate the heart and measure the responses with the 3D BOLD CMRI 
(as developed in chapter 3). The PaCO2-based repeat stimulations have the capacity to provide a 
 167 
unique opportunity to capture the BOLD signal across multiple data sets. This can offer 
unprecedented amplification in sensitivity and specificity for a reliable and noninvasive means 
for evaluating the myocardial perfusion reserve on the basis of BOLD CMR.  
Efforts from the past 20 years in the field of cardiac BOLD MRI have finally pushed the 
technique in the sight of clinical applications. The studies in this dissertation are expected to 
pave the way for more reliable detection and quantification of ischemic volume and to close the 
gap between research and clinical settings. Hence push BOLD CMR forward as a clinical useful 
instrument to benefit the needed patients and improve patient outcomes.  
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